<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002495</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><ST26SequenceListing><SequenceTotalQuantity>99</SequenceTotalQuantity><SequenceData sequenceIDNumber="1"><INSDSeq><INSDSeq_length>215</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..215</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..215</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="2"><INSDSeq><INSDSeq_length>448</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..448</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..448</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="3"><INSDSeq><INSDSeq_length>219</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..219</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..219</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="4"><INSDSeq><INSDSeq_length>447</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..447</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..447</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="5"><INSDSeq><INSDSeq_length>214</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..214</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..214</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPAECS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="6"><INSDSeq><INSDSeq_length>460</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..460</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..460</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="7"><INSDSeq><INSDSeq_length>214</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..214</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..214</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="8"><INSDSeq><INSDSeq_length>450</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..450</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..450</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="9"><INSDSeq><INSDSeq_length>219</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..219</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..219</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="10"><INSDSeq><INSDSeq_length>449</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..449</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..449</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="11"><INSDSeq><INSDSeq_length>214</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..214</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..214</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="12"><INSDSeq><INSDSeq_length>448</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..448</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..448</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="13"><INSDSeq><INSDSeq_length>113</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..113</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..113</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DVVMTQTPLSLPVSLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGSHVPPTFGGGTKLEIKR</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="14"><INSDSeq><INSDSeq_length>124</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..124</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..124</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="15"><INSDSeq><INSDSeq_length>107</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..107</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..107</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIQMTQSPLSLSASVGDRVTITCQASRDIRNYLNWYQQKPGKAPKLLIYDASSLQTGVPSRFGGSGSGTDFSFTIGSLQPEDIATYYCQQFDSLPHTFGQGTKLEIK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="16"><INSDSeq><INSDSeq_length>120</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..120</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..120</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYRMQWVRQAPGKGLEWVSGISPSGGTTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWSGGSGYAFDIWGQGTMVTVSS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="17"><INSDSeq><INSDSeq_length>11</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>RASQSVSSYLA</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="18"><INSDSeq><INSDSeq_length>7</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DASKRAT</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="19"><INSDSeq><INSDSeq_length>10</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..10</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..10</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QQRSKWPPWT</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="20"><INSDSeq><INSDSeq_length>5</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>SYGMH</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="21"><INSDSeq><INSDSeq_length>17</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..17</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..17</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>IIWFDGSSTYYADSVRG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="22"><INSDSeq><INSDSeq_length>9</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>ELGRRYFDL</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="23"><INSDSeq><INSDSeq_length>20</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..20</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..20</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>RSSQSIVHSNGNTYLQWYLQ</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="24"><INSDSeq><INSDSeq_length>7</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>KVSNRLY</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="25"><INSDSeq><INSDSeq_length>9</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>FQGSHVPWT</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="26"><INSDSeq><INSDSeq_length>6</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..6</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..6</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>GGYLWN</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="27"><INSDSeq><INSDSeq_length>16</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>YISYDGTNNYKPSLKD</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="28"><INSDSeq><INSDSeq_length>8</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..8</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..8</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>YGRVFFDY</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="29"><INSDSeq><INSDSeq_length>11</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QGDSLRSYYAT</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="30"><INSDSeq><INSDSeq_length>7</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>GENKRPS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="31"><INSDSeq><INSDSeq_length>11</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>KSRDGSGQHLV</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="32"><INSDSeq><INSDSeq_length>5</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>SYAIS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="33"><INSDSeq><INSDSeq_length>17</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..17</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..17</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>GIIPIFGTANYAQKFQG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="34"><INSDSeq><INSDSeq_length>21</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..21</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..21</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>APLRFLEWSTQDHYYYYYMDV</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="35"><INSDSeq><INSDSeq_length>11</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>RASQGIRNDLG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="36"><INSDSeq><INSDSeq_length>7</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>AASRLHR</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="37"><INSDSeq><INSDSeq_length>9</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>LQHNSYPCS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="38"><INSDSeq><INSDSeq_length>5</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>SYAMN</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="39"><INSDSeq><INSDSeq_length>17</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..17</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..17</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>AISGSGGTTFYADSVKG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="40"><INSDSeq><INSDSeq_length>16</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DLGWSDSYYYYYGMDV</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="41"><INSDSeq><INSDSeq_length>16</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>RSSQSLLHSNGYNYLD</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="42"><INSDSeq><INSDSeq_length>6</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..6</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..6</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>LGSNRA</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="43"><INSDSeq><INSDSeq_length>9</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>MQGTHWPLT</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="44"><INSDSeq><INSDSeq_length>7</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>SSSNWWS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="45"><INSDSeq><INSDSeq_length>16</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EIYHSGSTNYNPSLKS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="46"><INSDSeq><INSDSeq_length>10</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..10</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..10</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>WTGRTDAFDI</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="47"><INSDSeq><INSDSeq_length>11</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>RASQSIGSSLH</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="48"><INSDSeq><INSDSeq_length>7</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>YASQSLS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="49"><INSDSeq><INSDSeq_length>9</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>HQSSRLPHT</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="50"><INSDSeq><INSDSeq_length>5</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>SFAMH</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="51"><INSDSeq><INSDSeq_length>16</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>VIDTRGATYYADSVKG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="52"><INSDSeq><INSDSeq_length>10</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..10</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..10</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>LGNFYYGMDV</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="53"><INSDSeq><INSDSeq_length>16</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>RSSQSIVHSNVNTYLE</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="54"><INSDSeq><INSDSeq_length>7</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>KVSNRFS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="55"><INSDSeq><INSDSeq_length>9</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>FQGSHVPPT</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="56"><INSDSeq><INSDSeq_length>5</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>SYWMH</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="57"><INSDSeq><INSDSeq_length>18</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..18</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..18</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>GEINPSNGRTNYNQKFQG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="58"><INSDSeq><INSDSeq_length>15</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..15</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..15</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>GRPDYYGSSKWYFDV</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="59"><INSDSeq><INSDSeq_length>11</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QASRDIRNYLN</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="60"><INSDSeq><INSDSeq_length>7</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..7</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DASSLQT</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="61"><INSDSeq><INSDSeq_length>9</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QQFDSLPHT</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="62"><INSDSeq><INSDSeq_length>5</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>IYRMQ</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="63"><INSDSeq><INSDSeq_length>16</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..16</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>GISPSGGTTWYADSVK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="64"><INSDSeq><INSDSeq_length>11</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..11</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>WSGGSGYAFDI</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="65"><INSDSeq><INSDSeq_length>663</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..663</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..663</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="66"><INSDSeq><INSDSeq_length>666</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..666</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..666</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="67"><INSDSeq><INSDSeq_length>674</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..674</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..674</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPAECSEVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="68"><INSDSeq><INSDSeq_length>664</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..664</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..664</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECEVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="69"><INSDSeq><INSDSeq_length>668</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..668</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..668</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="70"><INSDSeq><INSDSeq_length>662</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..662</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..662</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECEVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="71"><INSDSeq><INSDSeq_length>673</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..673</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..673</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DVVMTQTPLSLPVSLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGSHVPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="72"><INSDSeq><INSDSeq_length>227</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..227</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..227</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIQMTQSPLSLSASVGDRVTITCQASRDIRNYLNWYQQKPGKAPKLLIYDASSLQTGVPSRFGGSGSGTDFSFTIGSLQPEDIATYYCQQFDSLPHTFGQGTKLEIKEVQLLESGGGLVQPGGSLRLSCAASGFTFSIYRMQWVRQAPGKGLEWVSGISPSGGTTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWSGGSGYAFDIWGQGTMVTVSS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="73"><INSDSeq><INSDSeq_length>5</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>MISC_FEATURE - n=1-5</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>GGGGS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="74"><INSDSeq><INSDSeq_length>5</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>MISC_FEATURE - n=1-5</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..5</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>GGGGA</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="75"><INSDSeq><INSDSeq_length>217</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..217</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..217</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="76"><INSDSeq><INSDSeq_length>217</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..217</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..217</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="77"><INSDSeq><INSDSeq_length>215</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..215</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..215</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="78"><INSDSeq><INSDSeq_length>232</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..232</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..232</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPSSFGQGTKLEIKEVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="79"><INSDSeq><INSDSeq_length>107</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..107</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..107</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPSSFGQGTKLEIK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="80"><INSDSeq><INSDSeq_length>125</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..125</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..125</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="81"><INSDSeq><INSDSeq_length>9</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..9</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>LQHNSYPSS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="82"><INSDSeq><INSDSeq_length>665</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..665</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..665</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="83"><INSDSeq><INSDSeq_length>446</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..446</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..446</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="84"><INSDSeq><INSDSeq_length>329</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..329</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..329</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="85"><INSDSeq><INSDSeq_length>673</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..673</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..673</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DVVMTQTPLSLPVSLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGSHVPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="86"><INSDSeq><INSDSeq_length>113</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..113</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..113</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DVVMTQTPLSLPVSLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGSHVPPTFGGGTKLEIKR</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="87"><INSDSeq><INSDSeq_length>330</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..330</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..330</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="88"><INSDSeq><INSDSeq_length>329</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..329</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..329</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="89"><INSDSeq><INSDSeq_length>329</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..329</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..329</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="90"><INSDSeq><INSDSeq_length>330</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..330</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..330</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="91"><INSDSeq><INSDSeq_length>124</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..124</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..124</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLVQSGAEVVKPGASVKLSSKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="92"><INSDSeq><INSDSeq_length>454</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..454</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..454</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="93"><INSDSeq><INSDSeq_length>219</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..219</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..219</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DVVMTQTPLSLPVSLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGSHVPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="94"><INSDSeq><INSDSeq_length>453</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..453</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..453</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="95"><INSDSeq><INSDSeq_length>453</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..453</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..453</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLVQSGAEVVKPGASVKLSSKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="96"><INSDSeq><INSDSeq_length>124</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..124</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..124</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLVQSGAEVVKPGASVKLSSKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSS</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="97"><INSDSeq><INSDSeq_length>112</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..112</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..112</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DVVMTQTPLSLPVSLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGSHVPPTFGGGTKLEIK</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="98"><INSDSeq><INSDSeq_length>113</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..113</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..113</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIKR</INSDSeq_sequence></INSDSeq></SequenceData><SequenceData sequenceIDNumber="99"><INSDSeq><INSDSeq_length>117</INSDSeq_length><INSDSeq_moltype>AA</INSDSeq_moltype><INSDSeq_division>PAT</INSDSeq_division><INSDSeq_feature-table><INSDFeature><INSDFeature_key>REGION</INSDFeature_key><INSDFeature_location>1..117</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>note</INSDQualifier_name><INSDQualifier_value>synthetic sequence</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature><INSDFeature><INSDFeature_key>source</INSDFeature_key><INSDFeature_location>1..117</INSDFeature_location><INSDFeature_quals><INSDQualifier><INSDQualifier_name>mol_type</INSDQualifier_name><INSDQualifier_value>protein</INSDQualifier_value></INSDQualifier><INSDQualifier><INSDQualifier_name>organism</INSDQualifier_name><INSDQualifier_value>synthetic construct</INSDQualifier_value></INSDQualifier></INSDFeature_quals></INSDFeature></INSDSeq_feature-table><INSDSeq_sequence>QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS</INSDSeq_sequence></INSDSeq></SequenceData></ST26SequenceListing></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002496A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002496</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17297421</doc-number><date>20191125</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>CN</country><doc-number>PCT/CN2018/117581</doc-number><date>20181127</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>28</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>79</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2866</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>79</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>565</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>24</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>52</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>92</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>94</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e61">ANTIBODIES SPECIFICALLY RECOGNIZING GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR ALPHA AND USES THEREOF</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.</orgname><address><city>Beijing</city><country>CN</country></address></addressbook><residence><country>CN</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>ZHU</last-name><first-name>Pingxia</first-name><address><city>Beijing</city><country>CN</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>WU</last-name><first-name>Ran</first-name><address><city>Beijing</city><country>CN</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>ZHANG</last-name><first-name>Qingshuang</first-name><address><city>Beijing</city><country>CN</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>HUANG</last-name><first-name>Qun</first-name><address><city>Beijing</city><country>CN</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/CN2019/120545</doc-number><date>20191125</date></document-id><us-371c12-date><date>20210526</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present application provides antibodies including antigen-binding fragment thereof that specifically recognizing Granulocyte-Macrophage Colony Stimulating Factor Receptor (GM-CSFR&#x3b1;). Also provided are methods of making and using these antibodies.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="60.96mm" wi="142.66mm" file="US20230002496A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="185.08mm" wi="116.50mm" file="US20230002496A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="180.09mm" wi="122.51mm" file="US20230002496A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="218.69mm" wi="144.70mm" file="US20230002496A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="205.23mm" wi="117.26mm" file="US20230002496A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="192.28mm" wi="115.32mm" file="US20230002496A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="224.87mm" wi="117.69mm" file="US20230002496A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="195.66mm" wi="144.70mm" file="US20230002496A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="207.77mm" wi="137.75mm" file="US20230002496A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="214.21mm" wi="137.24mm" file="US20230002496A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="188.21mm" wi="133.35mm" file="US20230002496A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="206.42mm" wi="131.74mm" file="US20230002496A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="205.49mm" wi="143.93mm" file="US20230002496A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="159.77mm" wi="144.27mm" file="US20230002496A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="224.87mm" wi="115.74mm" file="US20230002496A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="221.32mm" wi="122.60mm" file="US20230002496A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="218.52mm" wi="116.84mm" file="US20230002496A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="234.61mm" wi="118.87mm" file="US20230002496A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="223.94mm" wi="145.97mm" file="US20230002496A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="219.54mm" wi="148.34mm" file="US20230002496A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="206.16mm" wi="148.08mm" file="US20230002496A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CROSS REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application is a national stage application under 35 U.S.C. &#xa7; 371 of International Application No. PCT/CN2019/120545, filed internationally on Nov. 25, 2019, which claims the benefit of priority to international application PCT/CN2018/117581, filed Nov. 27, 2018, the contents of each of which are incorporated herein by reference in their entirety.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE</heading><p id="p-0003" num="0002">The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 710262000100SEQLIST.TXT, date recorded: Oct. 26, 2021, size: 254,014 bytes).</p><heading id="h-0003" level="1">FIELD OF THE APPLICATION</heading><p id="p-0004" num="0003">This application pertains to antibodies that specifically recognize granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFR&#x3b1;), and methods of manufacture and uses thereof, including methods of treating autoimmune and inflammatory conditions, and cancer.</p><heading id="h-0004" level="1">BACKGROUND OF THE APPLICATION</heading><p id="p-0005" num="0004">Granulocyte-macrophage colony stimulating factor (GM-CSF) is also known as colony-stimulating factor 2 (CSF2). GM-CSF is a type I proinflammatory cytokine which plays a role in exacerbating inflammatory, respiratory and autoimmune diseases. The GM-CSF receptor is a member of the hematopoietic receptor superfamily. It is heterodimeric, consisting of an alpha and a beta subunit. GM-CSF is able to bind with relatively low affinity to the &#x3b1; subunit alone (K<sub>d </sub>1-5 nM) but not at all to the &#x3b2; subunit alone. However, the presence of both &#x3b1; and &#x3b2; subunits results in a high affinity ligand-receptor complex (Kd&#x2248;100 pM). Neutralization of GM-CSF binding to GM-CSFR&#x3b1; is therefore a therapeutic approach to treating diseases and conditions mediated through GM-CSFR. An antibody against human GM-CSFR&#x3b1;, designated Mavrilimumab (Mab, used as a control in the Examples), is described in WO2007110631.</p><p id="p-0006" num="0005">The disclosures of all publications, patents, patent applications and published patent applications referred to herein are hereby incorporated herein by reference in their entirety.</p><heading id="h-0005" level="1">BRIEF SUMMARY OF THE APPLICATION</heading><p id="p-0007" num="0006">In one aspect, the present application provides an isolated anti-GM-CSFR&#x3b1; antibody that specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises one, two, three, four, five, or six amino acid residues selected from the group consisting of Val50, Glu59, Lys194, Lys195, Arg283, and Ile284 of human GM-CSFR&#x3b1;. In some embodiments, the epitope further comprises amino acid residues: (i) Val51, Thr63, and Ile196; (ii) Leu191 and Ile196; or (iii) Arg49, Val1, Asn57, and Ser61. In some embodiments, the isolated anti-GM-CSFR&#x3b1; antibody binds to the human GM-CSFR&#x3b1; with a K<sub>d </sub>from about 0.1 pM to about 1 nM.</p><p id="p-0008" num="0007">In some embodiments according to any one of the isolated anti-GM-CSFR&#x3b1; antibodies described above, the isolated anti-GM-CSFR&#x3b1;, antibody comprises: a heavy chain variable domain (V<sub>H</sub>) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising X<sub>1</sub>LX<sub>2</sub>X<sub>3</sub>H (SEQ ID NO: 76), wherein X<sub>1 </sub>is E, N, G, D, M, S, P, F, Y, A, V, K, W, R or C, X<sub>2 </sub>is S, C or P, and X<sub>3 </sub>is I or M; an HC-CDR2 comprising GFDX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>EX<sub>5</sub>X<sub>6</sub>YAQKX<sub>7</sub>QG (SEQ ID NO: 77), wherein X<sub>1 </sub>is P, G, T, S, or V, X<sub>2 </sub>is E, D, G, or A, X<sub>3 </sub>is D, G, W, S, or V, X<sub>4 </sub>is G, E, D, or H, X<sub>5 </sub>is T or A, X<sub>6 </sub>is N or I and X<sub>7 </sub>is S or F; and an HC-CDR3 comprising GRYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>YGFDY (SEQ ID NO: 78), wherein X<sub>1 </sub>is C, T, S, I, A, or V, X<sub>2 </sub>is S, G, E, F, W, H, I, V, N, Y, T, or R, X<sub>3 </sub>is T, H, L, F, P, I, S, Y, K, A, D, V, N, or G, X<sub>4 </sub>is D, A, M, Y, F, S, T, G, or W, X<sub>5 </sub>is T, S, F, Q, A, N, L, E, I, G, or M, and X<sub>6 </sub>is C, T, N, S, or A; and a light chain variable domain (V<sub>L</sub>) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RAX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>VX<sub>4</sub>X<sub>5</sub>X<sub>6</sub>LA (SEQ ID NO: 293), wherein X<sub>1 </sub>is S, L, N, A, K, R, I, Q, G, T, H, M, or C, X<sub>2 </sub>is Q, Y, P, A, I, F, T, R, V, L, E, S, or C, X<sub>3 </sub>is S, H, W, L, R, K, T, P, I, F, V, E, A, or Q, X<sub>4 </sub>is S, L, W, M, A, Y, K, R, G, T, E, V, N, F, or C, X<sub>5 </sub>is S, T, R, A, H, Q, P, M, L, or G, and X<sub>6 </sub>is Y, L, or F; a LC-CDR2 comprising X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>SRAT (SEQ ID NO: 294), wherein X<sub>1 </sub>is G or T, X<sub>2 </sub>is A, G, R, H, K, S, T, M, or F, and X<sub>3 </sub>is S, A, W, R, L, T, Q, F, Y, H, or N; and a LC-CDR3 comprising QQYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>PX<sub>4</sub>T (SEQ ID NO: 79), wherein X<sub>1 </sub>is N, D, S, R, A, T, L, Y, Q, W or G, X<sub>2 </sub>is N, D, E, T, Y, G, A, M, F, S, I or L, X<sub>3 </sub>is W, S, P, V, G, or R, and X<sub>4 </sub>is P, Y, H, S, F, N, D, V, or G. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises: a V<sub>H </sub>comprising a HC-CDR1 comprising ELX<sub>1</sub>X<sub>2</sub>H (SEQ ID NO: 295), wherein X<sub>1 </sub>is S, C or P, and X<sub>2 </sub>is I or M; an HC-CDR2 comprising GFDX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>EX<sub>5</sub>X<sub>6</sub>YAQKX<sub>7</sub>QG (SEQ ID NO: 77), wherein X<sub>1 </sub>is P, G, T, S, or V, X<sub>2 </sub>is E, D, C or A, X<sub>3 </sub>is D, G, I, W, S, or V, X<sub>4 </sub>is G, E, D, or I, X<sub>5 </sub>is T or A, X<sub>6 </sub>is N or I, and X<sub>7 </sub>is S or F; and an HC-CDR3 comprising GRYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>YGFDY (SEQ ID NO: 78), wherein X<sub>1 </sub>is C, T, S, I, A, or V, X<sub>2 </sub>is S, G, E, F, W, H, I, V, N, Y, T, or R, X<sub>3 </sub>is T, H, L, F, P, I, S, Y, K, A D, V, N, or G, X<sub>4 </sub>is D, A, M, Y, F, S, T, G, or W, X<sub>5 </sub>is T, S, F, Q, A, N, L, E, I, G, or M, and X<sub>6 </sub>is C, T, N, S, or A; and a V<sub>L </sub>comprising a LC-CDR1 comprising RASQSVSSYLA (SEQ ID NO: 51); a LC-CDR2 comprising GASSRAT (SEQ ID NO: 52); and a LC-CDR3 comprising QQYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>PX<sub>4</sub>T (SEQ ID NO: 79), wherein X<sub>1 </sub>is N, D, S, R, A, T, L, Y, Q, W or G, X<sub>2 </sub>is N, D, E, T, Y, C A, M, F, S, I or L, X<sub>3 </sub>is W, S, P, V, G, or R, and X<sub>4 </sub>is P, Y, H, S, F, N, D, V, or G.</p><p id="p-0009" num="0008">In some embodiments, there is provided an isolated anti-GM-CSFR&#x3b1; antibody comprises: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, or a variant thereof comprising up to about 3 amino acid substitutions; an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, or a variant thereof comprising up to about 3 amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50, or a variant thereof comprising up to about 3 amino acid substitutions; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, or a variant thereof comprising up to about 3 amino acid substitutions; a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, or a variant thereof comprising up to about 3 amino acid substitutions; and a LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75, or a variant thereof comprising up to about 3 amino acid substitutions.</p><p id="p-0010" num="0009">In some embodiments, there is provided an isolated anti-GM-CSFR&#x3b1; antibody comprising a V<sub>H </sub>comprising an HC-CDR1, an HC-CDR2, and an HC-CDR3 of a V<sub>H </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 80-121; and a V<sub>L </sub>comprising a LC-CDR1, a LC-CDR2, and a LC-CDR3 of a V<sub>L </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 122-144.</p><p id="p-0011" num="0010">In some embodiments, there is provided an isolated anti-GM-CSFR&#x3b1; antibody comprises: (i) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs; (ii) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs; (iii) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 23, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs; (iv) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs; (v) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 53, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs; (vi) a V<sub>H</sub>n comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs; (vii) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>1 </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs; (viii) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs; (ix) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0012" num="0011">In some embodiments according to any one of the isolated anti-GM-CSFR&#x3b1; antibodies described above, the isolated anti-GM-CSFR&#x3b1; antibody comprises amino acid residues: (i) E, H, N, G, D, M, S, P, F, Y, A, V, K, W, R, or C at position 31 of the V<sub>H</sub>; and/or (ii) S, L, N, A, K, R, I, Q, G, T, H, M, or C at position 26 of the V<sub>L</sub>; and/or (iii) Q, Y, P, A, I, F, T, R, V, L, E, S, or C at position 27 of the V<sub>L</sub>; and/or (iv) S, H, W, L, R, K, T, P, I, F, V, E, A, or Q at position 28 of the V<sub>L</sub>; and/or (v) S, L, W, M, A, Y, K, R, G, T, E, V, N, F, or C at position 30 of the V<sub>L</sub>; and/or (vi) S, T, R, A, H, Q, P, M, L, or G at position 31 of the V<sub>L</sub>; and/or (vii) Y, L or F at position 32 of the V<sub>L</sub>; and/or (viii) G, or T at position 50 of the V<sub>L</sub>; and/or (ix) A, G, R, H, K, S, T, M, F, N, or V at position 51 of the V<sub>L</sub>; and/or (x) S, A, W, R, L, T, Q, F, Y, H, or N at position 52 of the V<sub>L</sub>; and/or (xi) D, A, Q, or W at position 92 of the V<sub>L</sub>; and/or (xii) N, D, E, T, Y, G, A, M, F, S, I, or L at position 93 of the V<sub>L</sub>; and/or (xiii) amino acid residues selected from T, H, V, E, P, L, M, S, W, C, A, G, N, or K at position 28 of the V<sub>H</sub>; and/or (xiv) amino acid residues selected from T, P, D, E, Y, W, V, M, N, L, Q, G, S, A, K, or R at position 30 of the V<sub>H</sub>, wherein the numbering is according to the EU index of Kabat.</p><p id="p-0013" num="0012">In some embodiments, according to any one of the isolated anti-GM-CSFR&#x3b1; antibodies described above, the isolated anti-GM-CSFR&#x3b1; antibody comprises: a V<sub>H </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 80-121 and 246-287, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287; and a V<sub>L </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289. In some embodiments, the isolated anti-GM-CSFR&#x3b1; antibody comprises: (i) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 80; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123; (ii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 85; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 125; (iii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 86; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126; (iv) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 91; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126; (v) a V<sub>H </sub>composing the amino acid sequence of SEQ ID NO: 99; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 122; (vi) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 101; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126; (vii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 103; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123; (viii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 99; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126; (ix) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 121; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126; (x) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 241; (xi) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 193; (xii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 248; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 188; (xiii) a V<sub>1 </sub>comprising the amino acid sequence of SEQ ID NO: 248; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 193; (xiv) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 288; (xv) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 188; (xvi) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250; and a V<sub>1</sub>, comprising the amino acid sequence of SEQ ID NO: 236; or (xvii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 91; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 288.</p><p id="p-0014" num="0013">In some embodiments, there is provided an isolated anti-GM-CSFR&#x3b1; antibody that specifically binds to GM-CSFR&#x3b1; competitively with any one of the isolated anti-GM-CSFR&#x3b1; antibodies as described above. In some embodiments, there is provided an isolated anti-GM-CSFR&#x3b1; antibody that specifically binds to the same epitope as any one of isolated anti-GM-CSFR&#x3b1; antibodies as described above.</p><p id="p-0015" num="0014">In some embodiments according to any of the isolated anti-GM-CSFR&#x3b1; antibodies described above, the isolated anti-GM-CSFR&#x3b1; antibody comprises an Fe fragment. In some embodiments, the isolated anti-GM-CSFR&#x3b1; antibody is a full-length IgG antibody. In some embodiments, the isolated anti-GM-CSFR&#x3b1; antibody is a full-length IgG1 or IgG4 antibody. In some embodiments, the anti-GM-CSFR&#x3b1; antibody is chimeric, human, or humanized. In some embodiments, the anti-GM-CSFR&#x3b1; antibody is an antigen binding fragment selected from the group consisting of a Fab, a Fab&#x2032;, a F(ab)&#x2032;2, a Fab&#x2032;-SH, a single-chain Fv (scFv), an Fv fragment, a dAb, a Fd, a nanobody, a diabody, and a linear antibody.</p><p id="p-0016" num="0015">In some embodiments, there is provided isolated nucleic acid molecule(s) that encodes any one of the anti-GM-CSFR&#x3b1; antibodies described above. In some embodiments, there is provided a vector comprising a nucleic acid molecule according to any one of the nucleic acid molecules described above. In some embodiments, there is provided a host cell comprising any one of the anti-GM-CSFR&#x3b1; antibodies described above, any one of the nucleic acid molecules described above, or any one of the vectors described above. In some embodiments, there is provided a method of producing an anti-GM-CSFR&#x3b1; antibody, comprising: a) culturing any one of the host cells described above under conditions effective to express the anti-GM-CSFR&#x3b1; antibody; and b) obtaining the expressed anti-GM-CSFR&#x3b1; antibody from the host cell.</p><p id="p-0017" num="0016">In some embodiments, there is provided a method of treating a disease or condition in an individual in need thereof, comprising administering to the individual an effective amount of an anti-GM-CSFR&#x3b1; antibody according to any one of the anti-GM-CSFR&#x3b1; antibodies described above. In some embodiments, the disease or condition is an inflammatory, respiratory or autoimmune disease or condition. In some embodiments, the disease or condition is selected from the group consisting of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergic response, multiple sclerosis, myeloid leukemia, atherosclerosis.</p><p id="p-0018" num="0017">Also provided are pharmaceutical compositions, kits and articles of manufacture comprising any one of the anti-GM-CSFR&#x3b1; antibodies described above.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0006" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0019" num="0018"><figref idref="DRAWINGS">FIGS. <b>1</b>A-<b>1</b>C</figref> show the binding affinity of exemplary anti-GM-CSFR&#x3b1; antibodies to human GM-CSFR&#x3b1; as analyzed by ELISA. <figref idref="DRAWINGS">FIG. <b>1</b>A</figref> shows the binding curves of T119, E9, E16, E27, E29, E30, E35, E36, E54 and E34 to human GM-CSFR&#x3b1;. <figref idref="DRAWINGS">FIG. <b>1</b>B</figref> shows the binding curves of T119, E108, E105, E113, E87, E85, E39, E40, EII55, E200a, and EII8 to human GM-CSFR&#x3b1;. <figref idref="DRAWINGS">FIG. <b>1</b>C</figref> shows the binding curves of T119, E61, E83, E88, E90, E84, E172, E164, E1 and E31 to human GM-CSFR&#x3b1;.</p><p id="p-0020" num="0019"><figref idref="DRAWINGS">FIG. <b>2</b></figref> shows the binding affinity of E35, E200a, T119, E87, and E108 for cynomolgus monkey GM-CSFR&#x3b1; as analyzed by ELISA.</p><p id="p-0021" num="0020"><figref idref="DRAWINGS">FIG. <b>3</b></figref> shows the binding affinity of E35, E87, and E108 for IL3RA, IL5RA, and G-CSFR as compared to GM-CSFR&#x3b1;.</p><p id="p-0022" num="0021"><figref idref="DRAWINGS">FIG. <b>4</b></figref> shows the binding affinity of E35-IgG4 to WIL2S cells expressing GM-CSFR&#x3b1; as compared to control WIL2S cells that do not express GM-CSFR&#x3b1;, as analyzed by FACS.</p><p id="p-0023" num="0022"><figref idref="DRAWINGS">FIGS. <b>5</b>A-<b>5</b>D</figref> show results of the competitive binding assay for the ability of the parental antibody T119 and lead-optimized antibodies to compete with GM-CSF for binding to GM-CSFR&#x3b1;, as measured using competitive ELISA. <figref idref="DRAWINGS">FIG. <b>5</b>A</figref> shows results of the competitive binding assay for T119, E01, E09, E194, E27, E29, E34, E35, E40, and E30. <figref idref="DRAWINGS">FIG. <b>5</b>B</figref> shows results of the competitive binding assay for T119, E83, E87, EII81, E85, E54, EII55, E31, E105, and E84. <figref idref="DRAWINGS">FIG. <b>5</b>C</figref> shows results of the competitive binding assay for T119, E164, E172, E108, E16, E36, E61, E88, and E39. <figref idref="DRAWINGS">FIG. <b>5</b>D</figref> shows results of the competitive binding assay for T119, E90, EII33, E200a, E94, E113, and EII52.</p><p id="p-0024" num="0023"><figref idref="DRAWINGS">FIGS. <b>6</b>A and <b>6</b>B</figref> show the thermal melting profiles and the thermal aggregation profiles of the anti-GM-CSFR&#x3b1; antibodies Mab-IgG1, T119-IgG1, E35-IgG1 and E35b-IgG1 as analyzed by UNcle. <figref idref="DRAWINGS">FIG. <b>6</b>A</figref> shows the thermal melting profiles of the antibodies. <figref idref="DRAWINGS">FIG. <b>6</b>B</figref> shows the thermal aggregation profiles of the antibodies.</p><p id="p-0025" num="0024"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows results of the TF-1 proliferation assay for the parental antibody T119 and lead-optimized antibodies.</p><p id="p-0026" num="0025"><figref idref="DRAWINGS">FIG. <b>8</b></figref> shows results of the human granulocyte shape change assay for E35, E108 and E87b.</p><p id="p-0027" num="0026"><figref idref="DRAWINGS">FIG. <b>9</b></figref> shows results of the cynomolgus monkey granulocyte shape change assay for E35.</p><p id="p-0028" num="0027"><figref idref="DRAWINGS">FIG. <b>10</b></figref> shows results of the granulocyte survival assay for E35, E108, and E87b.</p><p id="p-0029" num="0028"><figref idref="DRAWINGS">FIG. <b>11</b></figref> shows results of the CD11b expression assay for E35 and E87b as compared to Mab.</p><p id="p-0030" num="0029"><figref idref="DRAWINGS">FIGS. <b>12</b>A and <b>12</b>B</figref> show results of the TNF&#x3b1; release assays for E35 and E87b as compared to Mab. <figref idref="DRAWINGS">FIG. <b>12</b>A</figref> shows results of the TNF&#x3b1; release assay for E35 and E87b as compared to Mab, as measured by the Human Macrophage/Microglia Panel. <figref idref="DRAWINGS">FIG. <b>12</b>B</figref> shows results of the TNF&#x3b1; release assay for E35 and E87b as compared to Mab, as measured by ELISA.</p><p id="p-0031" num="0030"><figref idref="DRAWINGS">FIG. <b>13</b></figref> shows results of the IL-1p production assay for E35 and E87b as compared to Mab.</p><p id="p-0032" num="0031"><figref idref="DRAWINGS">FIGS. <b>14</b>A and <b>14</b>B</figref> show results of pharmacokinetics analysis of Mab and E35 in rat as measured by ELISA. <figref idref="DRAWINGS">FIG. <b>14</b>A</figref> shows antibody serum concentrations of Mab and E35 upon intravenous injection of 2 mg/kg of the respective antibodies. <figref idref="DRAWINGS">FIG. <b>14</b>B</figref> shows pharmacokinetics of Mab and E35 upon intravenous injection of 20 mg/kg of the respective antibodies.</p><p id="p-0033" num="0032"><figref idref="DRAWINGS">FIG. <b>15</b></figref> shows results of pharmacokinetics analysis of Mab and E35 in cynomolgus monkey as measured by ELISA.</p><p id="p-0034" num="0033"><figref idref="DRAWINGS">FIGS. <b>16</b>A-D</figref> show FACS plots of in vivo granulocyte shape change analysis upon administration of Mab-IgG4 or E35-IgG4 in cynomolgus monkey. <figref idref="DRAWINGS">FIG. <b>16</b>A</figref> shows FACS plots of granulocytes prior to antibody administration. <figref idref="DRAWINGS">FIG. <b>16</b>B</figref> shows FACS plots of granulocytes 14 days after antibody administration. <figref idref="DRAWINGS">FIG. <b>16</b>C</figref> shows FACS plots of granulocytes 21 days after antibody administration. <figref idref="DRAWINGS">FIG. <b>16</b>D</figref> shows results of the in vivo granulocyte shape change analysis from prior to antibody administration up to 21 days following antibody administration.</p><p id="p-0035" num="0034"><figref idref="DRAWINGS">FIGS. <b>17</b>A-<b>17</b>G</figref> show results of the inhibitory effect of E35-IgG4 on GM-CSF-induced increase in inflammatory cells. <figref idref="DRAWINGS">FIG. <b>17</b>A</figref> shows results of the inhibitory effect of E35-IgG4 on GM-CSF-induced increase in white blood cells. <figref idref="DRAWINGS">FIG. <b>17</b>B</figref> shows results of the inhibitory effect of E35-IgG4 on GM-CSF-induced increase in neutrophils. <figref idref="DRAWINGS">FIG. <b>17</b>C</figref> shows results of the inhibitory effect of E35-IgG4 on GM-CSF-induced increase in lymphocytes. <figref idref="DRAWINGS">FIG. <b>17</b>D</figref> shows results of the inhibitory effect of E35-IgG4 on GM-CSF-induced increase in basophils. <figref idref="DRAWINGS">FIG. <b>17</b>E</figref> shows results of the inhibitory effect of E35-IgG4 on GM-CSF-induced increase in eosinophils.</p><p id="p-0036" num="0035"><figref idref="DRAWINGS">FIG. <b>17</b>F</figref> shows results of the inhibitory effect of E35-IgG4 on GM-CSF-induced increase in monocytes. <figref idref="DRAWINGS">FIG. <b>17</b>G</figref> shows results of the inhibitory effect of E35-IgG4 on GM-CSF-induced increase in red blood cells.</p><p id="p-0037" num="0036"><figref idref="DRAWINGS">FIGS. <b>18</b>A-<b>18</b>C</figref> show the binding affinity of E35-IgG4, E87b-IgG4 and T119-IgG4 for wild type GMRah and GMRah with mutations at exemplary amino acid residues as measured by ELISA. <figref idref="DRAWINGS">FIG. <b>18</b>A</figref> shows the binding affinity of E35-IgG4 for wild type GMRah and mutated GMRah. <figref idref="DRAWINGS">FIG. <b>18</b>B</figref> shows the binding affinity of E87b-IgG4 for wild type GMRah and mutated GMRah. <figref idref="DRAWINGS">FIG. <b>18</b>C</figref> shows the binding affinity of T119-IgG4 for wild type GMRah and mutated GMRah.</p><p id="p-0038" num="0037"><figref idref="DRAWINGS">FIGS. <b>19</b>A-<b>19</b>B</figref> show the sequence alignments of the variable domain sequences of the anti-GM-CSFR&#x3b1; antibodies. The complementarity determining regions are denoted. <figref idref="DRAWINGS">FIG. <b>19</b>A</figref> shows the sequence alignments of the heavy chain variable domain sequences. <figref idref="DRAWINGS">FIG. <b>19</b>B</figref> shows the sequence alignments of the light chain variable domain sequences.</p><p id="p-0039" num="0038"><figref idref="DRAWINGS">FIG. <b>20</b></figref> shows the numbering of amino acid residues 16-296 in GM-CSFR&#x3b1;.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0007" level="1">DETAILED DESCRIPTION OF THE APPLICATION</heading><p id="p-0040" num="0039">The present application in one aspect provides anti-GM-CSFR&#x3b1; antibodies. By using a combination of selections on na&#xef;ve scFv phage libraries, affinity maturation and appropriately designed biochemical and biological assays, we have identified highly potent antibody molecules that bind to human GM-CSFR&#x3b1; and inhibit the action of human GM-CSF at its receptor. The results presented herein indicate that our antibodies bind a different region or epitope of GM-CSFR&#x3b1; compared with the known anti-GM-CSFR&#x3b1; antibody Mavrilimumab, and surprisingly are even more potent than Mavrilimumab as demonstrated in a variety of biological assays.</p><p id="p-0041" num="0040">The anti-GM-CSFR&#x3b1; antibodies provided by the present application include, for example, full-length anti-GM-CSFR&#x3b1; antibodies, anti-GM-CSFR&#x3b1; scFvs, anti-GM-CSFR&#x3b1; Fe fusion proteins, multi-specific (such as bispecific) anti-GM-CSFR&#x3b1; antibodies, anti-GM-CSFR&#x3b1; immunoconjugates, and the like.</p><p id="p-0042" num="0041">In one aspect, there are provided anti-GM-CSFR&#x3b1; antibodies that specifically bind to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises amino acid residues Val50, Glu59, Lys194, Lys195, Arg283, and Ile284 of human GM-CSFR&#x3b1;.</p><p id="p-0043" num="0042">In another aspect, there is provided an anti-GM-CSFR&#x3b1; antibody, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain (V<sub>H</sub>) comprising a heavy chain variable domain (V<sub>H</sub>) comprising an HC-CDR1 comprising X<sub>1</sub>LX<sub>2</sub>X<sub>3</sub>H (SEQ ID NO: 76), wherein X<sub>1 </sub>is E, N, G, D, M, S, P, F, Y, A, V, K, W, R or C, X<sub>2 </sub>is S, C or P, and X<sub>3 </sub>is I or M; an HC-CDR2 comprising GFDX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>EX<sub>5</sub>X<sub>6</sub>YAQKX<sub>7</sub>QG (SEQ ID NO: 77), wherein X<sub>1 </sub>is P, G, T, S, or V, X<sub>2 </sub>is E, D, G, or A, X<sub>3 </sub>is D, G, I, W, S, or V, X<sub>4 </sub>is G, E, D, or H, X<sub>5 </sub>is T or A, X<sub>6 </sub>is N or I, and X<sub>7 </sub>is S or F; and an HC-CDR3 comprising GRYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>YGFDY (SEQ ID NO: 78), wherein X<sub>1 </sub>is C, T, T, I, A, or V, X<sub>2 </sub>is S, G, E, F, W, H, I, V, N, Y, T, or R, X<sub>3 </sub>is T, H, L, F, P, I, S, Y, K, A, D, V, N, or G, X<sub>4 </sub>is D, A, M, Y, F, S, T, G, or W, X<sub>5 </sub>is T, S, F, Q, A, N, L, E, I, G, or M, and X<sub>6 </sub>is C, T, N, S, or A; and a light chain variable domain (V<sub>L</sub>) comprising a LC-CDR1 comprising RAX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>VX<sub>4</sub>X<sub>5</sub>X<sub>6</sub>LA (SEQ ID NO: 293), wherein X<sub>1 </sub>is S, L, N, A, K, R, I, Q, G, T, H, M, or C, X<sub>2 </sub>is Q, Y, P, A, I, F, T, R, V, L, E, S, or C, X<sub>3 </sub>is S, H, W, L, R, K, T, P, I, F, V, E, A, or Q, X<sub>4 </sub>is S, L, W, M, A, Y, K, R, G, T, E, V, N F, or C, X<sub>5 </sub>is S, T, R A, H, Q, P, M, L, or G, and X<sub>6 </sub>is Y, L, or F; a LC-CDR2 comprising X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>SRAT (SEQ ID NO: 294), wherein X<sub>1 </sub>is G or T, X<sub>2 </sub>is A, G, R, H, K, S, T, M, or F, and X<sub>3 </sub>is S, A, W, R, L, T, Q, F, Y, H, or N; and a LC-CDR3 comprising QQYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>PX<sub>4</sub>T (SEQ ID NO: 79), wherein X<sub>1 </sub>is N, D, S, R, A, T, L, Y, Q, W or G X<sub>2 </sub>is N, D, E, T, Y, G, A, M, F, S, I or L, X<sub>3 </sub>is W, S, P, V, G, or R, and X<sub>4 </sub>is P, Y, H, S, F, N, D, V, or G.</p><p id="p-0044" num="0043">Also provided are nucleic acids encoding the anti-GM-CSFR&#x3b1; antibodies, compositions comprising the anti-GM-CSFR&#x3b1; antibodies, and methods of making and using the anti-GM-CSFR&#x3b1; antibodies.</p><heading id="h-0008" level="1">Definitions</heading><p id="p-0045" num="0044">As used herein, &#x201c;treatment&#x201d; or &#x201c;treating&#x201d; is an approach for obtaining beneficial or desired results, including clinical results. For purposes of this application, beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviating one or more symptoms resulting from the disease, diminishing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the worsening of the disease), preventing or delaying the spread (e.g., metastasis) of the disease, preventing or delaying the recurrence of the disease, delay or slowing the progression of the disease, ameliorating the disease state, providing a remission (partial or total) of the disease, decreasing the dose of one or more other medications required to treat the disease, delaying the progression of the disease, increasing or improving the quality of life, increasing weight gain, and/or prolonging survival. Also encompassed by &#x201c;treatment&#x201d; is a reduction of pathological consequence of the disease (such as, for example, tumor volume for cancer). The methods of the application contemplate any one or more of these aspects of treatment.</p><p id="p-0046" num="0045">The term &#x201c;antibody&#x201d; includes full-length antibodies and antigen-binding fragments thereof. A full-length antibody comprises two heavy chains and two light chains. The variable regions of the light and heavy chains are responsible for antigen binding. The variable regions in both chains generally contain three highly variable loops called the complementarity determining regions (CDRs) (light chain (LC) CDRs including LC-CDR1, LC-CDR2, and LC-CDR3, heavy chain (HC) CDRs including HC-CDR1, HC-CDR2, and HC-CDR3). CDR boundaries for the antibodies and antigen-binding fragments disclosed herein may be defined or identified by the conventions of Kabat, Chothia, or Al-Lazikani (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). The three CDRs of the heavy or light chains are interposed between flanking stretches known as framework regions (FRs), which are more highly conserved than the CDRs and form a scaffold to support the hypervariable loops. The constant regions of the heavy and light chains are not involved in antigen binding, but exhibit various effector functions. Antibodies are assigned to classes based on the amino acid sequence of the constant region of their heavy chain. The five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, which are characterized by the presence of &#x3b1;, &#x3b4;, &#x3b5;, &#x3b3;, and &#x3bc; heavy chains, respectively. Several of the major antibody classes are divided into subclasses such as IgG1 (&#x3b3;1 heavy chain), IgG2 (&#x3b3;2 heavy chain), IgG3 (&#x3b3;3 heavy chain), IgG4 (&#x3b3;4 heavy chain), IgA1 (&#x3b1;1 heavy chain), or IgA2 (&#x3b1;2 heavy chain).</p><p id="p-0047" num="0046">The term &#x201c;antigen-binding fragment&#x201d; as used herein refers to an antibody fragment including, for example, a diabody, a Fab, a Fab&#x2032;, a F(ab&#x2032;)<sub>2</sub>, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)<sub>2</sub>, a bispecific dsFv (dsFv-dsFv&#x2032;), a disulfide stabilized diabody (ds diabody), a single-chain Fv (scFv), an scFv diner (bivalent diabody), a multispecific antibody formed from a portion of an antibody comprising one or more CDRs, a single domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not comprise a complete antibody structure. An antigen-binding fragment is capable of binding to the same antigen to which the parent antibody or a parent antibody fragment (e.g., a parent scFv) binds. In some embodiments, an antigen-binding fragment may comprise one or more CDRs from a particular human antibody grafted to a framework region from one or more different human antibodies.</p><p id="p-0048" num="0047">The term &#x201c;epitope&#x201d; as used herein refers to the specific group of atoms or amino acids on an antigen to which an antibody or antibody moiety binds. Two antibodies or antibody moieties may bind the same epitope within an antigen if they exhibit competitive binding for the antigen.</p><p id="p-0049" num="0048">As used herein, a first antibody &#x201c;competes&#x201d; for binding to a target GM-CSFR&#x3b1; with a second antibody when the first antibody inhibits target GM-CSFR&#x3b1; binding of the second antibody by at least about 50% (such as at least about any of 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) in the presence of an equimolar concentration of the first antibody, or vice versa. A high throughput process for &#x201c;binning&#x201d; antibodies based upon their cross-competition is described in PCT Publication No. WO 03/48731.</p><p id="p-0050" num="0049">As use herein, the term &#x201c;specifically binds,&#x201d; &#x201c;specifically recognizing,&#x201d; or &#x201c;is specific for&#x201d; refers to measurable and reproducible interactions, such as binding between a target and an antibody that is determinative of the presence of the target in the presence of a heterogeneous population of molecules, including biological molecules. For example, an antibody that specifically recognizes a target (which can be an epitope) is an antibody that binds this target with greater affinity, avidity, more readily, and/or with greater duration than its bindings to other targets. In some embodiments, an antibody that specifically recognizes an antigen reacts with one or more antigenic determinants of the antigen with a binding affinity that is at least about 10 times its binding affinity for other targets.</p><p id="p-0051" num="0050">An &#x201c;isolated&#x201d; anti-GM-CSFR&#x3b1; antibody as used herein refers to an anti-GM-CSFR&#x3b1; antibody that (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, (3) is expressed by a cell from a different species, or, (4) does not occur in nature.</p><p id="p-0052" num="0051">The term &#x201c;isolated nucleic acid&#x201d; as used herein is intended to mean a nucleic acid of genomic, cDNA, or synthetic origin or some combination thereof, which by virtue of its origin the &#x201c;isolated nucleic acid&#x201d; (1) is not associated with all or a portion of a polynucleotide in which the &#x201c;isolated nucleic acid&#x201d; is found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence.</p><p id="p-0053" num="0052">As used herein, the term &#x201c;CDR&#x201d; or &#x201c;complementarity determining region&#x201d; is intended to mean the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. These particular regions have been described by Kabat et al., J. Biol. Chem. 252:6609-6616 (1977); Kabat et al., U.S. Dept. of Health and Human Services, &#x201c;Sequences of proteins of immunological interest&#x201d; (1991); Chothia et al., J. Mol. Biol. 196:901-917 (1987); Al-Lazikani B. el al., <i>J. Mol. Biol., </i>273: 927-948 (1997); MacCallum et al., J. Mol. Biol. 262:732-745 (1996); Abhinandan and Martin, <i>Mol. Immunol., </i>45: 3832-3839 (2008); Lefranc M. P. el al., <i>Dev. Comp. Immunol., </i>27: 55-77 (2003); and Honegger and Ph&#xfc;ckthun, <i>J. Mol. Biol., </i>309:657-670 (2001), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or grafted antibodies or variants thereof is intended to be within the scope of the term as defined and used herein. The amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth below in Table 1 as a comparison. CDR prediction algorithms and interfaces are known in the art, including, for example, Abhinandan and Martin, <i>Mol. Immunol., </i>45: 3832-3839 (2008); Ehrenmann F. et al., <i>Nucleic Acids Res., </i>38: D301-D307 (2010); and Adolf-Bryfogle J. et al., <i>Nucleic Acids Res., </i>43: D432-D438 (2015). The contents of the references cited in this paragraph are incorporated herein by reference in their entireties for use in the present application and for possible inclusion in one or more claims herein.</p><p id="p-0054" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>CDR DEFINITIONS</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><colspec colname="5" colwidth="28pt" align="left"/><colspec colname="6" colwidth="28pt" align="left"/><tbody valign="top"><row><entry/><entry>Kabat<sup>1</sup></entry><entry>Chothia<sup>2</sup></entry><entry>MacCallum<sup>3</sup></entry><entry>IMGT<sup>4</sup></entry><entry>AHo<sup>5</sup></entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>V<sub>H </sub>CDR1</entry><entry>31-35</entry><entry>26-32</entry><entry>30-35</entry><entry>&#x2002;27-38</entry><entry>&#x2002;25-40</entry></row><row><entry>V<sub>H </sub>CDR2</entry><entry>50-65</entry><entry>53-55</entry><entry>47-58</entry><entry>&#x2002;56-65</entry><entry>&#x2002;58-77</entry></row><row><entry>V<sub>H </sub>CDR3</entry><entry>95-102</entry><entry>96-101</entry><entry>93-101</entry><entry>105-117</entry><entry>109-137</entry></row><row><entry>V<sub>L </sub>CDR1</entry><entry>24-34</entry><entry>26-32</entry><entry>30-36</entry><entry>&#x2002;27-38</entry><entry>&#x2002;25-40</entry></row><row><entry>V<sub>L </sub>CDR2</entry><entry>50-56</entry><entry>50-52</entry><entry>46-55</entry><entry>&#x2002;56-65</entry><entry>&#x2002;58-77</entry></row><row><entry>V<sub>L </sub>CDR3</entry><entry>89-97</entry><entry>91-96</entry><entry>89-96</entry><entry>105-117</entry><entry>109-137</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry namest="1" nameend="6" align="left" id="FOO-00001"><sup>1</sup>Residue numbering follows the nomenclature of Kabat et al., supra</entry></row><row><entry namest="1" nameend="6" align="left" id="FOO-00002"><sup>2</sup>Residue numbering follows the nomenclature of Chothia et al., supra</entry></row><row><entry namest="1" nameend="6" align="left" id="FOO-00003"><sup>3</sup>Residue numbering follows the nomenclature of MacCallum et al., supra</entry></row><row><entry namest="1" nameend="6" align="left" id="FOO-00004"><sup>4</sup>Residue numbering follows the nomenclature of Lefranc et al., supra</entry></row><row><entry namest="1" nameend="6" align="left" id="FOO-00005"><sup>5</sup>Residue numbering follows the nomenclature of Honegger and Pl&#xfc;ckthun, supra</entry></row></tbody></tgroup></table></tables></p><p id="p-0055" num="0053">The term &#x201c;chimeric antibodies&#x201d; refer to antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit a biological activity of this application (see U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).</p><p id="p-0056" num="0054">&#x201c;Fv&#x201d; is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This fragment consists of a diner of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (<b>3</b> loops each from the heavy and light chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.</p><p id="p-0057" num="0055">&#x201c;Single-chain Fv,&#x201d; also abbreviated as &#x201c;sFv&#x201d; or &#x201c;scFv,&#x201d; are antibody fragments that comprise the V<sub>H </sub>and V<sub>L </sub>antibody domains connected into a single polypeptide chain. In some embodiments, the scFv polypeptide further comprises a polypeptide linker between the V<sub>H </sub>and V<sub>L </sub>domains which enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun in <i>The Pharmacology of Monoclonal Antibodies</i>, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).</p><p id="p-0058" num="0056">The term &#x201c;diabodies&#x201d; refers to small antibody fragments prepared by constructing scFv fragments (see preceding paragraph) typically with short linkers (such as about 5 to about 10 residues) between the V<sub>H </sub>and V<sub>L </sub>domains such that inter-chain but not intra-chain pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites. Bispecific diabodies are heterodimers of two &#x201c;crossover&#x201d; scFv fragments in which the V<sub>H </sub>and V<sub>L </sub>domains of the two antibodies are present on different polypeptide chains. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., <i>Proc. Natl. Acad. Sci. USA, </i>90:6444-6448 (1993).</p><p id="p-0059" num="0057">&#x201c;Humanized&#x201d; forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region (HVR) of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired antibody specificity, affinity, and capability. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies can comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fe), typically that of a human immunoglobulin. For further details, see Jones et al., <i>Nature </i>321:522-525 (1986); Riechmann et al., <i>Nature </i>332:323-329 (1988); and Presta, <i>Curr. Op. Struct. Biol. </i>2:593-596 (1992).</p><p id="p-0060" num="0058">&#x201c;Percent (%) amino acid sequence identity&#x201d; or &#x201c;homology&#x201d; with respect to the polypeptide and antibody sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the polypeptide being compared, after aligning the sequences considering any conservative substitutions as pail of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), or MUSCLE software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program MUSCLE (Edgar, R. C., <i>Nucleic Acids Research </i>32(5):1792-1797, 2004; Edgar, R. C., <i>BMC Bioinformatics </i>5(1):113, 2004).</p><p id="p-0061" num="0059">The terms &#x201c;Fc receptor&#x201d; or &#x201c;FcR&#x201d; are used to describe a receptor that binds to the Fc region of an antibody. In some embodiments, an FcR of this application is one that binds an IgG antibody (a &#x3b3; receptor) and includes receptors of the F&#x3f5;yRI, Fc&#x3b3;RII, and Fc&#x3b3;RIII subclasses, including allelic variants and alternatively spliced forms of these receptors. Fc&#x3b3;RII receptors include Fc&#x3b3;RIIA (an &#x201c;activating receptor&#x201d;) and Fc&#x3b3;RIIB (an &#x201c;inhibiting receptor&#x201d;), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor Fc&#x3b3;RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor Fc&#x3b3;RIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (see review M. in Da&#xeb;ron, <i>Annu. Rev. Immunol. </i>15:203-234 (1997)). The term includes allotypes, such as Fc&#x3b3;RIIIA allotypes: Fc&#x3b3;RIIIA-Phe158, Fc&#x3b3;RIIIA-Val158, Fc&#x3b3;RIIA-R131 and/or Fc&#x3b3;RIIA-H131. FeRs are reviewed in Ravetch and Kinet, <i>Annu. Rev. Immunol </i>9:457-92 (1991); Capel et al., <i>Immunomethods </i>4:25-34 (1994); and de Haas et al., <i>J. Lab Clin. Med. </i>126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term &#x201c;FcR&#x201d; herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., <i>J. Immunol. </i>117:587 (1976) and Kim et al., <i>J. Immunol. </i>24:249 (1994)).</p><p id="p-0062" num="0060">The term &#x201c;FcRn&#x201d; refers to the neonatal Fc receptor (FcRn). FcRn is structurally similar to major histocompatibility complex (MHC) and consists of an &#x3b1;-chain noncovalently bound to &#x3b2;2-microglobulin. The multiple functions of the neonatal Fc receptor FcRn are reviewed in Ghetie and Ward (2000) Annu. Rev. Immunol. 18, 739-766. FcRn plays a role in the passive delivery of immunoglobulin IgGs from mother to young and the regulation of serum IgG levels. FcRn can act as a salvage receptor, binding and transporting pinocytosed IgGs in intact form both within and across cells, and rescuing them from a default degradative pathway.</p><p id="p-0063" num="0061">The &#x201c;CH1 domain&#x201d; of a human IgG Fc region (also referred to as &#x201c;C1&#x201d; of &#x201c;H1&#x201d; domain) usually extends from about amino acid 118 to about amino acid 215 (EU numbering system).</p><p id="p-0064" num="0062">&#x201c;Hinge region&#x201d; is generally defined as stretching from Glu216 to Pro230 of human IgG1 (Burton, <i>Molec. Immunol. </i>22:161-206 (1985)). Hinge regions of other IgG isotypes may be 515 aligned with the IgG1 sequence by placing the first and last cysteine residues forming inter-heavy chain S&#x2014;S bonds in the same positions.</p><p id="p-0065" num="0063">The &#x201c;CH2 domain&#x201d; of a human IgG Fc region (also referred to as &#x201c;C2&#x201d; of &#x201c;H2&#x201d; domain) usually extends from about amino acid 231 to about amino acid 340. The CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG molecule. It has been speculated that the carbohydrate may provide a substitute for the domain-domain pairing and help stabilize the CH2 domain. Burton, <i>Molec Immunol. </i>22:161-206 (1985).</p><p id="p-0066" num="0064">The &#x201c;CH3 domain&#x201d; (also referred to as &#x201c;C2&#x201d; or &#x201c;H3&#x201d; domain) comprises the stretch of residues C-terminal to a CH2 domain in an Fc region (i.e. from about amino acid residue 341 to the C-terminal end of an antibody sequence, typically at amino acid residue 446 or 447 of an IgG).</p><p id="p-0067" num="0065">A &#x201c;functional Fc fragment&#x201d; possesses an &#x201c;effector function&#x201d; of a native sequence Fe region. Exemplary &#x201c;effector functions&#x201d; include C1q binding; complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor, BCR), etc. Such effector functions generally require the Fc region to be combined with a binding domain (e.g. an antibody variable domain) and can be assessed using various assays known in the art.</p><p id="p-0068" num="0066">An antibody with a variant IgG Fc with &#x201c;altered&#x201d; FcR binding affinity or ADCC activity is one which has either enhanced or diminished FcR binding activity (e.g., Fc&#x3b3;R or FcRn) and/or ADCC activity compared to a parent polypeptide or to a polypeptide comprising a native sequence Fc region. The variant Fc which &#x201c;exhibits increased binding&#x201d; to an FcR binds at least one FcR with higher affinity (e.g., lower apparent K<sub>d </sub>or IC<sub>50 </sub>value) than the parent polypeptide or a native sequence IgG Fc. According to some embodiments, the improvement in binding compared to a parent polypeptide is about 3 fold, such as about any of 5, 10, 25, 50, 60, 100, 150, 200, or up to 500 fold, or about 25% to 1000% improvement in binding. The polypeptide variant which &#x201c;exhibits decreased binding&#x201d; to an FcR, binds at least one FcR with lower affinity (e.g., higher apparent K, or higher IC<sub>50 </sub>value) than a parent polypeptide. The decrease in binding compared to a parent polypeptide may be about 40% or more decrease in binding.</p><p id="p-0069" num="0067">&#x201c;Antibody-dependent cell-mediated cytotoxicity&#x201d; or &#x201c;ADCC&#x201d; refers to a form of cytotoxicity in which secreted Ig bound to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., Natural Killer (NK) cells, neutrophils, and macrophages) enable these cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins. The antibodies &#x201c;arm&#x201d; the cytotoxic cells and are required for such killing. The primary cells for mediating ADCC. NK cells, express Fc&#x3b3;RIII only, whereas monocytes express Fc&#x3b3;RI, Fc&#x3b3;RII and Fc&#x3b3;RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, <i>Annu. Rev. Immunol </i>9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in U.S. Pat. No. 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally. ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. <i>PNAS </i>(<i>USA</i>) 95:652-656 (1998).</p><p id="p-0070" num="0068">The polypeptide comprising a variant Fc region which &#x201c;exhibits increased ADCC&#x201d; or mediates ADCC in the presence of human effector cells more effectively than a polypeptide having wild type IgG Fc or a parent polypeptide is one which in vitro or in vivo is substantially more effective at mediating ADCC, when the amounts of polypeptide with variant Fc region and the polypeptide with wild type Fc region (or the parent polypeptide) in the assay are essentially the same. Generally, such variants will be identified using any in vitro ADCC assay known in the art, such as assays or methods for determining ADCC activity, e.g., in an animal model etc. In some embodiments, the variant is from about 5 fold to about 100 fold, e.g. from about 25 to about 50 fold, more effective at mediating ADCC than the wild type Fc (or parent polypeptide).</p><p id="p-0071" num="0069">&#x201c;Complement dependent cytotoxicity&#x201d; or &#x201c;CDC&#x201d; refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass) which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g. as described in Gazzano-Santoro et al., <i>J. Immunol. Methods </i>202:163 (1996), may be performed. Polypeptide variants with altered Fc region amino acid sequences and increased or decreased C1q binding capability are described in U.S. Pat. No. 6,194,551B1 and WO99/51642. The contents of those patent publications are specifically incorporated herein by reference. See also, Idusogie et al. <i>J. Immunol. </i>164: 4178-4184 (2000).</p><p id="p-0072" num="0070">Unless otherwise specified, a &#x201c;nucleotide sequence encoding an amino acid sequence&#x201d; includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase nucleotide sequence that encodes a protein or a RNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).</p><p id="p-0073" num="0071">The term &#x201c;operably linked&#x201d; refers to functional linkage between a regulatory sequence and a heterologous nucleic acid sequence resulting in expression of the latter. For example, a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame.</p><p id="p-0074" num="0072">&#x201c;Homologous&#x201d; refers to the sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules. When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared times 100. For example, if 6 of 10 of the positions in two sequences are matched or homologous then the two sequences are 60% homologous. By way of example, the DNA sequences ATTGCC and TATGGC share 50% homology. Generally, a comparison is made when two sequences are aligned to give maximum homology.</p><p id="p-0075" num="0073">An &#x201c;effective amount&#x201d; of an anti-GM-CSFR&#x3b1; antibody or composition as disclosed herein, is an amount sufficient to carry out a specifically stated purpose. An &#x201c;effective amount&#x201d; can be determined empirically and by known methods relating to the stated purpose.</p><p id="p-0076" num="0074">The term &#x201c;therapeutically effective amount&#x201d; refers to an amount of an anti-GM-CSFR&#x3b1; antibody or composition as disclosed herein, effective to &#x201c;treat&#x201d; a disease or disorder in an individual. In the case of cancer, the therapeutically effective amount of the anti-GM-CSFR&#x3b1; antibody or composition as disclosed herein can reduce the number of cancer cells; reduce the tumor size or weight; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the anti-GM-CSFR&#x3b1; antibody or composition as disclosed herein can prevent growth and/or kill existing cancer cells, it can be cytostatic and/or cytotoxic. In some embodiments, the therapeutically effective amount is a growth inhibitory amount. In some embodiments, the therapeutically effective amount is an amount that extends the survival of a patient. In some embodiments, the therapeutically effective amount is an amount that improves progression free survival of a patient.</p><p id="p-0077" num="0075">As used herein, by &#x201c;pharmaceutically acceptable&#x201d; or &#x201c;pharmacologically compatible&#x201d; is meant a material that is not biologically or otherwise undesirable. e.g., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. Pharmaceutically acceptable carriers or excipients have preferably met the required standards of toxicological and manufacturing testing and/or are included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.</p><p id="p-0078" num="0076">It is understood that embodiments of the application described herein include &#x201c;consisting&#x201d; and/or &#x201c;consisting essentially of&#x201d; embodiments.</p><p id="p-0079" num="0077">Reference to &#x201c;about&#x201d; a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to &#x201c;about X&#x201d; includes description of &#x201c;X&#x201d;.</p><p id="p-0080" num="0078">As used herein, reference to &#x201c;not&#x201d; a value or parameter generally means and describes &#x201c;other than&#x201d; a value or parameter. For example, the method is not used to treat cancer of type X means the method is used to treat cancer of types other than X.</p><p id="p-0081" num="0079">As used herein and in the appended claims, the singular forms &#x201c;a,&#x201d; &#x201c;an,&#x201d; and &#x201c;the&#x201d; include plural referents unless the context clearly dictates otherwise.</p><heading id="h-0009" level="2">Anti-GM-CSFR&#x3b1; Antibodies</heading><p id="p-0082" num="0080">In one aspect, the present application provides anti-GM-CSFR&#x3b1; antibodies that specifically bind to GM-CSFR&#x3b1;. Anti-GM-CSFR&#x3b1; antibodies include, but are not limited to, 635 humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibodies comprising the heavy chain and/or light chain CDRs discussed herein. In one aspect, the present application provides isolated antibodies that bind to GM-CSFR&#x3b1;. Contemplated anti-GM-CSFR&#x3b1; antibodies include, for example, full-length anti-GM-CSFR&#x3b1; antibodies (e.g., full-length IgG1 or IgG4), anti-GM-CSFR&#x3b1; scFvs, anti-GM-CSFR&#x3b1; Fc fusion proteins, multi-specific (such as 640 bispecific) anti-GM-CSFR&#x3b1; antibodies, anti-GM-CSFR&#x3b1; immunoconjugates, and the like. In some embodiments, the anti-GM-CSFR&#x3b1; antibody is a full-length antibody (e.g., full-length IgG1 or IgG4) or antigen-binding fragment thereof, which specifically binds to GM-CSFR&#x3b1;. In some embodiments, the anti-GM-CSFR&#x3b1; antibody is a Fab, a Fab&#x2032;, a F(ab)&#x2032;<sub>2</sub>, a Fab&#x2032;-SH, a single-chain Fv (scFv), an Fv fragment, a dAb, a Fd, a nanobody, a diabody, or a linear antibody. In some embodiments, reference to an antibody that specifically binds to GM-CSFR&#x3b1; means that the antibody binds to GM-CSFR&#x3b1; with an affinity that is at least about 10 times (including for example at least about any one of 10, 10<sup>2</sup>, 10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup>, 10<sup>6</sup>, or 10<sup>7 </sup>times) more tightly than its binding affinity for a non-target. In some embodiments, the non-target is an antigen that is not GM-CSFR&#x3b1;. Binding affinity can be determined by methods known in the art, such as ELISA, fluorescence activated cell sorting (FACS) analysis, or radioimmunoprecipitation assay (RIA). K<sub>d </sub>can be determined by methods known in the art, such as surface plasmon resonance (SPR) assay or biolayer interferometry (BLI).</p><p id="p-0083" num="0081">Although anti-GM-CSFR&#x3b1; antibodies containing human sequences (e.g., human heavy and light chain variable domain sequences comprising human CDR sequences) are extensively discussed herein, non-human anti-GM-CSFR&#x3b1; antibodies are also contemplated. In some embodiments, non-human anti-GM-CSFR&#x3b1; antibodies comprise human CDR sequences from an anti-GM-CSFR&#x3b1; antibody as described herein and non-human framework sequences. Non-human framework sequences include, in some embodiments, any sequence that can be used for generating synthetic heavy and/or light chain variable domains using one or more human CDR sequences as described herein, including, e.g., mammals, e.g., mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat, chicken, cat, dog, ferret, primate (e.g., marmoset, rhesus monkey), etc. In some embodiments, a non-human anti-GM-CSFR&#x3b1; antibody includes an anti-GM-CSFR&#x3b1; antibody generated by grafting one or more human CDR sequences as described herein onto a non-human framework sequence (e.g., a mouse or chicken framework sequence).</p><p id="p-0084" num="0082">The complete amino acid sequence of an exemplary human GM-CSFR&#x3b1; comprises or consists of the amino acid sequence of SEQ ID NO: 148.</p><p id="p-0085" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="28pt" align="char"/><colspec colname="2" colwidth="189pt" align="left"/><tbody valign="top"><row><entry>1</entry><entry>MLLLVTSLLL&#x2003;CELPHPAFLL&#x2003;IPEKSDLRTV&#x2003;APASSLNVRF</entry></row><row><entry> </entry></row><row><entry/><entry>DSRTMNLSWD&#x2003;CQENTTFSKC</entry></row><row><entry> </entry></row><row><entry>61</entry><entry>FLTDKKNRVV&#x2003;EPRLSNNECS&#x2003;CTFREICLHE&#x2003;GVTFEVHVNT</entry></row><row><entry> </entry></row><row><entry/><entry>SQRGFQQKLL&#x2003;YPNSGREGTA</entry></row><row><entry> </entry></row><row><entry>121</entry><entry>AQNFSCFIYN&#x2003;ADLMNCTWAR&#x2003;GPTAPRDVQY&#x2003;FLYIRNSKRR</entry></row><row><entry> </entry></row><row><entry/><entry>REIRCPYYIQ&#x2003;DSGTHVGCHL</entry></row><row><entry> </entry></row><row><entry>181</entry><entry>DNLSGLTSRN&#x2003;YFLVNGTSRE&#x2003;IGIQFFDSLL&#x2003;DTKKIERFNP</entry></row><row><entry> </entry></row><row><entry/><entry>PSNVTVRCNT&#x2003;THCLVRWKQP</entry></row><row><entry> </entry></row><row><entry>241</entry><entry>RTYQKLSYLD&#x2003;FQYQLDVHRK&#x2003;NTQPGTENLL&#x2003;INVSGDLENR</entry></row><row><entry> </entry></row><row><entry/><entry>YNFPSSEPRA&#x2003;KHSVKIRAAD</entry></row><row><entry> </entry></row><row><entry>301</entry><entry>VRILNWSSWS&#x2003;EAIEFGSDDG&#x2003;NLGSVYIYVL&#x2003;LIVGTLVCGI</entry></row><row><entry> </entry></row><row><entry/><entry>VLGFLFKRFL&#x2003;RIQRLFPPVP</entry></row><row><entry> </entry></row><row><entry>361</entry><entry>QIKDKLNDNH&#x2003;EVEDEIIWEE&#x2003;FTPEEGKGYR&#x2003;EEVLTVKEIT</entry></row></tbody></tgroup></table></tables></p><p id="p-0086" num="0083">The amino acid sequence of the extracellular domain of an exemplary human GM-CSFR&#x3b1; comprises or consists of the amino acid sequence of SEQ ID NO: 149.</p><p id="p-0087" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="28pt" align="char"/><colspec colname="2" colwidth="189pt" align="left"/><tbody valign="top"><row><entry>1</entry><entry>MLLLVTSLLL&#x2003;CELPHPAFLL&#x2003;IPEKSDLRTV&#x2003;APASSLNVRF</entry></row><row><entry> </entry></row><row><entry/><entry>DSRTMNLSWD&#x2003;CQENTTFSKC</entry></row><row><entry> </entry></row><row><entry>61</entry><entry>FLTDKKNRVV&#x2003;EPRLSNNECS&#x2003;CTFREICLHE&#x2003;GVTFEVHVNT</entry></row><row><entry> </entry></row><row><entry/><entry>SQRGFQQKLL&#x2003;YPNSGREGTA</entry></row><row><entry> </entry></row><row><entry>121</entry><entry>AQNFSCFIYN&#x2003;ADLMNCTWAR&#x2003;GPTAPRDVQY&#x2003;FLYIRNSKRR</entry></row><row><entry> </entry></row><row><entry/><entry>REIRCPYYIQ&#x2003;DSGTHVGCHL</entry></row><row><entry> </entry></row><row><entry>181</entry><entry>DNLSGLTSRN&#x2003;YFLVNGTSRE&#x2003;IGIQFFDSLL&#x2003;DTKKIERFNP</entry></row><row><entry> </entry></row><row><entry/><entry>PSNVTVRCNT&#x2003;THCLVRWKQP</entry></row><row><entry> </entry></row><row><entry>241</entry><entry>RTYQKLSYLD&#x2003;FQYQLDVHRK&#x2003;NTQPGTENLL&#x2003;INVSGDLENR</entry></row><row><entry> </entry></row><row><entry/><entry>YNFPSSEPRA&#x2003;KHSVKIRAAD</entry></row><row><entry> </entry></row><row><entry>301</entry><entry>VRILNWSSWS&#x2003;EAIEFGSDDG</entry></row></tbody></tgroup></table></tables></p><p id="p-0088" num="0084">In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically recognizes an epitope within human GM-CSFR&#x3b1;. In some embodiments, the anti-GM-CSFR&#x3b1; antibody cross-reacts with GM-CSFR&#x3b1; from species other than human. In some embodiments, the anti-GM-CSFR&#x3b1; antibody is completely specific for human GM-CSFR&#x3b1; and does not exhibit species or other types of non-human cross-reactivity.</p><p id="p-0089" num="0085">In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to a linear epitope within human GM-CSFR&#x3b1;. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to a nonlinear epitope within human GM-CSFR&#x3b1;. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises one, two, three, four, five, or six amino acid residues selected from the group consisting of Val50, Glu59, Lys194, Lys195, Arg283, and Ile284 of human GM-CSFR&#x3b1;. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises Val50. Glu59, Lys194, Lys195, Arg283, and Ile284 of human GM-CSFR&#x3b1;. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises one, two, three, four, five, six, seven, eight, or nine amino acid residues selected from the group consisting of Val50, Glu59, Lys194, Lys195, Arg283. Ile284, Val51, Thr63, and Ile196. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises amino acid residues Val50. Glu59, Lys194, Lys195, Arg283, Ile284, Val51, Thr63, and Ile196. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises one, two, three, four, five, six, seven, or eight amino acid residues selected from the group consisting of Val50. Glu59, Lys194, Lys195, Arg283, Ile284, Leu191 and Ile196. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises amino acid residues Val50, Glu59, Lys194, Lys195. Arg283, Ile284, Leu191 and Ile196. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises one, two, three, four, five, six, seven, eight, nine, or ten amino acid residues selected from the group consisting of Val50, Glu59, Lys194, Lys195, Arg283, Ile284, Arg49, Val51, Asn57, and Ser61.</p><p id="p-0090" num="0086">In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises amino acid residues Val50. Glu59, Lys194, Lys195, Arg283, Ile284, Arg49, Val51, Asn57, and Ser61.</p><p id="p-0091" num="0087">In some embodiments, the anti-GM-CSFR&#x3b1; antibody cross-reacts with at least one allelic variant of the GM-CSFR&#x3b1; protein (or fragments thereof). In some embodiments, the allelic variant has up to about 30 (such as about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30) amino acid substitutions (such as a conservative substitution) when compared to the naturally occurring GM-CSFR&#x3b1; (or fragments thereof). In some embodiments, the anti-GM-CSFR&#x3b1; antibody does not cross-react with any allelic variant of the GM-CSFR&#x3b1; protein (or fragments thereof).</p><p id="p-0092" num="0088">In some embodiments, the anti-GM-CSFR&#x3b1; antibody cross-reacts with at least one interspecies variant of the GM-CSFR&#x3b1; protein. In some embodiments, for example, the GM-CSFR&#x3b1; protein (or fragments thereof) is human GM-CSFR&#x3b1; and the interspecies variant of the GM-CSFR&#x3b1; protein (or fragments thereof) is a cynomolgus monkey variant thereof. In some embodiments, the anti-GM-CSFR&#x3b1; antibody does not cross-react with any interspecies variant of the GM-CSFR&#x3b1; protein.</p><p id="p-0093" num="0089">In some embodiments, according to any of the anti-GM-CSFR&#x3b1; antibodies described herein, the anti-GM-CSFR&#x3b1; antibody comprises an antibody heavy chain constant region and an antibody light chain constant region. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises an IgG1 heavy chain constant region. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises an IgG2 heavy chain constant region. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises an IgG3 heavy chain constant region. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises an IgG4 heavy chain constant region. In some embodiments, the heavy chain constant region comprises (including consisting of or consisting essentially of) the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises (including consisting of or consisting essentially of) the amino acid sequence of SEQ ID NO: 146. In some embodiments, the anti-GM-CSFR&#x3b1; comprises a lambda light chain constant region. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a kappa light chain constant region. In some embodiments, the light chain constant region comprises (including consisting of or consisting essentially of) the amino acid sequence of SEQ ID NO: 147. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises an antibody heavy chain variable domain and an antibody light chain variable domain.</p><p id="p-0094" num="0090">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising an HC-CDR1 comprising X<sub>1</sub>LX<sub>2</sub>X<sub>3</sub>H (SEQ ID NO: 76), wherein X<sub>1 </sub>is E, N, G, D, M, S, P, F, Y, A, V, K, W, R or C, X<sub>2 </sub>is S, C or P, and X<sub>3 </sub>is I or M; an HC-CDR2 comprising GFDX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>EX<sub>5</sub>X<sub>6</sub>YAQKX<sub>7</sub>QG (SEQ ID NO: 77), wherein X<sub>1 </sub>is P, G, T, S, or V, X<sub>2 </sub>is E, D, G, or A, X<sub>3 </sub>is D, G, I, W, S, or V, X<sub>4 </sub>is G, E, D, or H, X<sub>5 </sub>is T or A, X<sub>6 </sub>is N or I, and X<sub>7 </sub>is S or F; and an HC-CDR3 comprising GRYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>YGFDY (SEQ ID NO: 78), wherein X<sub>1 </sub>is C, T, S, I, A, or V, X<sub>2 </sub>is S, G, E, F, W, H, I, V, N, Y, T, or R, X<sub>3 </sub>is T, H, L, F, P, I, S, Y, K, A, D, V, N, or G, X<sub>4 </sub>is D, A, M, Y, F, S, T, G, or W, X<sub>5 </sub>is T, S, F, Q, A, N, L, E, I, G, or M, and X<sub>6 </sub>is C, T, N, S, or A; and a V<sub>L </sub>comprising a LC-CDR1 comprising RAX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>VX<sub>4</sub>X<sub>5</sub>X<sub>6</sub>LA (SEQ ID NO: 293), wherein X<sub>1 </sub>is S, L, N, A, K, R, I, Q, G, T, H, M, or C, X<sub>2 </sub>is Q, Y, P, A, I, F, T, R, V, L, E, S, or C, X<sub>3 </sub>is S, H, W, L, R, K, T, P, I, F, V, E, A, or Q, X<sub>4 </sub>is S, L, W, M, A, Y, K, R, G, T, E, V, N, F, or C, X<sub>5 </sub>is S, T, R, A, H, Q, P, M, L, or G, and X<sub>6 </sub>is Y, L, or F; a LC-CDR2 comprising X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>SRAT (SEQ ID NO: 294), wherein X<sub>1 </sub>is G or T, X<sub>2 </sub>is A, G, R, H, K, S, T, M, or F, and X<sub>3 </sub>is S, A, W, R, L, T, Q, F, Y, H, or N; and a LC-CDR3 comprising QQYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>PX<sub>4</sub>T (SEQ ID NO: 79), wherein X<sub>1 </sub>is N, D, S, R, A, T, L, Y, Q, W or G, X<sub>2 </sub>is N, D, E, T, Y, G, A, M, F, S, I or L, X<sub>3 </sub>is W, S, P, V, G, or R, and X<sub>4 </sub>is P, Y, H, S, F, N, D, V, or G.</p><p id="p-0095" num="0091">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising a HC-CDR1 comprising ELX<sub>1</sub>X<sub>2</sub>H (SEQ ID NO: 295), wherein X<sub>1 </sub>is S, C or P, and X<sub>2 </sub>is I or M; an HC-CDR2 comprising GFDX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>EX<sub>5</sub>X<sub>6</sub>YAQKX<sub>7</sub>QG (SEQ ID NO: 77), wherein X<sub>1 </sub>is P, G, T, S, or V, X<sub>2 </sub>is E, D, G, or A, X<sub>3 </sub>is D, G, I, W, S, or V, X<sub>4 </sub>is G, E, D, or H, X<sub>5 </sub>is T or A, X<sub>6 </sub>is N or I, and X<sub>7 </sub>is S or F; and an HC-CDR3 comprising GRYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>YGFDY (SEQ ID NO: 78), wherein X<sub>1 </sub>is C, T, S, I, A, or V, X<sub>2 </sub>is S, G, E, F, W, H, I, V, N, Y, T, or R, X<sub>3 </sub>is T, H, L, F, P, I, S, Y, K, A, D, V, N, or G, X<sub>4 </sub>is D, A, M, Y, F, S, T, G, or W, X<sub>5 </sub>is T, S, F, Q, A, N, L, E, I, G, or M, and X<sub>6 </sub>is C, T, N, S, or A; and a V<sub>L </sub>comprising: a LC-CDR1 comprising RASQSVSSYLA (SEQ ID NO: 51); a LC-CDR2 comprising GASSRAT (SEQ ID NO: 52); and a LC-CDR3 comprising QQYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>PX<sub>4</sub>T (SEQ ID NO: 79), wherein X<sub>1 </sub>is N, D, S, R, A, T, L, Y, Q, W or G, X<sub>2 </sub>is N, D, E, T, Y, G, A, M, F, S, I or L, X<sub>3 </sub>is W, S, P, V, G, or R, and X<sub>4 </sub>is P, Y, H, S, F, N, D, V, or G.</p><p id="p-0096" num="0092">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions.</p><p id="p-0097" num="0093">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50.</p><p id="p-0098" num="0094">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>L </sub>comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions.</p><p id="p-0099" num="0095">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>L </sub>comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NOs: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75.</p><p id="p-0100" num="0096">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions; and a V<sub>L </sub>comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions.</p><p id="p-0101" num="0097">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50; and a V<sub>L </sub>comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NOs: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75.</p><p id="p-0102" num="0098">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0103" num="0099">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54.</p><p id="p-0104" num="0100">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0105" num="0101">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56.</p><p id="p-0106" num="0102">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 23, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0107" num="0103">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 23; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57.</p><p id="p-0108" num="0104">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0109" num="0105">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57.</p><p id="p-0110" num="0106">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 53, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0111" num="0107">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 53.</p><p id="p-0112" num="0108">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0113" num="0109">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57.</p><p id="p-0114" num="0110">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0115" num="0111">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54.</p><p id="p-0116" num="0112">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0117" num="0113">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57.</p><p id="p-0118" num="0114">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50, or a variant thereof comprising up to about 5 amino acid substitutions in the HC-CDRs; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the LC-CDRs.</p><p id="p-0119" num="0115">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57.</p><p id="p-0120" num="0116">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1-50, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51-75, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1-50; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51-75.</p><p id="p-0121" num="0117">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 5 and 17, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 54, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 5 and 17; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 54.</p><p id="p-0122" num="0118">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 8 and 22, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51.52 and 56, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 8 and 22; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 56.</p><p id="p-0123" num="0119">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 23, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 57, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 23; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 57.</p><p id="p-0124" num="0120">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 6 and 27, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51.52 and 57, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 6 and 27; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 57.</p><p id="p-0125" num="0121">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 35, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 53, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 35; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 53.</p><p id="p-0126" num="0122">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 37, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 57, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 37; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 57.</p><p id="p-0127" num="0123">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 3, 6 and 39, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 54, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 3, 6 and 39; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 54.</p><p id="p-0128" num="0124">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 35, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 57, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 35; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 57.</p><p id="p-0129" num="0125">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 50, or a variant thereof comprising up to about 5 amino acid substitutions; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 57, or a variant thereof comprising up to about 5 amino acid substitutions. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequences of SEQ ID NOs: 1, 7 and 50; and a V<sub>L </sub>comprising the amino acid sequences of SEQ ID NOs: 51, 52 and 57.</p><p id="p-0130" num="0126">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising an HC-CDR1, an HC-CDR2 and an HC-CDR3 of the V<sub>H </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287; and a V<sub>L </sub>comprising a LC-CDR1, a LC-CDR2, and a LC-CDR3 of the V<sub>L </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289.</p><p id="p-0131" num="0127">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising one, two or three HC-CDRs of SEQ ID NO: 80. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising one, two or three HC-CDRs of SEQ ID NO: 85. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising one, two or three HC-CDRs of SEQ ID NO: 86. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising one, two or three HC-CDRs of SEQ ID NO: 91. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising one, two or three HC-CDRs of SEQ ID NO: 99. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising one, two or three HC-CDRs of SEQ ID NO: 101. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising one, two or three HC-CDRs of SEQ ID NO: 103. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising one, two or three HC-CDRs of SEQ ID NO: 121.</p><p id="p-0132" num="0128">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>L </sub>comprising one, two or three LC-CDRs of SEQ ID NO: 123. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>L </sub>comprising one, two or three LC-CDRs of SEQ ID NO: 125. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>L </sub>comprising one, two or three LC-CDRs of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>L </sub>comprising one, two or three LC-CDRs of SEQ ID NO: 122.</p><p id="p-0133" num="0129">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising HC-CDR1. HC-CDR2 and HC-CDR3 of the V<sub>H </sub>of SEQ ID NO: 80, and a V<sub>L </sub>comprising LC-CDR1, LC-CDR2 and LC-CDR3 of the V<sub>L </sub>of SEQ ID NO: 123. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising HC-CDR1. HC-CDR2 and HC-CDR3 of the V<sub>H </sub>of SEQ ID NO: 85, and a V<sub>L </sub>comprising LC-CDR1, LC-CDR2 and LC-CDR3 of the V<sub>L </sub>of SEQ ID NO: 125. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising HC-CDR1. HC-CDR2 and HC-CDR3 of the V<sub>H </sub>of SEQ ID NO: 86, and a V<sub>L </sub>comprising LC-CDR1, LC-CDR2 and LC-CDR3 of the V<sub>L </sub>of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising HC-CDR1, HC-CDR2 and HC-CDR3 of the V<sub>H </sub>of SEQ ID NO: 91, and a V<sub>L </sub>comprising LC-CDR1, LC-CDR2 and LC-CDR3 of the V<sub>L </sub>of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising HC-CDR1, HC-CDR2 and HC-CDR3 of the V<sub>H </sub>of SEQ ID NO: 99, and a V<sub>L </sub>comprising LC-CDR1. LC-CDR2 and LC-CDR3 of the V<sub>L </sub>of SEQ ID NO: 122. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising HC-CDR1, HC-CDR2 and HC-CDR3 of the V<sub>H </sub>of SEQ ID NO: 101, and a V<sub>L </sub>comprising LC-CDR1, LC-CDR2 and LC-CDR3 of the V<sub>L </sub>of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising HC-CDR1. HC-CDR2 and HC-CDR3 of the V<sub>H </sub>of SEQ ID NO: 103, and a V<sub>L </sub>comprising LC-CDR1. LC-CDR2 and LC-CDR3 of the V<sub>L </sub>of SEQ ID NO: 123. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising HC-CDR1, HC-CDR2 and HC-CDR3 of the V<sub>H </sub>of SEQ ID NO: 99, and a V<sub>L </sub>comprising LC-CDR1, LC-CDR2 and LC-CDR3 of the V<sub>L </sub>of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising HC-CDR1, HC-CDR2 and HC-CDR3 of the V<sub>H </sub>of SEQ ID NO: 121, and a V<sub>L </sub>comprising LC-CDR1, LC-CDR2 and LC-CDR3 of the V<sub>L </sub>of SEQ ID NO: 126.</p><p id="p-0134" num="0130">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 80-121 and 246-287, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 80-121 and 246-287, and a V<sub>L </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289.</p><p id="p-0135" num="0131">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 80, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 80 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123.</p><p id="p-0136" num="0132">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 85, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 125, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 85 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 125.</p><p id="p-0137" num="0133">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 86, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 86 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126.</p><p id="p-0138" num="0134">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 91, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 91 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126.</p><p id="p-0139" num="0135">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 99, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 122, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 99 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 122.</p><p id="p-0140" num="0136">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 101, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence 1105 identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 101 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126.</p><p id="p-0141" num="0137">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the 1110 amino acid sequence of SEQ ID NO: 103, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 103 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123.</p><p id="p-0142" num="0138">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 99, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 99 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126.</p><p id="p-0143" num="0139">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 121, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 121 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126.</p><p id="p-0144" num="0140">In some embodiments, functional epitopes can be mapped by combinatorial alanine scanning. In this process, a combinatorial alanine-scanning strategy can be used to identify amino acids in the GM-CSFR&#x3b1; protein that are necessary for interaction with GM-CSFR&#x3b1; antibodies. In some embodiments, the epitope is conformational and crystal structure of anti-GM-CSFR&#x3b1; antibodies bound to GM-CSFR&#x3b1; may be employed to identify the epitopes.</p><p id="p-0145" num="0141">In some embodiments, the present application provides antibodies which compete with any one of the GM-CSFR&#x3b1; antibodies described herein for binding to GM-CSFR&#x3b1;. In some embodiments, the present application provides antibodies which compete with any one of the anti-GM-CSFR&#x3b1; antibodies provided herein for binding to an epitope on the GM-CSFR&#x3b1;. In some embodiments, an anti-GM-CSFR&#x3b1; antibody is provided that binds to the same epitope as an anti-GM-CSFR&#x3b1; antibody comprising a V<sub>H </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287, and a V<sub>L </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289. In some embodiments, an anti-GM-CSFR&#x3b1; antibody is provided that specifically binds to GM-CSFR&#x3b1; competitively with an anti-GM-CSFR&#x3b1; antibody comprising a V<sub>H </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287 and a V<sub>L </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289.</p><p id="p-0146" num="0142">In some embodiments, competition assays may be used to identify a monoclonal antibody that competes with an anti-GM-CSFR&#x3b1; antibody described herein for binding to GM-CSFR&#x3b1;. Competition assays can be used to determine whether two antibodies bind the same epitope by recognizing identical or sterically overlapping epitopes or one antibody competitively inhibits binding of another antibody to the antigen. In certain embodiments, such a competing antibody binds to the same epitope that is bound by an antibody described herein. Exemplary competition assays include, but are not limited to, routine assays such as those provided in Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) &#x201c;Epitope Mapping Protocols.&#x201d; in Methods in Molecular Biology vol. 66 (Humana Press. Totowa, N.J.). In some embodiments, two antibodies are said to bind to the same epitope if each blocks binding of the other by 50% or more. In some embodiments, the antibody that competes with an anti-GM-CSFR&#x3b1; antibody described herein is a chimeric, humanized or human antibody.</p><p id="p-0147" num="0143">Exemplary anti-GM-CSFR&#x3b1; antibody sequences are shown in Tables 2, 3 and 18, and in <figref idref="DRAWINGS">FIGS. <b>19</b>A, <b>19</b>B</figref>. Those skilled in the art will recognize that many algorithms are known for prediction of CDR positions and for delimitation of antibody heavy chain and light chain variable regions. Anti-GM-CSFR&#x3b1; antibodies comprising CDRs. V<sub>H </sub>and/or V<sub>L </sub>sequences from antibodies described herein, but based on prediction algorithms other than those exemplified in the tables below, are within the scope of this invention.</p><p id="p-0148" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="350pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;2</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Exemplary&#x2003;anti-GM-CSFR&#x3b1;&#x2003;antibody&#x2003;CDR&#x2003;sequences.</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="91pt" align="left"/><colspec colname="3" colwidth="105pt" align="left"/><colspec colname="4" colwidth="112pt" align="left"/><tbody valign="top"><row><entry>Antibody</entry><entry/><entry/><entry/></row><row><entry>Name</entry><entry>HC-CDR1</entry><entry>HC-CDR2</entry><entry>HC-CDR3</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>T119</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETNYAQKSQG</entry><entry>GRYCSTDTCYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;5)</entry><entry>NO:&#x2003;17)</entry></row><row><entry> </entry></row><row><entry>E01</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETNYAQKSQG</entry><entry>GRYCSTDTCYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;5)</entry><entry>NO:&#x2003;17)</entry></row><row><entry> </entry></row><row><entry>E09</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYCGHASCYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;18)</entry></row><row><entry> </entry></row><row><entry>E105</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTSLMFTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;19)</entry></row><row><entry> </entry></row><row><entry>E108</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTELYQNYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;20)</entry></row><row><entry> </entry></row><row><entry>E113</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYTELFASYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;21)</entry></row><row><entry> </entry></row><row><entry>E16</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGEAIYAQKSQG</entry><entry>GRYSEHSTSYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;8)</entry><entry>NO:&#x2003;22)</entry></row><row><entry> </entry></row><row><entry>E194</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYTGLMNSYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;23)</entry></row><row><entry> </entry></row><row><entry>E27</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYISFMFTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;24)</entry></row><row><entry> </entry></row><row><entry>E29</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYCFPDTCYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;25)</entry></row><row><entry> </entry></row><row><entry>E30</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYCSTDTCYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;17)</entry></row><row><entry> </entry></row><row><entry>E34</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYSFTDLAYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;26)</entry></row><row><entry> </entry></row><row><entry>E35</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTSLATTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;27)</entry></row><row><entry> </entry></row><row><entry>E36</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYAFIDTAYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;28)</entry></row><row><entry> </entry></row><row><entry>E39</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYCSSDLCYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;29)</entry></row><row><entry> </entry></row><row><entry>E40</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTSLDESYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;30)</entry></row><row><entry> </entry></row><row><entry>E54</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYSSYDIAYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;31)</entry></row><row><entry> </entry></row><row><entry>E61</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYAWTDIAYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;32)</entry></row><row><entry> </entry></row><row><entry>E83</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYCFYDLCYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;33)</entry></row><row><entry> </entry></row><row><entry>E85</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYSSYFTNYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;34)</entry></row><row><entry> </entry></row><row><entry>E87</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYVSLFFNYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;35)</entry></row><row><entry> </entry></row><row><entry>E88</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYCHKDGCYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;36)</entry></row><row><entry> </entry></row><row><entry>E90</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYTGLYASYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;37)</entry></row><row><entry> </entry></row><row><entry>E94</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYCETDICYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;38)</entry></row><row><entry> </entry></row><row><entry>E200a</entry><entry>ELPMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;3)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTIITTNYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;39)</entry></row><row><entry> </entry></row><row><entry>EII33</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDGDGEETIYAQKFQG</entry><entry>GRYTSLAATYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;9)</entry><entry>NO:&#x2003;40)</entry></row><row><entry> </entry></row><row><entry>EII52</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDGDIEETIYAQKFQG</entry><entry>GRYTSLATTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;10)</entry><entry>NO:&#x2003;27)</entry></row><row><entry> </entry></row><row><entry>EII81</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTSLAATYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;40)</entry></row><row><entry> </entry></row><row><entry>E161</entry><entry>ELCMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYAVTDMAYGFDY(SEQ</entry></row><row><entry/><entry>4)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>ID&#x2003;NO:&#x2003;41)</entry></row><row><entry> </entry></row><row><entry>E163</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYAFAGLAYGFDY(SEQ</entry></row><row><entry/><entry>1)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>ID&#x2003;NO:&#x2003;42)</entry></row><row><entry> </entry></row><row><entry>E164</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYTNDFANYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;43)</entry></row><row><entry> </entry></row><row><entry>E170</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYSSVGSTYGFDY(SEQ</entry></row><row><entry/><entry>2)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>ID&#x2003;NO:&#x2003;44)</entry></row><row><entry> </entry></row><row><entry>E172</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYANLYNNYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;45)</entry></row><row><entry> </entry></row><row><entry>E174</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYVYLASNYGFDY(SEQ</entry></row><row><entry/><entry>1)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>ID&#x2003;NO:&#x2003;46)</entry></row><row><entry> </entry></row><row><entry>E181</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYSTNFSNYGFDY(SEQ</entry></row><row><entry/><entry>2)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>ID&#x2003;NO:&#x2003;47)</entry></row><row><entry> </entry></row><row><entry>E84</entry><entry>ELSMH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYTRGWFNYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;48)</entry></row><row><entry> </entry></row><row><entry>EII55</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDGDWHETIYAQKFQG</entry><entry>GRYTSLDATYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;14)</entry><entry>NO:&#x2003;49)</entry></row><row><entry> </entry></row><row><entry>E87b</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYVSLFFNYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;35)</entry></row><row><entry> </entry></row><row><entry>E31</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKSQG</entry><entry>GRYSESFASYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry><entry>NO:&#x2003;50)</entry></row><row><entry> </entry></row><row><entry>E41</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPAWGETIYAQKFQG</entry><entry>GRYTSLATTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;15)</entry><entry>NO:&#x2003;27)</entry></row><row><entry> </entry></row><row><entry>EII41</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDTGDDETIYAQKFQG</entry><entry>GRYTSLDATYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;11)</entry><entry>NO:&#x2003;49)</entry></row><row><entry> </entry></row><row><entry>EII46</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDSEWGETIYAQKFQG</entry><entry>GRYTSLATTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;12)</entry><entry>NO:&#x2003;27)</entry></row><row><entry> </entry></row><row><entry>EII49</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDVASGETIYAQKFQG</entry><entry>GRYTSLDATYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;13)</entry><entry>NO:&#x2003;49)</entry></row><row><entry> </entry></row><row><entry>EII7</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDSEVGETIYAQKFQG</entry><entry>GRYTSLAATYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;16)</entry><entry>NO:&#x2003;40)</entry></row><row><entry> </entry></row><row><entry>E35a</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTSLATTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;27)</entry></row><row><entry> </entry></row><row><entry>E35b</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTSLATTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;27)</entry></row><row><entry> </entry></row><row><entry>E35c</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTSLATTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;27)</entry></row><row><entry> </entry></row><row><entry>E35d</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTSLATTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;27)</entry></row><row><entry> </entry></row><row><entry>E35e</entry><entry>ELSIH&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry><entry>GFDPEDGETIYAQKFQG</entry><entry>GRYTSLATTYGFDY(SEQ&#x2003;ID</entry></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry><entry>NO:&#x2003;27)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Antibody</entry><entry/><entry/><entry/></row><row><entry>Name</entry><entry>LC-CDR1</entry><entry>LC-CDR2</entry><entry>LC-CDR3</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>T119</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>53)</entry></row><row><entry> </entry></row><row><entry>E01</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>54)</entry></row><row><entry> </entry></row><row><entry>E09</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>53)</entry></row><row><entry> </entry></row><row><entry>E105</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>53)</entry></row><row><entry> </entry></row><row><entry>E108</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>53)</entry></row><row><entry> </entry></row><row><entry>E113</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>55)</entry></row><row><entry> </entry></row><row><entry>E16</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDSWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>56)</entry></row><row><entry> </entry></row><row><entry>E194</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>57)</entry></row><row><entry> </entry></row><row><entry>E27</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>53)</entry></row><row><entry> </entry></row><row><entry>E29</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNSPHT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>58)</entry></row><row><entry> </entry></row><row><entry>E30</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNSPHT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>58)</entry></row><row><entry> </entry></row><row><entry>E34</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDSSPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;59)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>E35</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>57)</entry></row><row><entry> </entry></row><row><entry>E36</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYSNSPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;60)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>E39</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNSPHT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>58)</entry></row><row><entry> </entry></row><row><entry>E40</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNSPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>61)</entry></row><row><entry> </entry></row><row><entry>E54</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNSSPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;62)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>E61</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNSPST&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;63)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>E83</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYSNSPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;60)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>E85</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>55)</entry></row><row><entry> </entry></row><row><entry>E87</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>53)</entry></row><row><entry> </entry></row><row><entry>E88</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDSSPHT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;64)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>E90</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>57)</entry></row><row><entry> </entry></row><row><entry>E94</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>53)</entry></row><row><entry> </entry></row><row><entry>E200a</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>54)</entry></row><row><entry> </entry></row><row><entry>EII33</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYRNWPFT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>65)</entry></row><row><entry> </entry></row><row><entry>EII52</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYANPPNT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>66)</entry></row><row><entry> </entry></row><row><entry>EII81</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYTNVPDT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>67)</entry></row><row><entry> </entry></row><row><entry>E161</entry><entry>RASQSVSSYLA</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNSPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>68)</entry></row><row><entry> </entry></row><row><entry>E163</entry><entry>RASQSVSSYLA</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNSPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>69)</entry></row><row><entry> </entry></row><row><entry>E164</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>55)</entry></row><row><entry> </entry></row><row><entry>E170</entry><entry>RASQSVSSYLA</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNSPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>61)</entry></row><row><entry> </entry></row><row><entry>E172</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>53)</entry></row><row><entry> </entry></row><row><entry>E174</entry><entry>RASQSVSSYLA</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>53)</entry></row><row><entry> </entry></row><row><entry>E181</entry><entry>RASQSVSSYLA</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNWPYT&#x2003;(SEQ&#x2003;ID</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>NO:&#x2003;57)</entry></row><row><entry> </entry></row><row><entry>E84</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYNNWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>55)</entry></row><row><entry> </entry></row><row><entry>EII55</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYGNRPDT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>73)</entry></row><row><entry> </entry></row><row><entry>E87b</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>57)</entry></row><row><entry> </entry></row><row><entry>E31</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNWPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>57)</entry></row><row><entry> </entry></row><row><entry>E41</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNGPET&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>74)</entry></row><row><entry> </entry></row><row><entry>EII41</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYLNSPFT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;70)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>EII46</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYSNVPVT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>71)</entry></row><row><entry> </entry></row><row><entry>EII49</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYYNGPGT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>72)</entry></row><row><entry> </entry></row><row><entry>EII7</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYRNGPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;75)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>E35a</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNSPHT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>58)</entry></row><row><entry> </entry></row><row><entry>E35b</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNSPYT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>61)</entry></row><row><entry> </entry></row><row><entry>E35c</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDSSPHT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;64)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>E35d</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYDNWPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry><entry/><entry>54)</entry></row><row><entry> </entry></row><row><entry>E35e</entry><entry>RASQSVSSYLA&#x2003;(SEQ</entry><entry>GASSRAT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry>QQYSNSPPT&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;60)</entry></row><row><entry/><entry>ID&#x2003;NO:&#x2003;51)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0149" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="336pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Exemplary&#x2003;sequences.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="21pt" align="center"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="245pt" align="left"/><tbody valign="top"><row><entry>SEQ</entry><entry/><entry/></row><row><entry>ID</entry><entry/><entry/></row><row><entry>NO</entry><entry>Description</entry><entry>Sequence</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="21pt" align="char" char="."/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="245pt" align="left"/><tbody valign="top"><row><entry>148</entry><entry>hGM-CSFR&#x3b1;</entry><entry>MLLLVTSLLLCELPHPAFLLIPEKSDLRTVAPASSLNVRFDSRTMNLSWDCQENT</entry></row><row><entry/><entry/><entry>TFSKCFLTDKKNRVVEPRLSNNECSCTFREICLHEGVTFEVHVNTSQRGFQQKLL</entry></row><row><entry/><entry/><entry>YPNSGREGTAAQNFSCFIYNADLMNCTWARGPTAPRDVQYFLYIRNSKRRREIR</entry></row><row><entry/><entry/><entry>CPYYIQDSGTHVGCHLDNLSGLTSRNYFLVNGTSREIGIQFFDSLLDTKKIERFNP</entry></row><row><entry/><entry/><entry>PSNVTVRCNTTHCLVRWKQPRTYQKLSYLDFQYQLDVHRKNTQPGTENLLINV</entry></row><row><entry/><entry/><entry>SGDLENRYNFPSSEPRAKHSVKIRAADVRILNWSSWSEAIEFGSDDGNLGSVYIY</entry></row><row><entry/><entry/><entry>VLLIVGTLVCGIVLGFLFKRFLRIQRLFPPVPQIKDKLNDNHEVEDEIIWEEFTPEE</entry></row><row><entry/><entry/><entry>GKGYREEVLTVKEIT</entry></row><row><entry> </entry></row><row><entry>80</entry><entry>E01,&#x2003;T119&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETNYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYCSTDT</entry></row><row><entry/><entry/><entry>CYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>81</entry><entry>E09&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYCGHA</entry></row><row><entry/><entry/><entry>SCYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>82</entry><entry>E105&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLMF</entry></row><row><entry/><entry/><entry>TYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>83</entry><entry>E108&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTELYQ</entry></row><row><entry/><entry/><entry>NYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>84</entry><entry>E113&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTELFA</entry></row><row><entry/><entry/><entry>SYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>85</entry><entry>E16&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGEAIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYSEHST</entry></row><row><entry/><entry/><entry>SYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>86</entry><entry>E194&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTGLMN</entry></row><row><entry/><entry/><entry>SYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>87</entry><entry>E27&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYISFMFT</entry></row><row><entry/><entry/><entry>YGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>88</entry><entry>E29&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYCFPDT</entry></row><row><entry/><entry/><entry>CYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>89</entry><entry>E30&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYCSTDT</entry></row><row><entry/><entry/><entry>CYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>90</entry><entry>E34&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYSFTDL</entry></row><row><entry/><entry/><entry>AYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>91</entry><entry>E35,&#x2003;E35<sub>a-e</sub>&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLAT</entry></row><row><entry/><entry/><entry>TYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>92</entry><entry>E36&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTAIYYCATGRYAFID</entry></row><row><entry/><entry/><entry>TAYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>93</entry><entry>E39&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYCSSDL</entry></row><row><entry/><entry/><entry>CYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>94</entry><entry>E40&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLDE</entry></row><row><entry/><entry/><entry>SYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>95</entry><entry>E54&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYSSYDI</entry></row><row><entry/><entry/><entry>AYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>96</entry><entry>E61&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGITIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYAWT</entry></row><row><entry/><entry/><entry>DIAYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>97</entry><entry>E83&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYCFYDL</entry></row><row><entry/><entry/><entry>CYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>98</entry><entry>E85&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYSSYFT</entry></row><row><entry/><entry/><entry>NYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>99</entry><entry>E87,&#x2003;E87b&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYVSLFF</entry></row><row><entry/><entry/><entry>NYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>100</entry><entry>E88&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGITIYAQKFQGRVTMTGDTSTDTAYLELSSLRSED1ALYYCATGRYCHKD</entry></row><row><entry/><entry/><entry>GCYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>101</entry><entry>E90&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTGLYA</entry></row><row><entry/><entry/><entry>SYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>102</entry><entry>E94&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYCETD</entry></row><row><entry/><entry/><entry>ICYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>103</entry><entry>E200a&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELPMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTIITT</entry></row><row><entry/><entry/><entry>NYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>104</entry><entry>EII33&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>GDGEETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSED1ALYYCATGRYTSLAA</entry></row><row><entry/><entry/><entry>TYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>105</entry><entry>EII52&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>GDIEETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLATT</entry></row><row><entry/><entry/><entry>YGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>106</entry><entry>EII81&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLAA</entry></row><row><entry/><entry/><entry>TYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>107</entry><entry>E161&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELCMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYWATGRYAVT</entry></row><row><entry/><entry/><entry>DMAYGFDYWGQETLVSVSS</entry></row><row><entry> </entry></row><row><entry>108</entry><entry>E163&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRWMTGDTSTDTAYLELSSLRSEDTALYYCATGRYAFAGL</entry></row><row><entry/><entry/><entry>AYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>109</entry><entry>E164&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTNDF</entry></row><row><entry/><entry/><entry>ANYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>110</entry><entry>E170&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYSSVG</entry></row><row><entry/><entry/><entry>STYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>111</entry><entry>E172&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYANLY</entry></row><row><entry/><entry/><entry>NNYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>112</entry><entry>E174&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGHTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYVYLAS</entry></row><row><entry/><entry/><entry>NYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>113</entry><entry>E181&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYSTNF</entry></row><row><entry/><entry/><entry>SNYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>114</entry><entry>E84&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGF</entry></row><row><entry/><entry/><entry>DPEDGETIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTRG</entry></row><row><entry/><entry/><entry>WFNYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>115</entry><entry>EII41&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>TGDDETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLDA</entry></row><row><entry/><entry/><entry>TYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>116</entry><entry>EII46&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>SEWGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLAT</entry></row><row><entry/><entry/><entry>TYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>117</entry><entry>EII49&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>VASGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLDA</entry></row><row><entry/><entry/><entry>TYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>118</entry><entry>EII55&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>GDWHETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLD</entry></row><row><entry/><entry/><entry>ATYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>119</entry><entry>E41&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PAWGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLAT</entry></row><row><entry/><entry/><entry>TYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>120</entry><entry>EII7&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>SEVGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLAA</entry></row><row><entry/><entry/><entry>TYGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>121</entry><entry>E31&#x2003;V<sub>H</sub></entry><entry>QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFD</entry></row><row><entry/><entry/><entry>PEDGETIYAQKSQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYSESFAS</entry></row><row><entry/><entry/><entry>YGFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>122</entry><entry>T119,E87,</entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry>E09,&#x2003;E105,</entry><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYNNWPPTFGQGTKLE1K</entry></row><row><entry/><entry>E108,&#x2003;E27,</entry><entry/></row><row><entry/><entry>E94,&#x2003;E172,</entry><entry/></row><row><entry/><entry>E174,&#x2003;V<sub>L</sub></entry><entry/></row><row><entry> </entry></row><row><entry>123</entry><entry>E01,&#x2003;E200a,</entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry>E35d&#x2003;V<sub>L</sub></entry><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDNWPPTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>124</entry><entry>E113,&#x2003;E85,</entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry>E164,&#x2003;E84,&#x2003;V<sub>L</sub></entry><entry>TGIPDRFSGSGSGTDFTLT1SRLEPEDFAVYYCQQYNNWPYTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>125</entry><entry>E16&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDSWPYTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>126</entry><entry>E194,&#x2003;E35,</entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry>E90,&#x2003;E181,</entry><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDNWPYTFGQGTKLEIK</entry></row><row><entry/><entry>E87b,&#x2003;E31</entry><entry/></row><row><entry/><entry>V<sub>L</sub></entry><entry/></row><row><entry> </entry></row><row><entry>127</entry><entry>E29,&#x2003;E30,&#x2003;E39,</entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry>E35aV<sub>L</sub></entry><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDNSPHTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>128</entry><entry>E34&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDSSPPTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>129</entry><entry>E36,&#x2003;E83,&#x2003;E35e</entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry>V<sub>L</sub></entry><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYSNSPPTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>130</entry><entry>E40,&#x2003;E170,</entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry>E35b&#x2003;V<sub>L</sub></entry><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDNSPYTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>131</entry><entry>E54&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYNSSPPTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>132</entry><entry>E61&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDNSPSTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>133</entry><entry>E88,&#x2003;E35c&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDSSPHTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>134</entry><entry>EII33&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYRNWPFTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>135</entry><entry>EII52&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYANPPNTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>136</entry><entry>EII81&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYTNVPDTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>137</entry><entry>E161&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYNNSPPTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>138</entry><entry>E163&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDNSPPTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>139</entry><entry>EII41&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYLNSPFTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>140</entry><entry>EII46&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYSNVPVTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>141</entry><entry>EII49&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYYNGPGTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>142</entry><entry>EII55&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNRPDTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>143</entry><entry>E41&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDNGPETFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>144</entry><entry>EII7&#x2003;V<sub>L</sub></entry><entry>EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRA</entry></row><row><entry/><entry/><entry>TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYRNGPPTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>145</entry><entry>IgG1&#x2003;heavy</entry><entry>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA</entry></row><row><entry/><entry>chain,&#x2003;constant</entry><entry>VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP</entry></row><row><entry/><entry>region.</entry><entry>PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG</entry></row><row><entry/><entry/><entry>VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK</entry></row><row><entry/><entry/><entry>TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN</entry></row><row><entry/><entry/><entry>NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS</entry></row><row><entry/><entry/><entry>LSPGK</entry></row><row><entry> </entry></row><row><entry>146</entry><entry>IgG4&#x2003;heavy</entry><entry>ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA</entry></row><row><entry/><entry>chain&#x2003;constant</entry><entry>VLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCP</entry></row><row><entry/><entry>region</entry><entry>APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV</entry></row><row><entry/><entry/><entry>HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK</entry></row><row><entry/><entry/><entry>AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK</entry></row><row><entry/><entry/><entry>TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG</entry></row><row><entry/><entry/><entry>K</entry></row><row><entry> </entry></row><row><entry>147</entry><entry>Light&#x2003;chain</entry><entry>RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE</entry></row><row><entry/><entry>constant&#x2003;region</entry><entry>SVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0010" level="2">GM-CSF</heading><p id="p-0150" num="0144">Granulocyte-macrophage colony stimulating factor (GM-CSF), also known as colony-stimulating factor 2 (CSF2), is produced by macrophages. T cells, mast cells, natural killer cells, endothelial cells, and fibroblasts. GM-CSF is a type I proinflammatory cytokine which enhances survival, proliferation, and/or differentiation of a broad range of hematopoietic cell types including neutrophils, eosinophils, monocytes, and macrophages, such as, myeloid differentiation, recruitment and differentiation of monocyte-derived dendritic cells, initiation and activation of neutrophils. It is also involved in promoting formation of blood vessels as well as tumor growth. Clinically, GM-CSF is often used to enhance the restoration of bone marrow following radiation procedures.</p><p id="p-0151" num="0145">GM-CSF is one of the first proinflammatory cytokines that arm present at the inflammation sites and is critical in the regulation of the inflammatory process, by for example, enhancing the differentiation of hematopoietic cell types into neutrophils, eosinophils, monocytes, and macrophages (Nature Reviews Rheumatology 2015; 7(11):415-430). By activating the vascular endothelial cells. GM-CSF promotes the recruitment of monocytes and macrophages. GM-CSF also enhances the proliferation of monocytes and macrophages, such as macrophages of the synovial joints in rheumatoid arthritis; as well as promoting cytokine production from macrophages, including GM-CSF and other inflammatory cytokines such as TNF-&#x3b1;, IL-6, IL-1 and chemokines. GM-CSF is further involved in modulating antigen-presenting cells in the inflammatory tissues, and promoting IL-23 production by macrophages and dendritic cells, which together with IL-6 and IL-1, modulates T cell differentiation. Endogenous GM-CSF modulates sensory neurons by relying pain signals and promoting sensitivity to pain. In GM-CSF knockout mice, myeloid cell development was not affected, suggesting a limited role for GM-CSF in promoting myeloid cell development (Stanley et al. PNAS 1994; 91(12): 5592-5594). However, due to the lack of appropriate inflammatory reactions, GM-CSF knockout mice were more prone to infections (Trapnell et al. N Engl J Med 2003; 349:2527-2539; Dranoff et al. Science 1994; 264:713-716). Lack of GM-CSF reduced the occurrence of rheumatoid arthritis, encephalomyelitis, and autoimmune myocardioptis, suggesting that GM-CSF is primarily involved in the inflammatory process (Lawlor et al. Arthritis &#x26; Rheumatism 2005; (52) 3749-3754; McQualter et al. Journal of Experimental Medicine 2001; 194(7): 873-882; Sonderegger et al. Journal of Experimental Medicine 2008; 205(10): 2281-2294).</p><heading id="h-0011" level="2">GM-CSFR</heading><p id="p-0152" num="0146">The GM-CSF receptor is a member of the hematopoietic receptor superfamily. It is heterodimeric, consisting of an alpha and a beta subunit. The alpha subunit is highly specific for GM-CSF whereas the beta subunit is shared with other cytokine receptors, including IL3 and IL5. This is reflected in a broader tissue distribution of the beta receptor subunit. The alpha subunit, GM-CSFR&#x3b1;, is primarily expressed on myeloid cells and non-hematopoietic cells, such as neutrophils, macrophages, eosinophils, dendritic cells, endothelial cells and respiratory epithelial cells. Full length GM-CSFR&#x3b1; is a 400 amino acid type I membrane glycoprotein that belongs to the type I cytokine receptor family, and consists of a 22 amino acid signal peptide (positions 1-22), a 298 amino acid extracellular domain (positions 23-320), a transmembrane domain from positions 321-345 and a short 55 amino acid intra-cellular domain. The signal peptide is cleaved to provide the mature form of GM-CSFR&#x3b1; as a 378 amino acid protein. cDNA clones of the human and murine GM-CSFR&#x3b1; are available and, at the protein level, the receptor subunits have 36% identity. GM-CSF is able to bind with relatively low affinity to the a subunit alone (Kd 1-5 nM) but not at all to the R subunit alone. However, the presence of both &#x3b1; and &#x3b2; subunits results in a high affinity ligand-receptor complex (Kd&#x2248;100 pM). GM-CSF signaling occurs through its initial binding to the GM-CSFR &#x3b1; chain and then cross-linking with a larger subunit the common &#x3b2; chain to generate the high affinity interaction, which phosphorylates the JAK-STAT pathway. GM-CSFR binding to GM-CSF is reviewed in Haman et al. Journal of Biological Chemistry 1999; 274(48). This interaction is also capable of signaling through tyrosine phosphorylation and activation of the MAP kinase pathway. Pathologically, GM-CSF has been shown to play a role in exacerbating inflammatory, respiratory and autoimmune diseases. Neutralization of GM-CSF binding to GM-CSFR&#x3b1; is therefore a therapeutic approach to treating diseases and conditions mediated through GM-CSFR.</p><heading id="h-0012" level="2">Full-Length Anti-GM-CSFR&#x3b1; Antibody</heading><p id="p-0153" num="0147">The anti-GM-CSFR&#x3b1; antibody in some embodiments is a full-length anti-GM-CSFR&#x3b1; antibody. In some embodiments, the full-length anti-GM-CSFR&#x3b1; antibody is an IgA, IgD, IgE, IgG, or IgM. In some embodiments, the full-length anti-GM-CSFR&#x3b1; antibody comprises IgG constant domains, such as constant domains of any of IgG1, IgG2, IgG3, and IgG4 including variants thereof. In some embodiments, the full-length anti-GM-CSFR&#x3b1; antibody comprises a lambda light chain constant region. In some embodiments, the full-length anti-GM-CSFR&#x3b1; antibody comprises a kappa light chain constant region. In some embodiments, the full-length anti-GM-CSFR&#x3b1; antibody is a full-length human anti-GM-CSFR&#x3b1; antibody. In some embodiments, the full-length anti-GM-CSFR&#x3b1; antibody comprises an Fc sequence of a mouse immunoglobulin. In some embodiments, the full-length anti-GM-CSFR&#x3b1; antibody comprises an Fe sequence that has been altered or otherwise changed so that it has enhanced antibody dependent cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) effector function.</p><p id="p-0154" num="0148">Thus, for example, in some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody specifically binds to GM-CSFR&#x3b1;. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0155" num="0149">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG2 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody specifically binds to GM-CSFR&#x3b1;. In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0156" num="0150">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG3 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody specifically binds to GM-CSFR&#x3b1;. In some embodiments, the IgG3 is human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0157" num="0151">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody specifically binds to GM-CSFR&#x3b1;. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0158" num="0152">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0159" num="0153">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG2 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions. In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0160" num="0154">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG3 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions. In some embodiments, the IgG3 is human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0161" num="0155">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0162" num="0156">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions in the HC-CDR sequences; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions in the LC-CDR sequences. In some embodiments, the IgG1 is human IgG1. In some embodiments, the anti-GM-CSFR&#x3b1; heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the anti-GM-CSFR&#x3b1; light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0163" num="0157">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions in the HC-CDR sequences; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75, or a variant thereof comprising up to about 3 (such as about any of 1, 2, or 3) amino acid substitutions in the LC-CDR sequences. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0164" num="0158">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0165" num="0159">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0166" num="0160">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0167" num="0161">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0168" num="0162">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 23; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0169" num="0163">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0170" num="0164">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 53. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0171" num="0165">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0172" num="0166">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0173" num="0167">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0174" num="0168">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0175" num="0169">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0176" num="0170">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0177" num="0171">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 23; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0178" num="0172">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0179" num="0173">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 53. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0180" num="0174">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0181" num="0175">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence 1605 of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0182" num="0176">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0183" num="0177">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0184" num="0178">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a light chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0185" num="0179">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG2 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a light chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity. In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0186" num="0180">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG3 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a light chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity. In some embodiments, the IgG3 is human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0187" num="0181">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a light chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0188" num="0182">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287, and a light chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0189" num="0183">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287, and a light chain variable domain comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0190" num="0184">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 123. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0191" num="0185">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 85 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 125. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0192" num="0186">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 86 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0193" num="0187">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0194" num="0188">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 99 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 122. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0195" num="0189">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0196" num="0190">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 103 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 123. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0197" num="0191">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 99 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0198" num="0192">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0199" num="0193">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 123. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or 1800 consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0200" num="0194">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 85 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 125. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0201" num="0195">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 86 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0202" num="0196">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0203" num="0197">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 99 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 122. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0204" num="0198">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0205" num="0199">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 103 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 123. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0206" num="0200">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 99 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0207" num="0201">In some embodiments, there is provided a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG4 constant domains, wherein the anti-GM-CSFR&#x3b1; antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:146 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><heading id="h-0013" level="2">Binding Affinity</heading><p id="p-0208" num="0202">Binding affinity can be indicated by K<sub>d</sub>, K<sub>off</sub>, K<sub>on</sub>, or K<sub>a</sub>. The term &#x201c;K<sub>off</sub>&#x201d;, as used herein, is intended to refer to the off-rate constant for dissociation of an antibody from the antibody/antigen complex, as determined from a kinetic selection set up. The term &#x201c;K<sub>on</sub>&#x201d;, as used herein, is intended to refer to the on-rate constant for association of an antibody to the antigen to form the antibody/antigen complex. The term equilibrium dissociation constant &#x201c;K<sub>d</sub>&#x201d;, as used herein, refers to the dissociation constant of a particular antibody-antigen interaction, and describes the concentration of antigen required to occupy one half of all of the antibody-binding domains present in a solution of antibody molecules at equilibrium, and is equal to K<sub>off</sub>/K<sub>on</sub>. The measurement of K<sub>d </sub>presupposes that all binding agents are in solution. In the case where the antibody is tethered to a cell wall, e.g., in a yeast expression system, the corresponding equilibrium rate constant is expressed as EC50, which gives a good approximation of K<sub>d</sub>. The affinity constant, K<sub>a</sub>, is the inverse of the dissociation constant, K<sub>d</sub>.</p><p id="p-0209" num="0203">The dissociation constant (K<sub>d</sub>) is used as an indicator showing affinity of antibody moieties to antigens. For example, easy analysis is possible by the Scatchard method using antibodies marked with a variety of marker agents, as well as by using Biacore (made by Amersham Biosciences), analysis of biomolecular interactions by surface plasmon resonance, according to the user's manual and attached kit. The K<sub>d </sub>value that can be derived using these methods is expressed in units of M (Mols). An antibody that specifically binds to a target may have a K<sub>d </sub>of, for example, &#x2264;10<sup>&#x2212;7 </sup>M, &#x2264;10<sup>&#x2212;8 </sup>M, &#x2264;10<sup>&#x2212;9 </sup>M, &#x2264;10<sup>&#x2212;10 </sup>M, &#x2264;10<sup>&#x2212;11 </sup>M, 10<sup>&#x2212;12 </sup>M, or &#x2264;10<sup>&#x2212;13 </sup>M.</p><p id="p-0210" num="0204">Binding specificity of the antibody can be determined experimentally by methods known in the art. Such methods comprise, but are not limited to. Western blots, ELISA-, RIA-, ECL-, IRMA-, EIA-, BIAcore-tests and peptide scans.</p><p id="p-0211" num="0205">In some embodiments, the anti-GM-CSFR&#x3b1; antibody specifically binds to a target GM-CSFR&#x3b1; with a K<sub>d </sub>of about 10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;13 </sup>M (such as about 10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;13 </sup>M, about 10<sup>&#x2212;8 </sup>M to about 10<sup>&#x2212;13 </sup>M, about 10<sup>&#x2212;9 </sup>M to about 10<sup>&#x2212;13 </sup>M. or about 10<sup>&#x2212;10 </sup>M to about 10<sup>&#x2212;12 </sup>M). Thus in some embodiments, the K<sub>d </sub>of the binding between the anti-GM-CSFR&#x3b1; antibody and GM-CSFR&#x3b1;, is about 10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;13 </sup>M, about 1&#xd7;10<sup>&#x2212;7 </sup>M to about 5&#xd7;10<sup>&#x2212;13 </sup>M, about 10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;12 </sup>M, about 10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;11 </sup>M, about 10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;10 </sup>M, about 10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;9 </sup>M, about 10<sup>&#x2212;8 </sup>M to about 10<sup>&#x2212;13 </sup>M, about 1&#xd7;10<sup>&#x2212;8 </sup>M to about 5&#xd7;10<sup>&#x2212;13 </sup>M, about 10<sup>&#x2212;18 </sup>M to about 10<sup>&#x2212;12 </sup>M, about 10<sup>&#x2212;8 </sup>M to about 10<sup>&#x2212;11 </sup>M, about 10<sup>&#x2212;8 </sup>M to about 10<sup>&#x2212;10 </sup>M, about 10<sup>&#x2212;8 </sup>M to about 10<sup>&#x2212;9 </sup>M, about 5&#xd7;10<sup>&#x2212;9 </sup>M to about 1&#xd7;10<sup>&#x2212;13 </sup>M, about 5&#xd7;10<sup>&#x2212;9 </sup>M to about 1&#xd7;10<sup>&#x2212;12 </sup>M, about 5&#xd7;10<sup>&#x2212;9 </sup>M to about 1&#xd7;10<sup>&#x2212;11 </sup>M, about 5&#xd7;10<sup>&#x2212;9 </sup>M to about 1&#xd7;10<sup>&#x2212;10 </sup>M, about 10<sup>&#x2212;9 </sup>M to about 10<sup>&#x2212;13 </sup>M, about 10<sup>&#x2212;9 </sup>M to about 10<sup>&#x2212;12 </sup>M, about 10<sup>&#x2212;9 </sup>M to about 10<sup>&#x2212;11 </sup>M, about 10<sup>&#x2212;9 </sup>M to about 10<sup>&#x2212;10 </sup>M, about 5&#xd7;10<sup>&#x2212;10 </sup>M to about 1&#xd7;10<sup>&#x2212;13 </sup>M, about 5&#xd7;10<sup>&#x2212;10 </sup>M to about 1&#xd7;10<sup>&#x2212;12 </sup>M, about 5&#xd7;10<sup>&#x2212;10 </sup>M to about 1&#xd7;10<sup>&#x2212;11 </sup>M, about 10<sup>&#x2212;0 </sup>M to about 10<sup>&#x2212;13 </sup>M, about 1&#xd7;10<sup>&#x2212;10 </sup>M to about 5&#xd7;10<sup>&#x2212;13 </sup>M, about 1&#xd7;10<sup>&#x2212;10 </sup>M to about 1&#xd7;10<sup>&#x2212;12 </sup>M, about 1&#xd7;10<sup>&#x2212;10 </sup>M to about 5&#xd7;10<sup>&#x2212;12 </sup>M, about 1&#xd7;10<sup>&#x2212;0 </sup>M to about 1&#xd7;10<sup>&#x2212;11 </sup>M, about 10<sup>&#x2212;11 </sup>M to about 10<sup>&#x2212;13 </sup>M, about 1&#xd7;10<sup>&#x2212;11 </sup>M to about 5&#xd7;10<sup>&#x2212;13 </sup>M, about 10<sup>&#x2212;11 </sup>M to about 10<sup>&#x2212;12 </sup>M. or about 10<sup>&#x2212;12 </sup>M to about 10<sup>&#x2212;13 </sup>M. In some 1925 embodiments, the K<sub>d </sub>of the binding between the anti-GM-CSFR&#x3b1; antibody and a GM-CSFR&#x3b1; is about 10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;13 </sup>M.</p><p id="p-0212" num="0206">In some embodiments, the K<sub>d </sub>of the binding between the anti-GM-CSFR&#x3b1; antibody and a non-target is more than the K<sub>d </sub>of the binding between the anti-GM-CSFR&#x3b1; antibody and the target, and is herein referred to in some embodiments as the binding affinity of the anti-GM-CSFR&#x3b1; antibody to the target (e.g., GM-CSFR&#x3b1;) is higher than that to a non-target. In some embodiments, the non-target is an antigen that is not GM-CSFR&#x3b1;. In some embodiments, the K<sub>d </sub>of the binding between the anti-GM-CSFR&#x3b1; antibody (against GM-CSFR&#x3b1;) and a non-GM-CSFR&#x3b1; target can be at least about 10 times, such as about 10-100 times, about 100-1000 times, about 10<sup>3</sup>-10<sup>4 </sup>times, about 10<sup>4</sup>-10<sup>5 </sup>times, about 10<sup>5</sup>-10<sup>6 </sup>times, about 10<sup>6</sup>-10<sup>7 </sup>times, about 10<sup>7</sup>-10<sup>8 </sup>times, about 10<sup>8</sup>-10<sup>9 </sup>times, about 10<sup>9</sup>-10<sup>10 </sup>times, about 10<sup>10</sup>-10<sup>11 </sup>times, or about 10<sup>11</sup>-10<sup>12 </sup>times of the K<sub>d </sub>of the binding between the anti-GM-CSFR&#x3b1; antibody and a target GM-CSFR&#x3b1;.</p><p id="p-0213" num="0207">In some embodiments, the anti-GM-CSFR&#x3b1; antibody binds to a non-target with a K<sub>d </sub>of about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;6 </sup>M (such as about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;6 </sup>M, about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;5 </sup>M. or about 10<sup>&#x2212;2 </sup>M to about 10<sup>&#x2212;14 </sup>M). In some embodiments, the non-target is an antigen that is 1940 not GM-CSFR&#x3b1;. Thus in some embodiments, the K<sub>d </sub>of the binding between the anti-GM-CSFR&#x3b1; antibody and a non-GM-CSFR&#x3b1; target is about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;6 </sup>M, about 1&#xd7;10<sup>&#x2212;1 </sup>M to about 5&#xd7;10<sup>&#x2212;6 </sup>M, about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;5 </sup>M, about 1&#xd7;10<sup>&#x2212;1 </sup>M to about 5&#xd7;10<sup>&#x2212;5 </sup>M, about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;4 </sup>M, about 1&#xd7;10<sup>&#x2212;1 </sup>M to about 5&#xd7;10<sup>&#x2212;4 </sup>M, about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;3 </sup>M, about 1&#xd7;10<sup>&#x2212;1 </sup>M to about 5&#xd7;10<sup>&#x2212;3 </sup>M, about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;2 </sup>M, about 10<sup>&#x2212;2 </sup>M to about 10<sup>&#x2212;6 </sup>M, about 1&#xd7;10<sup>&#x2212;2 </sup>M to about 5&#xd7;10<sup>&#x2212;6 </sup>M, about 10<sup>&#x2212;2 </sup>M to about 10<sup>&#x2212;5 </sup>M, about 1&#xd7;10<sup>&#x2212;2 </sup>M to about 5&#xd7;10<sup>&#x2212;5 </sup>M, about 10<sup>&#x2212;2 </sup>M to about 10<sup>&#x2212;4 </sup>M, about 1&#xd7;10<sup>&#x2212;2 </sup>M to about 5&#xd7;10<sup>&#x2212;4 </sup>M, about 10<sup>&#x2212;2 </sup>M to about 10<sup>&#x2212;3 </sup>M, about 10<sup>&#x2212;3 </sup>M to about 10<sup>&#x2212;6 </sup>M, about 1&#xd7;10<sup>&#x2212;3 </sup>M to about 5&#xd7;10<sup>&#x2212;6 </sup>M, about 10<sup>&#x2212;3 </sup>M to about 10<sup>&#x2212;5 </sup>M, about 1&#xd7;10<sup>&#x2212;3 </sup>M to about 5&#xd7;10<sup>&#x2212;5 </sup>M, about 10<sup>&#x2212;3 </sup>M to about 10<sup>&#x2212;4 </sup>M, about 10<sup>&#x2212;4 </sup>M to about 10<sup>&#x2212;6 </sup>M, about 1&#xd7;10<sup>&#x2212;4 </sup>M to about 5&#xd7;10<sup>&#x2212;6 </sup>M, about 10<sup>&#x2212;4 </sup>M to about 10<sup>&#x2212;5 </sup>M, or about 10<sup>&#x2212;5 </sup>M to about 10<sup>&#x2212;6 </sup>M.</p><p id="p-0214" num="0208">In some embodiments, when referring to that the anti-GM-CSFR&#x3b1; antibody specifically recognizes a target GM-CSFR&#x3b1; at a high binding affinity, and binds to a non-target at a low binding affinity, the anti-GM-CSFR&#x3b1; antibody will bind to the target GM-CSFR&#x3b1; with a K<sub>a </sub>of about 10<sup>&#x2212;7</sup>M to about 10<sup>&#x2212;13 </sup>M (such as about 10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;13 </sup>M, about 10<sup>&#x2212;8 </sup>M to about 10<sup>&#x2212;13 </sup>M, about 10<sup>&#x2212;9 </sup>M to about 10<sup>&#x2212;13 </sup>M, or about 10<sup>&#x2212;10 </sup>M to about 10<sup>&#x2212;12 </sup>M), and will bind to the non-target with a K<sub>d </sub>of about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;6 </sup>M (such as about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;6 </sup>M, about 10<sup>&#x2212;1 </sup>M to about 10<sup>&#x2212;5 </sup>M, or about 10<sup>&#x2212;2 </sup>M to about 10<sup>&#x2212;4 </sup>M).</p><p id="p-0215" num="0209">In some embodiments, when referring to that the anti-GM-CSFR&#x3b1; antibody specifically recognizes GM-CSFR&#x3b1;, the binding affinity of the anti-GM-CSFR&#x3b1; antibody is compared to a control anti-GM-CSFR&#x3b1; antibody (such as Mavrilimumab). In some embodiments, the K<sub>a </sub>of the binding between the control anti-GM-CSFR&#x3b1; antibody and GM-CSFR&#x3b1; can be at least about 2 times, such as about 2 times, about 3 times, about 4 times, about 5 times, about 6 times, about 7 times, about 8 times, about 9 times, about 10 times, about 10-100 times, about 100-1000 times, about 10<sup>3</sup>-10<sup>4 </sup>times of the K<sub>a </sub>of the binding between the anti-GM-CSFR&#x3b1; antibody described herein and GM-CSFR&#x3b1;.</p><heading id="h-0014" level="2">Nucleic Acids</heading><p id="p-0216" num="0210">Nucleic acid molecules encoding the anti-GM-CSFR&#x3b1; antibodies are also contemplated. In some embodiments, there is provided a nucleic acid (or a set of nucleic acids) encoding a full-length anti-GM-CSFR&#x3b1; antibody, including any of the full-length anti-GM-CSFR&#x3b1; antibodies described herein. In some embodiments, the nucleic acid (or a set of nucleic acids) encoding the anti-GM-CSFR&#x3b1; antibody described herein may further comprises a nucleic acid sequence encoding a peptide tag (such as protein purification tag, e.g., His-tag, HA tag).</p><p id="p-0217" num="0211">Also contemplated here are isolated host cells comprising an anti-GM-CSFR&#x3b1; antibody, an isolated nucleic acid encoding the polypeptide components of the anti-GM-CSFR&#x3b1; antibody, or a vector comprising a nucleic acid encoding the polypeptide components of the anti-GM-CSFR&#x3b1; antibody described herein.</p><p id="p-0218" num="0212">The present application also includes variants to these nucleic acid sequences. For example, the variants include nucleotide sequences that hybridize to the nucleic acid sequences encoding the anti-GM-CSFR&#x3b1; antibodies of the present application under at least moderately stringent hybridization conditions.</p><p id="p-0219" num="0213">The present application also provides vectors in which a nucleic acid of the present application is inserted.</p><p id="p-0220" num="0214">In brief summary, the expression of an anti-GM-CSFR&#x3b1; antibody (e.g., full-length anti-GM-CSFR&#x3b1; antibody) by a natural or synthetic nucleic acid encoding the anti-GM-CSFR&#x3b1; antibody can be achieved by inserting the nucleic acid into an appropriate expression vector, such that the nucleic acid is operably linked to 5&#x2032; and 3&#x2032; regulatory elements, including for example a promoter (e.g., a lymphocyte-specific promoter) and a 3&#x2032; untranslated region (UTR). The vectors can be suitable for replication and integration in eukaryotic host cells. Typical cloning and expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence.</p><p id="p-0221" num="0215">The nucleic acids of the present application may also be used for nucleic acid immunization and gene therapy, using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g., U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466, incorporated by reference herein in their entireties. In some embodiments, the application provides a gene therapy vector.</p><p id="p-0222" num="0216">The nucleic acid can be cloned into a number of types of vectors. For example, the nucleic acid can be cloned into a vector including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus, and a cosmid. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.</p><p id="p-0223" num="0217">Further, the expression vector may be provided to a cell in the form of a viral vector. Viral vector technology is well known in the art and is described, for example, in Green and Sambrook (2013, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in other virology and molecular biology manuals. Viruses which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses. In general, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers (see, e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193).</p><p id="p-0224" num="0218">A number of viral based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. A selected gene can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo. A number of retroviral systems are known in the art. In some embodiments, adenovirus vectors are used. A number of adenovirus vectors are known in the art. In some embodiments, lentivirus vectors are used. Vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells. Lentiviral vectors have the added advantage over vectors derived from onco-retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low immunogenicity.</p><p id="p-0225" num="0219">Additional promoter elements, e.g., enhancers, regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline.</p><p id="p-0226" num="0220">One example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto. Another example of a suitable promoter is Elongation Growth Factor-1&#x3b1; (EF-1&#x3b1;). However, other constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter. Further, the application should not be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the application. The use of an inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to a metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.</p><p id="p-0227" num="0221">In some embodiments, the expression of the anti-GM-CSFR&#x3b1; antibody is inducible. In some embodiments, a nucleic acid sequence encoding the anti-GM-CSFR&#x3b1; antibody is operably linked to an inducible promoter, including any inducible promoter described herein.</p><heading id="h-0015" level="2">Inducible Promoters</heading><p id="p-0228" num="0222">The use of an inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. Exemplary inducible promoter systems for use in eukaryotic cells include, but are not limited to, hormone-regulated elements (e.g., see Mader, S. and White, J. H. (1993) Proc. Natl. Acad. Sci. USA 90:5603-5607), synthetic ligand-regulated elements (see, e.g., Spencer, D. M. et al 1993) Science 262: 1019-1024) and ionizing radiation-regulated elements (e.g., see Manome, Y. et al. (1993) Biochemistry 32: 10607-10613; Datta, R. et al. (1992) Proc. Natl. Acad. Sci. USA 89: 1014-10153). Further exemplary inducible promoter systems for use in in vitro or in vivo mammalian systems are reviewed in Gingrich et al. (1998) Annual Rev. Neurosci 21:377-405. In some embodiments, the inducible promoter system for use to express the anti-GM-CSFR&#x3b1; antibody is the Tet system. In some embodiments, the inducible promoter system for use to express the anti-GM-CSFR&#x3b1; antibody is the lac repressor system from <i>E. coli. </i></p><p id="p-0229" num="0223">An exemplary inducible promoter system for use in the present application is the Tet system. Such systems are based on the Tet system described by Gossen et al. (1993). In an exemplary embodiment, a polynucleotide of interest is under the control of a promoter that comprises one or more Tet operator (TetO) sites. In the inactive state, Tet repressor (TetR) will bind to the TetO sites and repress transcription from the promoter. In the active state, e.g., in the presence of an inducing agent such as tetracycline (Tc), anhydrotetracycline, doxycycline (Dox), or an active analog thereof, the inducing agent causes release of TetR from TetO, thereby allowing transcription to take place. Doxycycline is a member of the tetracycline family of antibiotics having the chemical name of 1-dimethylamino-2,4a,5,7,12-pentahydroxy-11-methyl-4,6-dioxo-1,4a,11,11a,12,12a-hexahydrotetracene-3-carboxamide.</p><p id="p-0230" num="0224">In one embodiment, a TetR is codon-optimized for expression in mammalian cells, e.g., murine or human cells. Most amino acids are encoded by more than one codon due to the degeneracy of the genetic code, allowing for substantial variations in the nucleotide sequence of a given nucleic acid without any alteration in the amino acid sequence encoded by the nucleic acid. However, many organisms display differences in codon usage, also known as &#x201c;codon bias&#x201d; (i.e., bias for use of a particular codon(s) for a given amino acid). Codon bias often correlates with the presence of a predominant species of tRNA for a particular codon, which in turn increases efficiency of mRNA translation. Accordingly, a coding sequence derived from a particular organism (e.g., a prokaryote) may be tailored for improved expression in a different organism (e.g., a eukaryote) through codon optimization.</p><p id="p-0231" num="0225">Other specific variations of the Tet system include the following &#x201c;Tet-Off&#x201d; and &#x201c;Tet-On&#x201d; systems. In the Tet-Off system, transcription is inactive in the presence of Tc or Dox. In that system, a tetracycline-controlled transactivator protein (tTA), which is composed of TetR fused to the strong transactivating domain of VP16 from Herpes simplex virus, regulates expression of a target nucleic acid that is under transcriptional control of a tetracycline-responsive promoter element (TRE). The TRE is made up of TetO sequence concatamers fused to a promoter (commonly the minimal promoter sequence derived from the human cytomegalovirus (hCMV) immediate-early promoter). In the absence of Tc or Dox, tTA binds to the TRE and activates transcription of the target gene. In the presence of Tc or Dox, tTA cannot bind to the TRE, and expression from the target gene remains inactive.</p><p id="p-0232" num="0226">Conversely, in the Tet-On system, transcription is active in the presence of Tc or Dox. The Tet-On system is based on a reverse tetracycline-controlled transactivator, rtTA. Like tTA, rtTA is a fusion protein comprised of the TetR repressor and the VP16 transactivation domain. However, a four amino acid change in the TetR DNA binding moiety alters rtTA's binding characteristics such that it can only recognize the tetO sequences in the TRE of the target transgene in the presence of Dox. Thus, in the Tet-On system, transcription of the TRE-regulated target gene is stimulated by rtTA only in the presence of Dox.</p><p id="p-0233" num="0227">Another inducible promoter system is the lac repressor system from <i>E. coli </i>(See Brown et al., Cell 49:603-612 (1987)). The lac repressor system functions by regulating transcription of a polynucleotide of interest operably linked to a promoter comprising the lac operator (lacO). The lac repressor (lacR) binds to LacO, thus preventing transcription of the polynucleotide of interest. Expression of the polynucleotide of interest is induced by a suitable inducing agent, e.g., isopropyl-&#x3b2;-D-thiogalactopyranoside (IPTG).</p><p id="p-0234" num="0228">In order to assess the expression of a polypeptide or portions thereof, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors. In other aspects, the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers include, for example, antibiotic-resistance genes, such as neo and the like.</p><p id="p-0235" num="0229">Reporter genes are used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences. In general, a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a polypeptide whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells. Suitable reporter genes may include genes encoding luciferase, &#x3b2;-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene (e.g., Ui-Tel et al., 2000 <i>FEBS Letters </i>479: 79-82). Suitable expression systems are well known and may be prepared using known techniques or obtained commercially. In general, the construct with the minimal 5&#x2032; flanking region showing the highest level of expression of reporter gene is identified as the promoter. Such promoter regions may be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter-driven transcription.</p><p id="p-0236" num="0230">In some embodiments, there is provided nucleic acid encoding a full-length anti-GM-CSFR&#x3b1; antibody according to any of the full-length anti-GM-CSFR&#x3b1; antibodies described herein. In some embodiments, the nucleic acid comprises one or more nucleic acid sequences encoding the heavy and light chains of the full-length anti-GM-CSFR&#x3b1; antibody. In some embodiments, each of the one or more nucleic acid sequences are contained in separate vectors. In some embodiments, at least some of the nucleic acid sequences are contained in the same vector. In some embodiments, all of the nucleic acid sequences are contained in the same vector. Vectors may be selected, for example, from the group consisting of mammalian expression vectors and viral vectors (such as those derived from retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses).</p><p id="p-0237" num="0231">Methods of introducing and expressing genes into a cell are known in the art. In the context of an expression vector, the vector can be readily introduced into a host cell, e.g., mammalian, bacterial, yeast, or insect cell by any method in the art. For example, the expression vector can be transferred into a host cell by physical, chemical, or biological means.</p><p id="p-0238" num="0232">Physical methods for introducing a polynucleotide into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells comprising vectors and/or exogenous nucleic acids are well-known in the art. See, for example, Green and Sambrook (2013, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). In some embodiments, the introduction of a polynucleotide into a host cell is carried out by calcium phosphate transfection.</p><p id="p-0239" num="0233">Biological methods for introducing a polynucleotide of interest into a host cell include the use of DNA and RNA vectors. Viral vectors, and especially retroviral vectors, have become the most widely used method of inserting genes into mammalian, e.g., human cells. Other viral vectors can be derived from lentivirus, poxviruses, herpes simplex virus 1, adenoviruses and adeno-associated viruses, and the like. See, for example, U.S. Pat. Nos. 5,350,674 and 5,585,362.</p><p id="p-0240" num="0234">Chemical means for introducing a polynucleotide into a host cell include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).</p><p id="p-0241" num="0235">In the case where a non-viral delivery system is utilized, an exemplary delivery vehicle is a liposome. The use of lipid formulations is contemplated for the introduction of the nucleic acids into a host cell (in vitro, ex vivo or in vivo). In another aspect, the nucleic acid may be associated with a lipid. The nucleic acid associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles, or with a &#x201c;collapsed&#x201d; structure. They may also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which may be naturally occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.</p><p id="p-0242" num="0236">Regardless of the method used to introduce exogenous nucleic acids into a host cell or otherwise expose a cell to the inhibitor of the present application, in order to confirm the presence of the recombinant DNA sequence in the host cell, a variety of assays may be performed. Such assays include, for example. &#x201c;molecular biological&#x201d; assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; &#x201c;biochemical&#x201d; assays, such as detecting the presence or absence of a particular peptide, e.g., by immunological means (ELISAs and Western blots) or by assays described herein to identify agents falling within the scope of the application.</p><heading id="h-0016" level="2">Preparation of Anti-GM-CSFR&#x3b1; Antibodies</heading><p id="p-0243" num="0237">In some embodiments, the anti-GM-CSFR&#x3b1; antibody is a monoclonal antibody or derived from a monoclonal antibody. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises V<sub>H </sub>and V<sub>L </sub>domains, or variants thereof, from the monoclonal antibody. In some embodiments, the anti-GM-CSFR&#x3b1; antibody further comprises C<sub>H</sub>1 and C<sub>L </sub>domains, or variants thereof, from the monoclonal antibody. Monoclonal antibodies can be prepared, e.g., using known methods in the art, including hybridoma methods, phage display methods, or using recombinant DNA methods. Additionally, exemplary phage display methods are described herein and in the Examples below.</p><p id="p-0244" num="0238">In a hybridoma method, a hamster, mouse, or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro. The immunizing agent can include a polypeptide or a fusion protein of the protein of interest. Generally, peripheral blood lymphocytes (&#x201c;PBLs&#x201d;) are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (&#x201c;HAT medium&#x201d;), which prevents the growth of HGPRT-deficient cells.</p><p id="p-0245" num="0239">In some embodiments, the immortalized cell lines fuse efficiently, support stable high-level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. In some embodiments, the immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies.</p><p id="p-0246" num="0240">The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the polypeptide. The binding specificity of monoclonal antibodies produced by the hybridoma cells can be determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, <i>Anal. Biochem., </i>107:220 (1980).</p><p id="p-0247" num="0241">After the desired hybridoma cells are identified, the clones can be sub cloned by limiting dilution procedures and grown by standard methods. Goding, supra. Suitable culture media for this purpose include, for example. Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.</p><p id="p-0248" num="0242">The monoclonal antibodies secreted by the sub clones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.</p><p id="p-0249" num="0243">In some embodiments, according to any of the anti-GM-CSFR&#x3b1; antibodies described herein, the anti-GM-CSFR&#x3b1; antibody comprises sequences from a clone selected from an antibody library (such as a phage library presenting scFv or Fab fragments). The clone may be identified by screening combinatorial libraries for antibody fragments with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed. e.g., in Hoogenboom et al., <i>Methods in Molecular Biology </i>178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., 2001) and further described, e.g., in McCafferty et al., <i>Nature </i>348:552-554; Clackson et al., <i>Nature </i>352: 624-628 (1991); Marks et al., <i>J. Mol. Biol. </i>222: 581-597 (1992); Marks and Bradbury, <i>Methods in Molecular Biology </i>248:161-175 (Lo, ed., Human Press, Totowa, N.J., 2003); Sidhu et al., <i>J. Mol. Biol. </i>338(2): 299-310 (2004); Lee et al., <i>J. Mol. Biol. </i>340(5): 1073-1093 (2004); Fellouse, <i>Proc. Natl. Acad. Sci. USA </i>101(34): 12467-12472 (2004); and Lee et al., <i>J. Immunol. Methods </i>284(1-2): 119-132(2004).</p><p id="p-0250" num="0244">In certain phage display methods, repertoires of V<sub>H </sub>and V<sub>L </sub>genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al., <i>Ann. Rev. Immunol., </i>12: 433-455 (1994). Phage typically display antibody fragments, either as scFv fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self-antigens without any immunization as described by Griffiths et al., <i>EMBO J, </i>12: 725-734 (1993). Finally, naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter, <i>J. Mol. Biol., </i>227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 20050119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.</p><p id="p-0251" num="0245">The anti-GM-CSFR&#x3b1; antibodies can be prepared using phage display to screen libraries for anti-GM-CSFR&#x3b1; antibody moieties specific to the target GM-CSFR&#x3b1;. The library can be a human scFv phage display library having a diversity of at least one&#xd7;10<sup>9 </sup>(such as at least about any of 1&#xd7;10<sup>9</sup>, 2.5&#xd7;10<sup>9</sup>, 5&#xd7;10<sup>9</sup>, 7.5&#xd7;10<sup>9</sup>, 1&#xd7;10<sup>10</sup>, 2.5&#xd7;10<sup>10</sup>, 5&#xd7;10<sup>10</sup>, 7.5&#xd7;10<sup>10</sup>, or 1&#xd7;10<sup>11</sup>) unique human antibody fragments. In some embodiments, the library is a na&#xef;ve human library constructed from DNA extracted from human PMBCs and spleens from healthy donors, encompassing all human heavy and light chain subfamilies. In some embodiments, the library is a na&#xef;ve human library constructed from DNA extracted from PBMCs isolated from patients with various diseases, such as patients with autoimmune diseases, cancer patients, and patients with infectious diseases. In some embodiments, the library is a semi-synthetic human library, wherein heavy chain CDR3 is completely randomized, with all amino acids (with the exception of cysteine) equally likely to be present at any given position (see, e.g., Hoet, R. M. et al., <i>Nat. Biotechnol. </i>23(3):344-348, 2005). In some embodiments, the heavy chain CDR3 of the semi-synthetic human library has a length from about 5 to about 24 (such as about any of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24) amino acids. In some embodiments, 2270 the library is a fully-synthetic phage display library. In some embodiments, the library is a non-human phage display library.</p><p id="p-0252" num="0246">Phage clones that bind to the target GM-CSFR&#x3b1; with high affinity can be selected by iterative binding of phage to the target GM-CSFR&#x3b1;, which is bound to a solid support (such as, for example, beads for solution panning or mammalian cells for cell panning), followed by removal of non-bound phage and by elution of specifically bound phage. The bound phage clones are then eluted and used to infect an appropriate host cell, such as <i>E. coli </i>XL1-Blue, for expression and purification. The panning can be performed for multiple (such as about any of 2, 3, 4, 5, 6 or more) rounds with solution panning, cell panning, or a combination of both, to enrich for phage clones binding specifically to the target GM-CSFR&#x3b1;. Enriched phage clones can be tested for specific binding to the target GM-CSFR&#x3b1; by any methods known in the art, including for example ELISA and FACS.</p><p id="p-0253" num="0247">Monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the application can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Hybridoma cells as described above or GM-CSFR&#x3b1;-specific phage clones of the application can serve as a source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains and/or framework regions in place of the homologous non-human sequences (U.S. Pat. No. 4,816,567; Morrison et al., supra) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the application, or can be substituted for the variable domains of one antigen-combining site of an antibody of the application to create a chimeric bivalent antibody.</p><p id="p-0254" num="0248">The antibodies can be monovalent antibodies. Methods for preparing monovalent antibodies are known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy-chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.</p><p id="p-0255" num="0249">In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly Fab fragments, can be accomplished using any method known in the art.</p><p id="p-0256" num="0250">Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant-domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. In some embodiments, the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding is present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism.</p><heading id="h-0017" level="2">Human and Humanized Antibodies</heading><p id="p-0257" num="0251">The anti-GM-CSFR&#x3b1; antibodies (e.g., full-length anti-GM-CSFR&#x3b1; antibodies) can be humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibody moieties are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab&#x2032;, F(ab&#x2032;)<sub>2</sub>, scFv. or other antigen-binding subsequences of antibodies) that typically contain minimal sequence derived from non-human immunoglobulin. Humanized antibody moieties include human immunoglobulins, immunoglobulin chains, or fragments thereof (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibody moieties can also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody can comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.</p><p id="p-0258" num="0252">Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as &#x201c;import&#x201d; residues, which are typically taken from an &#x201c;import&#x201d; variable domain. According to some embodiments, humanization can be essentially performed following the method of Winter and co-workers (Jones et al., <i>Nature, </i>321: 522-525 (1986); Riechmann et al., <i>Nature, </i>332: 323-327 (1988); Verhoeyen et al., <i>Science, </i>239: 1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such &#x201c;humanized&#x201d; antibody moieties are antibody moieties (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibody moieties are typically human antibody moieties in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.</p><p id="p-0259" num="0253">As an alternative to humanization, human antibody moieties can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (JH) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array into such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See. e.g., Jakobovits et al., <i>PNAS USA, </i>90:2551 (1993); Jakobovits et al., <i>Nature, </i>362:255-258 (1993); Bruggemann et al., <i>Year in Immunol., </i>7:33 (1993); U.S. Pat. Nos. 5,545,806, 5,569,825, 5,591,669; 5,545,807; and WO 97/17852. Alternatively, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed that closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016, and Marks et al., <i>Bio/Technology, </i>10: 779-783 (1992); Lonberg et al., <i>Nature, </i>368: 856-859 (1994); Morrison, <i>Nature, </i>368: 812-813 (1994); Fishwild et al., <i>Nature Biotechnology, </i>14: 845-851 (1996); Neuberger, <i>Nature Biotechnology, </i>14: 826 (1996); Lonberg and Huszar, <i>Intern. Rev. Immunol., </i>13: 65-93 (1995).</p><p id="p-0260" num="0254">Human antibodies may also be generated by in vitro activated B cells (see U.S. Pat. Nos. 5,567,610 and 5,229,275) or by using various techniques known in the art, including phage display libraries. Hoogenboom and Winter. <i>J. Mol. Biol., </i>227:381 (1991); Marks et al., <i>J. Mol. Biol., </i>222:581 (1991). The techniques of Cole et al, and Boemer et al. are also available for the preparation of human monoclonal antibodies. Cole et al., <i>Monoclonal Antibodies and Cancer Therapy</i>, Alan R. Liss, p. 77 (1985) and Boerner et al., <i>J. Immunol., </i>147(1): 86-95 (1991).</p><heading id="h-0018" level="2">Anti-GM-CSFR&#x3b1; Antibody Variants</heading><p id="p-0261" num="0255">In some embodiments, amino acid sequence variants of the anti-GM-CSFR&#x3b1; antibodies (e.g., full-length anti-GM-CSFR&#x3b1; antibody) provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics. e.g., antigen-binding.</p><p id="p-0262" num="0256">In some embodiments, anti-GM-CSFR&#x3b1; antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., improved bioactivity, retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.</p><p id="p-0263" num="0257">Conservative substitutions are shown in Table 4 below.</p><p id="p-0264" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>CONSERVATIVE SUBSTITUTIONS</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="119pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry>Original</entry><entry>Exemplary</entry><entry>Preferred</entry></row><row><entry/><entry>Residue</entry><entry>Substitutions</entry><entry>Substitutions</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Ala (A)</entry><entry>Val; Leu; Ile</entry><entry>Val</entry></row><row><entry/><entry>Arg (R)</entry><entry>Lys; Gln; Asn</entry><entry>Lys</entry></row><row><entry/><entry>Asn (N)</entry><entry>Gln; His; Asp, Lys; Arg</entry><entry>Gln</entry></row><row><entry/><entry>Asp (D)</entry><entry>Glu; Asn</entry><entry>Glu</entry></row><row><entry/><entry>Cys (C)</entry><entry>Ser; Ala</entry><entry>Ser</entry></row><row><entry/><entry>Gln (Q)</entry><entry>Asn; Glu</entry><entry>Asn</entry></row><row><entry/><entry>Glu (E)</entry><entry>Asp; Gln</entry><entry>Asp</entry></row><row><entry/><entry>Gly (G)</entry><entry>Ala</entry><entry>Ala</entry></row><row><entry/><entry>His (H)</entry><entry>Asn; Gln; Lys; Arg</entry><entry>Arg</entry></row><row><entry/><entry>Ile (I)</entry><entry>Leu; Val; Met; Ala; Phe; Norleucine</entry><entry>Leu</entry></row><row><entry/><entry>Leu (L)</entry><entry>Norleucine; Ile; Val; Met; Ala; Phe</entry><entry>Ile</entry></row><row><entry/><entry>Lys (K)</entry><entry>Arg; Gln; Asn</entry><entry>Arg</entry></row><row><entry/><entry>Met (M)</entry><entry>Leu; Phe; Ile</entry><entry>Leu</entry></row><row><entry/><entry>Phe (F)</entry><entry>Trp; Leu; Val; Ile; Ala; Tyr</entry><entry>Tyr</entry></row><row><entry/><entry>Pro (P)</entry><entry>Ala</entry><entry>Ala</entry></row><row><entry/><entry>Ser (S)</entry><entry>Thr</entry><entry>Thr</entry></row><row><entry/><entry>Thr (T)</entry><entry>Val; Ser</entry><entry>Ser</entry></row><row><entry/><entry>Trp (W)</entry><entry>Tyr; Phe</entry><entry>Tyr</entry></row><row><entry/><entry>Tyr (Y)</entry><entry>Trp; Phe; Thr; Ser</entry><entry>Phe</entry></row><row><entry/><entry>Val (V)</entry><entry>Ile; Leu; Met; Phe; Ala; Norleucine</entry><entry>Leu</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0265" num="0258">Amino acids may be grouped into different classes according to common side-chain properties:</p><p id="p-0266" num="0000">a. hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;<br/>b. neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;<br/>c. acidic: Asp, Glu;<br/>d. basic: His, Lys, Arg;<br/>e. residues that influence chain orientation: Gly, Pro;<br/>f. aromatic: Trp, Tyr, Phe.</p><p id="p-0267" num="0259">Non-conservative substitutions will entail exchanging a member of one of these classes for another class.</p><p id="p-0268" num="0260">An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques. Briefly, one or more CDR residues are mutated and the variant antibody moieties displayed on phage and screened for a particular biological activity (e.g., bioactivity based on TF-1 cell proliferation assay or binding affinity). Alterations (e.g., substitutions) may be made in HVRs. e.g., to improve bioactivity based on TF-1 cell proliferation assay or antibody affinity. Such alterations may be made in HVR &#x201c;hotspots,&#x201d; i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, <i>Methods Mol. Biol. </i>207:179-196 (2008)), and/or specificity determining residues (SDRs), with the resulting variant V<sub>H </sub>or V<sub>L </sub>being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described. e.g., in Hoogenboom et al. in <i>Methods in Molecular Biology </i>178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., (2001)).</p><p id="p-0269" num="0261">In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.</p><p id="p-0270" num="0262">In some embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may be outside of HVR &#x201c;hotspots&#x201d; or SDRs. In some embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.</p><p id="p-0271" num="0263">A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called &#x201c;alanine scanning mutagenesis&#x201d; as described by Cunningham and Wells (1989) <i>Science, </i>244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex can be determined to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.</p><p id="p-0272" num="0264">Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme <b>2440</b> (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody. In some embodiments, provided herein are anti-GM-CSFR&#x3b1; antibodies comprising a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27, or a variant thereof comprising up to about 5 amino acid substitutions in the Vu; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to about 5 amino acid substitutions in the V<sub>L</sub>.</p><p id="p-0273" num="0265">In some embodiments, provided herein are anti-GM-CSFR&#x3b1; antibodies comprising a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27, wherein the V<sub>1 </sub>comprises amino acid substitutions comprising amino acid residues E, H, N, G, D, M, S, P, F, Y, A, V, K, W, R, or C at position 31.</p><p id="p-0274" num="0266">In some embodiments, provided herein are anti-GM-CSFR&#x3b1; antibodies comprising a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27, wherein the V<sub>1 </sub>comprises amino acid residues selected from T, H, V, E, P, L, M, S, W, C, A, G, N, or K at position 28, and/or amino acid residues selected from T, P, D, E, Y, W, V, M, N, L, Q, G, S, A, K, or R at position 30.</p><p id="p-0275" num="0267">In some embodiments, provided herein are anti-GM-CSFR&#x3b1; antibodies comprising a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, wherein the V<sub>L </sub>comprises amino acid substitutions comprising S, L, N, A, K, R, I, Q, G, T, H, M, or C at position 26; and/or Q, Y, P, A, I, F, T, R, V, L, E, S, or C at position 27; and/or S, H, W, L, R, K, T, P, I, F, V, E, A, or Q at position 28; and/or S, L, W, M, A, Y, K, R, G, T, E, V, N, F, or C at position 30; and/or S, T, R, A, H, Q, P, M, L, or G at position 31; and/or Y, L or F at position 32; and/or G or T at position 50; and/or A, G, R, H, K, S, T, M, F, N, or V at position 51; and/or S, A, W, R, L, T, Q, F, Y, H, or N at position 52; and/or D, A, Q, or W at position 92; and/or N, D, E, T, Y, G, A, M, F, S, I, or L at position 93.</p><p id="p-0276" num="0268">In some embodiments, any one or combination of the amino acid substitutions as shown in Table 15 is contemplated.</p><p id="p-0277" num="0269">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 241, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 241.</p><p id="p-0278" num="0270">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 193, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 193.</p><p id="p-0279" num="0271">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 248, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 188, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 248 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 188.</p><p id="p-0280" num="0272">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 248, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 193, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 248 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 193.</p><p id="p-0281" num="0273">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 288, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 288.</p><p id="p-0282" num="0274">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 188, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 188.</p><p id="p-0283" num="0275">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 236, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 236.</p><p id="p-0284" num="0276">In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 91, or a variant thereof having at least about 90% (for example at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 288, or a variant thereof having at least about 90% sequence identity. In some embodiments, the anti-GM-CSFR&#x3b1; antibody comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 91 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 288.</p><heading id="h-0019" level="2">Fc Region Variants</heading><p id="p-0285" num="0277">In some embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody (e.g., a full-length anti-GM-CSFR&#x3b1; antibody or anti-GM-CSFR&#x3b1; Fc fusion protein) provided herein, thereby generating an Fc region variant. In some embodiments, the Fc region variant has enhanced ADCC effector function, often related to binding to Fc receptors (FcRs). In some embodiments, the Fc region variant has decreased ADCC effector function. There are many examples of changes or mutations to Fc sequences that can alter effector function. For example, WO 00/42072 and Shields et al. <i>J Biol. Chem. </i>9(2): 6591-6604 (2001) describe antibody variants with improved or diminished binding to FcRs. The contents of those publications are specifically incorporated herein by reference.</p><p id="p-0286" num="0278">Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) is a mechanism of action of therapeutic antibodies against tumor cells. ADCC is a cell-mediated immune defense whereby an effector cell of the immune system actively lyses a target cell (e.g., a cancer cell), whose membrane-surface antigens have been bound by specific antibodies (e.g., an anti-GM-CSFR&#x3b1; antibody). The typical ADCC involves activation of NK cells by antibodies. An NK cell expresses CD16 which is an Fc receptor. This receptor recognizes, and binds to, the Fc portion of an antibody bound to the surface of a target cell. The most common Fc receptor on the surface of an NK cell is called CD16 or Fc&#x3b3;RIII. Binding of the Fc receptor to the Fc region of an antibody results in NK cell activation, release of cytolytic granules and consequent target cell apoptosis. The contribution of ADCC to tumor cell killing can be measured with a specific test that uses NK-92 cells that have been transfected with a high-affinity FcR. Results are compared to wild-type NK-92 cells that do not express the FcR.</p><p id="p-0287" num="0279">In some embodiments, the application contemplates an anti-GM-CSFR&#x3b1; antibody variant (such as a full-length anti-GM-CSFR&#x3b1; antibody variant) comprising an Fc region that possesses some but not all effector functions, which makes it a desirable candidate for applications in which the half-life of the anti-GM-CSFR&#x3b1; antibody in vivo is important yet certain effector functions (such as CDC and ADCC) are unnecessary or deleterious. In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks Fc&#x3b3;R binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, express Fc&#x3b3;RIII only, whereas monocytes express Fc&#x3b3;RI, Fc&#x3b3;RII and Fc&#x3b3;RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet. <i>Annu. Rev. Immunol. </i>9:457-492 (1991). Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (see. e.g. Hellstrom, I. et al. <i>Proc. Nat'l Acad. Sci. USA </i>83:7059-7063 (1986)) and Hellstrom. I et al., <i>Proc. Nat'l Acad. Sci. USA </i>82:1499-1502 (1985); U.S. Pat. No. 5,821,337 (see Bruggemann, M. et al., <i>J. Exp. Med. </i>166:1351-1361 (1987)). Alternatively, non-radioactive assay methods may be employed (see, for example, ACTI&#x2122; non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.; and CYTOTOX 96&#x2122; non-radioactive cytotoxicity assay (Promega. Madison. Wis.). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively. or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. <i>Proc. Nat'l Acad. Sci. USA </i>95:652-656 (1998). C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See. e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example. Gazzano-Santoro et al., <i>J. Immunol. Methods </i>202:163 (1996); Cragg, M. S. et al., <i>Blood </i>101:1045-1052 (2003); and Cragg, M. S. and M. J. Glennie, Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance/half-life determinations can also be performed using methods known in the art (see, e.g., Petkova, S. B. et al., <i>Int'l. Immunol. </i>18(12):1759-1769 (2006)).</p><p id="p-0288" num="0280">Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called &#x201c;DANA&#x201d; Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).</p><p id="p-0289" num="0281">Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Pat. No. 6,737,056; WO 2004/056312, and Shields et al., <i>J. Biol. Chem. </i>9(2): 6591-6604 (2001).)</p><p id="p-0290" num="0282">In some embodiments, there is provided an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) variant comprising a variant Fc region comprising one or more amino acid substitutions which improve ADCC. In some embodiments, the variant Fc region comprises one or more amino acid substitutions which improve ADCC, wherein the substitutions are at positions 298, 333, and/or 334 of the variant Fc region (EU numbering of residues). In some embodiments, the anti-GM-CSFR&#x3b1; antibody (e.g., full-length anti-GM-CSFR&#x3b1; antibody) variant comprises the following amino acid substitution in its variant Fc region: S298A. E333A, and K334A.</p><p id="p-0291" num="0283">In some embodiments, alterations are made in the Fc region that result in altered (i.e., either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC). e.g., as described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et al., <i>J. Immunol. </i>164: 4178-4184 (2000).</p><p id="p-0292" num="0284">In some embodiments, there is provided an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) variant comprising a variant Fc region comprising one or more amino acid substitutions which increase half-life and/or improve binding to the neonatal Fc receptor (FcRn). Antibodies with increased half-lives and improved binding to FcRn are described in US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (U.S. Pat. No. 7,371,826).</p><p id="p-0293" num="0285">See also Duncan &#x26; Winter, <i>Nature </i>322:738-40 (1988); U.S. Pat. Nos. 5,648,260; 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.</p><p id="p-0294" num="0286">Anti-GM-CSFR&#x3b1; antibodies (such as full-length anti-GM-CSFR&#x3b1; antibodies) comprising any of the Fc variants described herein, or combinations thereof, are contemplated.</p><heading id="h-0020" level="2">Glycosylation Variants</heading><p id="p-0295" num="0287">In some embodiments, an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) provided herein is altered to increase or decrease the extent to which the anti-GM-CSFR&#x3b1; antibody is glycosylated. Addition or deletion of glycosylation sites to an anti-GM-CSFR&#x3b1; antibody may be conveniently accomplished by altering the amino acid sequence of the anti-GM-CSFR&#x3b1; antibody or polypeptide portion thereof such that one or more glycosylation sites is created or removed.</p><p id="p-0296" num="0288">Wherein the anti-GM-CSFR&#x3b1; antibody comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al., <i>TIBTECH </i>15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose. N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the &#x201c;stem&#x201d; of 2625 the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in an anti-GM-CSFR&#x3b1; antibody of the application may be made in order to create anti-GM-CSFR&#x3b1; antibody variants with certain improved properties.</p><p id="p-0297" num="0289">The N-glycans attached to the CH2 domain of Fc is heterogeneous. Antibodies or Fc fusion proteins generated in CHO cells are fucosylated by fucosyltransferase activity. See Shoji-Hosaka et al., J. Biochem. 2006, 140:777-83. Normally, a small percentage of naturally occurring afucosylated IgGs may be detected in human serum. N-glycosylation of the Fe is important for binding to Fc&#x3b3;R; and afucosylation of the N-glycan increases Fc's binding capacity to Fc&#x3b3;RIIIa. Increased Fc&#x3b3;RIIIa binding can enhance ADCC, which can be advantageous in certain antibody therapeutic applications in which cytotoxicity is desirable.</p><p id="p-0298" num="0290">In some embodiments, an enhanced effector function can be detrimental when Fc-mediated cytotoxicity is undesirable. In some embodiments, the Fe fragment or CH2 domain is not glycosylated. In some embodiments, the N-glycosylation site in the CH2 domain is mutated to prevent from glycosylation.</p><p id="p-0299" num="0291">In some embodiments, anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) variants are provided comprising an Fc region wherein a carbohydrate structure attached to the Fc region has reduced fucose or lacks fucose, which may improve ADCC function. Specifically, anti-GM-CSFR&#x3b1; antibodies are contemplated herein that have reduced fucose relative to the amount of fucose on the same anti-GM-CSFR&#x3b1; antibody produced in a wild-type CHO cell. That is, they are characterized by having a lower amount of fucose than they would otherwise have if produced by native CHO cells (e.g., a CHO cell that produce a native glycosylation pattern, such as, a CHO cell containing a native FUT8 gene). In some embodiments, the anti-GM-CSFR&#x3b1; antibody is one wherein less than about 50%, 40%, 30%, 20%, 10%, or 5% of the N-linked glycans thereon comprise fucose. For example, the amount of fucose in such an anti-GM-CSFR&#x3b1; antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. In some embodiments, the anti-GM-CSFR&#x3b1; antibody is one wherein none of the N-linked glycans thereon comprise fucose, i.e., wherein the anti-GM-CSFR&#x3b1; antibody is completely without fucose, or has no fucose or is afucosylated. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example. Asn297 refers to the asparagine residue located at about position 297 in the Fc region (EU numbering of Fc region residues); however, Asn297 may also be located about &#xb1;3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to &#x201c;defucosylated&#x201d; or &#x201c;fucose-deficient&#x201d; antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. <i>J. Mol. Biol. </i>336:1239-1249 (2004); Yamane-Ohnuki et al. <i>Biotech. Bioeng. </i>87: 614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. <i>Arch. Biochem. Biophys. </i>249:533-545 (1986); US Pat Appl No US 2003/0157108 A1, Presta. L; and WO 2004/056312 A1. Adams et al., especially at Example 11), and knockout cell lines, such as &#x3b1;-1,6-fucosyltransferase gene. FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. <i>Biotech. Bioeng. </i>87: 614 (2004); Kanda, Y. et al., <i>Biotechnol. Bioeng., </i>94(4):680-688 (2006); and WO2003/085107).</p><p id="p-0300" num="0292">Anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the anti-GM-CSFR&#x3b1; antibody is bisected by GlcNAc. Such anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean-Mairet et al.): U.S. Pat. No. 6,602,684 (Umana et al.); US 2005/0123546 (Umana et al.), and Ferrara et al., <i>Biotechnology and Bioengineering, </i>93(5): 851-861 (2006). Anti-GM-CSFR&#x3b1; antibody (such as full-length anti-GM-CSFR&#x3b1; antibody) variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such anti-GM-CSFR&#x3b1; antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).</p><p id="p-0301" num="0293">In some embodiments, the anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) variants comprising an Fc region are capable of binding to an Fc&#x3b3;RIII. In some embodiments, the anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) variants comprising an Fc region have ADCC activity in the presence of human effector cells (e.g., T cell) or have increased ADCC activity in the presence of human effector cells compared to the otherwise same anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) comprising a human wild-type IgG1Fc region.</p><heading id="h-0021" level="2">Cysteine Engineered Variants</heading><p id="p-0302" num="0294">In some embodiments, it may be desirable to create cysteine engineered anti-GM-CSFR&#x3b1; antibodies (such as a full-length anti-GM-CSFR&#x3b1; antibody) in which one or more amino acid residues are substituted with cysteine residues. In some embodiments, the substituted residues occur at accessible sites of the anti-GM-CSFR&#x3b1; antibody. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the anti-GM-CSFR&#x3b1; antibody and may be used to conjugate the anti-GM-CSFR&#x3b1; antibody to other moieties, such as drug moieties or linker-drug moieties, to create an anti-GM-CSFR&#x3b1; immunoconjugate, as described further herein. Cysteine engineered anti-GM-CSFR&#x3b1; antibodies (e.g., full-length anti-GM-CSFR&#x3b1; antibodies) may be generated as described, e.g., in U.S. Pat. No. 7,521,541.</p><heading id="h-0022" level="2">Derivatives</heading><p id="p-0303" num="0295">In some embodiments, an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) provided herein may be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the anti-GM-CSFR&#x3b1; antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the anti-GM-CSFR&#x3b1; antibody may vary, and if more than one polymer are attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of anti-GM-CSFR&#x3b1; antibody to be improved, whether the anti-GM-CSFR&#x3b1; antibody derivative will be used in a therapy under defined conditions, etc.</p><heading id="h-0023" level="2">Pharmaceutical Compositions</heading><p id="p-0304" num="0296">Also provided herein are compositions (such as pharmaceutical compositions, also referred to herein as formulations) comprising any of the anti-GM-CSFR&#x3b1; antibodies (such as a full-length anti-GM-CSFR&#x3b1; antibody), nucleic acids encoding the antibodies, vectors comprising the nucleic acids encoding the antibodies, or host cells comprising the nucleic acids or vectors described herein. In some embodiments, there is provided a pharmaceutical composition comprising any one of the anti-GM-CSFR&#x3b1; antibodies described herein and a pharmaceutically acceptable carrier.</p><p id="p-0305" num="0297">Suitable formulations of the anti-GM-CSFR&#x3b1; antibodies are obtained by mixing an anti-GM-CSFR&#x3b1; antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (<i>Remington's Pharmaceutical Sciences </i>16th edition. Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as olyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as TWEEN&#x2122;, PLURONICS&#x2122; or polyethylene glycol (PEG). Exemplary formulations are described in WO98/56418, expressly incorporated herein by reference. Lyophilized formulations adapted for subcutaneous administration are described in WO97/04801. Such lyophilized formulations may be reconstituted with a suitable diluent to a high protein concentration and the reconstituted formulation may be administered subcutaneously to the individual to be treated herein. Lipofectins or liposomes can be used to deliver the anti-GM-CSFR&#x3b1; antibodies of this application into cells.</p><p id="p-0306" num="0298">The formulation herein may also contain one or more active compounds in addition to the anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide an antineoplastic agent, a growth inhibitory agent, a cytotoxic agent, or a chemotherapeutic agent in addition to the anti-GM-CSFR&#x3b1; antibody. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. The effective amount of such other agents depends on the amount of anti-GM-CSFR&#x3b1; antibody present in the formulation, the type of disease or disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein or about from 1 to 99% of the heretofore employed dosages.</p><p id="p-0307" num="0299">The anti-GM-CSFR&#x3b1; antibodies (e.g., full-length anti-GM-CSFR&#x3b1; antibodies) may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Sustained-release preparations may be prepared.</p><p id="p-0308" num="0300">Sustained-release preparations of the anti-GM-CSFR&#x3b1; antibodies (e.g., full-length anti-GM-CSFR&#x3b1; antibodies) can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody (or fragment thereof), which matrices are in the form of shaped articles. e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT&#x2122; (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D (&#x2212;)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydro gels release proteins for shorter time periods. When encapsulated antibody remain in the body for a long time, they can denature or aggregate as a result of exposure to moisture at 37&#xb0; C., resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization of anti-GM-CSFR&#x3b1; antibodies depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S&#x2014;S bond formation through thio-disulfide interchange, stabilization can be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.</p><p id="p-0309" num="0301">In some embodiments, the anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) is formulated in a buffer comprising a citrate. NaCl, acetate, succinate, glycine, polysorbate 80 (Tween 80), or any combination of the foregoing.</p><p id="p-0310" num="0302">The formulations to be used for in vivo administration must be sterile. This is readily accomplished by, e.g., filtration through sterile filtration membranes.</p><heading id="h-0024" level="2">Methods of Treatment Using Anti-GM-CSFR&#x3b1; Antibodies</heading><p id="p-0311" num="0303">The anti-GM-CSFR&#x3b1; antibodies (e.g., full-length anti-GM-CSFR&#x3b1; antibodies) and/or compositions of the application can be administered to individuals (e.g., mammals such as humans) to treat a disease and/or disorder associated with high expression levels of GM-CSF and/or GM-CSFR&#x3b1;, and disease and/or disorder with deregulated GM-CSF and/or GM-CSFR&#x3b1; function, such as autoimmune and/or inflammatory conditions or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function, for example, rheumatoid arthritis, asthma, and myeloid leukemia pulmonary disease. The present application thus in some embodiments provides a method of treating an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) in an individual comprising administering to the individual an effective amount of a composition (such as a pharmaceutical composition) comprising an anti-GM-CSFR&#x3b1; antibody (e.g., a full-length anti-GM-CSFR&#x3b1; antibody), such as any one of the anti-GM-CSFR&#x3b1; antibodies (e.g., full-length anti-GM-CSFR&#x3b1; antibodies) described herein.</p><p id="p-0312" num="0304">In some embodiments, the disease or condition is selected, for example, from the group consisting of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergic response, multiple sclerosis, myeloid leukemia, and atherosclerosis. In some embodiments, the individual is human.</p><p id="p-0313" num="0305">For example, in some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a pharmaceutical composition comprising an anti-GM-CSFR&#x3b1; antibody (e.g., full-length anti-GM-CSFR&#x3b1; antibody) specifically binding to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises amino acid residues Val50. Glu59, Lys194, Lys195, Arg283, and Ile284 of human GM-CSFR&#x3b1;. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises amino acid residues Val50, Glu59, Lys194, Lys195, Arg283, Ile284, Val51, Thr63, and Ile196. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises amino acid residues Val50, Glu59, Lys194, Lys195, Arg283. Ile284, Leu191 and Ile196. In some embodiments, the anti-GM-CSFR&#x3b1; antibody described herein specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises amino acid residues Val50. Glu59, Lys194, Lys195, Arg283, Ile284, Arg49, Val51, Asn57, and Ser61. In some embodiments, the anti-GM-CSFR&#x3b1; antibody is a full-length antibody. In some embodiments, the full-length anti-GM-CSFR&#x3b1; antibody is an IgG1 or IgG4 antibody. In some embodiments, the disease or condition is selected from the group consisting of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergic response, multiple sclerosis, myeloid leukemia, and atherosclerosis. In some embodiments, the individual is human.</p><p id="p-0314" num="0306">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a pharmaceutical composition comprising an anti-GM-CSFR&#x3b1; antibody (e.g., full-length anti-GM-CSFR&#x3b1; antibody) comprising a heavy chain variable domain (V<sub>H</sub>) comprising an HC-CDR1 comprising X<sub>1</sub>LX<sub>2</sub>X<sub>3</sub>H (SEQ ID NO: 76), wherein X<sub>1 </sub>is E, N, G, D, M, S, P, F, Y, A, V, K, W, R or C, X<sub>2 </sub>is S, C or P, and X<sub>3 </sub>is I or M; an HC-CDR2 comprising GFDX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>EX<sub>5</sub>X<sub>6</sub>YAQKX<sub>7</sub>QG (SEQ ID NO: 77), wherein X<sub>1 </sub>is P, G, T, S, or V, X<sub>2 </sub>is E, D, G, or A, X<sub>3 </sub>is D, G, I, W, S, or V, X<sub>4 </sub>is G, E, D, or H, X<sub>5 </sub>is T or A, X<sub>6 </sub>is N or I, and X<sub>7 </sub>is S or F; and an HC-CDR3 comprising GRYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>YGFDY (SEQ ID NO: 78), wherein X<sub>1 </sub>is C, T, S, I, A, or V, X<sub>2 </sub>is S, G, E, F, W, H, I, V, N, Y, T, or R, X<sub>3 </sub>is T, H, L, F, P, I, S, Y, K, A, D, V, N, or G, X<sub>4 </sub>is D, A, M, Y, F, S, T, G, or W, X<sub>5 </sub>is T, S, F, Q, A, N, L, E, I, G, or M, and X<sub>6 </sub>is C, T, N, S, or A; and a V<sub>L </sub>comprising a LC-CDR1 comprising RAX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>VX<sub>4</sub>X<sub>5</sub>X<sub>6</sub>LA (SEQ ID NO: 293), wherein X<sub>1 </sub>is S, L, N, A, K, R, I, Q, G, T, H, M, or C, X<sub>2 </sub>is Q, Y, P, A, I, F, T, R, V, L, E, S, or C, X<sub>3 </sub>is S, H, W, L, R, K, T, P, I, F, V, E, A, or Q, X<sub>4 </sub>is S, L, W, M, A, Y, K, R, G, T, E, V, N, F, or C, X<sub>5 </sub>is S, T, R, A, H, Q, P, M, L, or G, and X<sub>6 </sub>is Y, L, or F; a LC-CDR2 comprising X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>SRAT (SEQ ID NO: 294), wherein X<sub>1 </sub>is G or T, X<sub>2 </sub>is A, G, R, H, K, S, T, M, or F, and X<sub>3 </sub>is S, A, W, R, L, T, Q, F, Y, H, or N; and a LC-CDR3 comprising QQYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>PX<sub>4</sub>T (SEQ ID NO: 79), wherein X<sub>1 </sub>is N, D, S, R, A, T, L, Y, Q, W or G, X<sub>2 </sub>is N, D, E, T, Y, G, A, M, F, S, I or L, X<sub>3 </sub>is W, S, P, V, G, or R, and X<sub>4 </sub>is P, Y, H, S, F, N, D, V, or G.</p><p id="p-0315" num="0307">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NOs: 1-4, an HC-CDR2 comprising the amino acid sequence of SEQ ID NOs: 5-16, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NOs: 17-50, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NOs: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NOs: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NOs: 53-75, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0316" num="0308">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NOs: 80-121, and 246-287 or a variant thereof having at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287, and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NOs: 122-144, 150-245, and 288-289, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289.</p><p id="p-0317" num="0309">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0318" num="0310">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0319" num="0311">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 80 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123. In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0320" num="0312">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0321" num="0313">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 85 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 125. In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0322" num="0314">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 23, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0323" num="0315">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 86 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0324" num="0316">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0325" num="0317">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 91 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0326" num="0318">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 53, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0327" num="0319">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 99 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 122. In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0328" num="0320">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0329" num="0321">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 101 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0330" num="0322">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0331" num="0323">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 103 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123. In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0332" num="0324">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0333" num="0325">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein comprises a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 99 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0334" num="0326">In some embodiments, there is provided a method of treating an individual having an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia) comprising administering to the individual an effective amount of a composition comprising an anti-GM-CSFR&#x3b1; antibody comprising: a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50, or a variant thereof comprising up to 5 amino acid substitutions; and a V<sub>L </sub>comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57, or a variant thereof comprising up to 5 amino acid substitutions.</p><p id="p-0335" num="0327">In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein comprises a Vu comprising the amino acid sequence of SEQ ID NO: 121 and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the anti-GM-CSFR&#x3b1; antibody provided herein is a full-length anti-GM-CSFR&#x3b1; antibody comprising IgG1 or IgG4 constant domains. In some embodiments, the IgG1 is human IgG1. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 145. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 146. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 147.</p><p id="p-0336" num="0328">In some embodiments, the individual is a mammal (e.g., human, non-human primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc.). In some embodiments, the individual is a human. In some embodiments, the individual is a clinical patient, a clinical trial volunteer, an experimental animal, etc. In some embodiments, the individual is younger than about 60 years old (including for example younger than about any of 50, 40, 30, 25, 20, 15, or 10 years old). In some embodiments, the individual is older than about 60 years old (including for example older than about any of 70, 80, 90, or 100 years old). In some embodiments, the individual is diagnosed with or genetically prone to one or more of the diseases or disorders described herein (such as rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergic response, multiple sclerosis, myeloid leukemia, or atherosclerosis). In some embodiments, the individual has one or more risk factors associated with one or more diseases or disorders described herein.</p><p id="p-0337" num="0329">The present application in some embodiments provides a method of delivering an anti-GM-CSFR&#x3b1; antibody (such as any one of the anti-GM-CSFR&#x3b1; antibodies described herein, e.g., an isolated anti-GM-CSFR&#x3b1; antibody) to a cell expressing GM-CSFR&#x3b1; on its surface in an individual, the method comprising administering to the individual a composition comprising the anti-GM-CSFR&#x3b1; antibody.</p><p id="p-0338" num="0330">Many diagnostic methods for cancer or any other disease exhibiting abnormal GM-CSF and/or GM-CSFR&#x3b1; expression and the clinical delineation of those diseases are known in the art. Such methods include, but are not limited to, e.g., immunohistochemistry, PCR, and fluorescent in situ hybridization (FISH).</p><p id="p-0339" num="0331">In some embodiments, the anti-GM-CSFR&#x3b1; antibodies (e.g., full-length anti-GM-CSFR&#x3b1; antibodies) and/or compositions of the application are administered in combination with a second, third, or fourth agent (including. e.g., an antineoplastic agent, a growth inhibitory agent, a cytotoxic agent, or a chemotherapeutic agent) to treat diseases or disorders involving abnormal GM-CSF/GM-CSFR&#x3b1; expression.</p><p id="p-0340" num="0332">Cancer treatments can be evaluated by, e.g., tumor regression, tumor weight or size shrinkage, time to progression, duration of survival, progression free survival, overall response rate, duration of response, quality of life, protein expression and/or activity. Approaches to determining efficacy of the therapy can be employed, including for example, measurement of response through radiological imaging.</p><p id="p-0341" num="0333">In some embodiments, the efficacy of treatment is measured as the percentage tumor growth inhibition (% TGI), calculated using the equation 100-(T/C&#xd7;100), where T is the mean relative tumor volume of the treated tumor, and C is the mean relative tumor volume of a non-treated tumor. In some embodiments, the % TGI is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, or more than 95%. In some embodiments, the efficacy of treatment is measured using shape change of granulocytes and/or increase in the survival of granulocytes. In some embodiments, the efficacy of treatment is measured by the increase of cytokine secretion by monocytes.</p><p id="p-0342" num="0334">Dosing and Method of Administering the Anti-GM-CSFR&#x3b1; Antibodies</p><p id="p-0343" num="0335">The dose of the anti-GM-CSFR&#x3b1; antibody (such as isolated anti-GM-CSFR&#x3b1; antibody) compositions administered to an individual (such as a human) may vary with the particular composition, the mode of administration, and the type of disease being treated. In some embodiments, the amount of the composition (such as composition comprising isolated anti-GM-CSFR&#x3b1; antibody) is effective to result in an objective response (such as a partial response or a complete response) in the treatment of cancer. In some embodiments, the amount of the anti-GM-CSFR&#x3b1; antibody composition is sufficient to result in a complete response in the individual. In some embodiments, the amount of the anti-GM-CSFR&#x3b1; antibody composition is sufficient to result in a partial response in the individual. In some embodiments, the amount of the anti-GM-CSFR&#x3b1; antibody composition administered (for example when administered alone) is sufficient to produce an overall response rate of more than about any of 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 64%, 65%, 70%, 75%, 80%, 85%, or 90% among a population of individuals 3125 treated with the anti-GM-CSFR&#x3b1; antibody composition. Responses of an individual to the treatment of the methods described herein can be determined, for example, based on RECIST levels.</p><p id="p-0344" num="0336">In some embodiments, the amount of the composition (such as composition comprising isolated anti-GM-CSFR&#x3b1; antibody) is sufficient to prolong progress-free survival of the individual. In some embodiments, the amount of the composition is sufficient to prolong overall survival of the individual. In some embodiments, the amount of the composition (for example when administered along) is sufficient to produce clinical benefit of more than about any of 50%, 60%, 70%, or 77% among a population of individuals treated with the anti-GM-CSFR&#x3b1; antibody composition.</p><p id="p-0345" num="0337">In some embodiments, the amount of the composition (such as composition comprising isolated anti-GM-CSFR&#x3b1; antibody), alone or in combination with a second, third, and/or fourth agent, is an amount sufficient to decrease the size of a tumor, decrease the number of cancer cells, or decrease the growth rate of a tumor by at least about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100% compared to the corresponding tumor size, number of cancer cells, or tumor growth rate in the same subject prior to treatment or compared to the corresponding activity in other subjects not receiving the treatment. Standard methods can be used to measure the magnitude of this effect, such as in vitro assays with purified enzyme, cell-based assays, animal models, or human testing.</p><p id="p-0346" num="0338">In some embodiments, the amount of the anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) in the composition is below the level that induces a toxicological effect (i.e., an effect above a clinically acceptable level of toxicity) or is at a level where a potential side effect can be controlled or tolerated when the composition is administered to the individual.</p><p id="p-0347" num="0339">In some embodiments, the amount of the composition is close to a maximum tolerated dose (MTD) of the composition following the same dosing regimen. In some embodiments, the amount of the composition is more than about any of 80%, 90%, 95%, or 98% of the MTD.</p><p id="p-0348" num="0340">In some embodiments, the amount of an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) in the composition is included in a range of about 0.001 &#x3bc;g to about 1000 &#x3bc;g.</p><p id="p-0349" num="0341">In some embodiments of any of the above aspects, the effective amount of anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) in the composition is in the range of about 0.1 &#x3bc;g/kg to about 100 mg/kg of total body weight.</p><p id="p-0350" num="0342">The anti-GM-CSFR&#x3b1; antibody compositions can be administered to an individual (such as human) via various routes, including, for example, intravenous, intra-arterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosal, and transdermal. In some embodiments, sustained continuous release formulation of the composition may be used. In some embodiments, the composition is administered intravenously. In some embodiments, the composition is administered intraportally. In some embodiments, the composition is administered intraarterially. In some embodiments, the composition is administered intraperitoneally. In some embodiments, the composition is administered intrahepatically. In some embodiments, the composition is administered by hepatic arterial infusion. In some embodiments, the administration is to an injection site distal to a first disease site.</p><heading id="h-0025" level="2">Articles of Manufacture and Kits</heading><p id="p-0351" num="0343">In some embodiments of the application, there is provided an article of manufacture containing materials useful for the treatment of autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia), or for delivering an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) to a cell expressing GM-CSFR&#x3b1; on its surface. The article of manufacture can comprise a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. Generally, the container holds a composition which is effective for treating a disease or disorder described herein, and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an anti-GM-CSFR&#x3b1; antibody of the application. The label or package insert indicates that the composition is used for treating the particular condition. The label or package insert will further comprise instructions for administering the anti-GM-CSFR&#x3b1; antibody composition to the patient. Articles of manufacture and kits comprising combinatorial therapies described herein are also contemplated.</p><p id="p-0352" num="0344">Package insert refers to instructions customarily included in commercial packages of therapeutic products that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. In some embodiments, the package insert indicates that the composition is used for treating autoimmune and/or inflammatory conditions (such as rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergic response, multiple sclerosis, myeloid leukemia, and atherosclerosis). In some embodiments, the package insert indicates that the composition is used for treating cancer (e.g. myeloid leukemia).</p><p id="p-0353" num="0345">Additionally, the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.</p><p id="p-0354" num="0346">Kits are also provided that are useful for various purposes, e.g., for treatment of an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia), or for delivering an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) to a cell expressing GM-CSFR&#x3b1; on its surface, optionally in combination with the articles of manufacture. Kits of the application include one or more containers comprising anti-GM-CSFR&#x3b1; antibody composition (or unit dosage form and/or article of manufacture), and in some embodiments, further comprise another agent (such as the agents described herein) and/or instructions for use in accordance with any of the methods described herein. The kit may further comprise a description of selection of individuals suitable for treatment. Instructions supplied in the kits of the application are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.</p><p id="p-0355" num="0347">For example, in some embodiments, the kit comprises a composition comprising an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody). In some embodiments, the kit comprises a) a composition comprising any one of the anti-GM-CSFR&#x3b1; antibodies described herein, and b) an effective amount of at least one other agent, wherein the other agent enhances the effect (e.g., treatment effect, detecting effect) of the anti-GM-CSFR&#x3b1; antibody. In some embodiments, the kit comprises a) a composition comprising any one of the anti-GM-CSFR&#x3b1; antibodies described herein, and b) instructions for administering the anti-GM-CSFR&#x3b1; antibody composition to an individual for treatment of an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia). In some embodiments, the kit comprises a) a composition comprising any one of the anti-GM-CSFR&#x3b1; antibodies described herein, b) an effective amount of at least one other agent, wherein the other agent enhances the effect (e.g., treatment effect, detecting effect) of the anti-GM-CSFR&#x3b1; antibody, and c) instructions for administering the anti-GM-CSFR&#x3b1; antibody composition and the other agent(s) to an individual for treatment of an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia). The anti-GM-CSFR&#x3b1; antibody and the other agent(s) can be present in separate containers or in a single container. For example, the kit may comprise one distinct composition or two or more compositions wherein one composition comprises an anti-GM-CSFR&#x3b1; antibody and another composition comprises another agent.</p><p id="p-0356" num="0348">In some embodiments, the kit comprises a nucleic acid (or set of nucleic acids) encoding an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody). In some embodiments, the kit comprises a) a nucleic acid (or set of nucleic acids) encoding an anti-GM-CSFR&#x3b1; antibody, and b) a host cell for expressing the nucleic acid (or set of nucleic acids). In some embodiments, the kit comprises a) a nucleic acid (or set of nucleic acids) encoding an anti-GM-CSFR&#x3b1; antibody, and b) instructions for i) expressing the anti-GM-CSFR&#x3b1; antibody in a host cell, ii) preparing a composition comprising the anti-GM-CSFR&#x3b1; antibody, and iii) administering the composition comprising the anti-GM-CSFR&#x3b1; antibody to an individual for the treatment of an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia). In some embodiments, the kit comprises a) a nucleic acid (or set of nucleic acids) encoding an anti-GM-CSFR&#x3b1; antibody, b) a host cell for expressing the nucleic acid (or set of nucleic acids), and c) instructions for i) expressing the anti-GM-CSFR&#x3b1; antibody in the host cell, ii) preparing a composition comprising the anti-GM-CSFR&#x3b1; antibody, and iii) administering the composition comprising the anti-GM-CSFR&#x3b1; antibody to an individual for the treatment of an autoimmune and/or inflammatory condition or cancer characterized by high GM-CSF and/or GM-CSFR&#x3b1; expression and/or abnormal GM-CSF/GM-CSFR&#x3b1; function (e.g., rheumatoid arthritis, asthma, or myeloid leukemia).</p><p id="p-0357" num="0349">The kits of the application are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. Kits may optionally provide additional components such as buffers and interpretative information. The present application thus also provides articles of manufacture, which include vials (such as sealed vials), bottles, jars, flexible packaging, and the like.</p><p id="p-0358" num="0350">The instructions relating to the use of the anti-GM-CSFR&#x3b1; antibody compositions generally include information as to dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses. For example, kits may be provided that contain sufficient dosages of an anti-GM-CSFR&#x3b1; antibody (such as a full-length anti-GM-CSFR&#x3b1; antibody) as disclosed herein to provide effective treatment of an individual for an extended period, such as any of a week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. Kits may also include multiple unit doses of the anti-GM-CSFR&#x3b1; antibody and pharmaceutical compositions and instructions for use and packaged in quantities sufficient for storage and use in pharmacies, for example, hospital pharmacies and compounding pharmacies.</p><p id="p-0359" num="0351">Those skilled in the art will recognize that several embodiments are possible within the scope and spirit of this application. The application will now be described in greater detail by reference to the following non-limiting examples. The following examples further illustrate the application but, of course, should not be construed as in any way limiting its scope.</p><heading id="h-0026" level="1">EXAMPLES</heading><p id="p-0360" num="0352">In the experimental disclosure which follows, the following abbreviations apply: GMF (human GM-CSF); GMRa (human GM-CSFR&#x3b1;); GMRb (human GM-CSFR&#x3b2;); Mab (Mavrilimumab); GMRah (human GM-CSFR&#x3b1;-6His); BGMRa (Biotin-Avi-GM-CSFR&#x3b1;); 3275 mGMRa (cynomolgus monkey GM-CSFR&#x3b1;); mGMRah (cynomolgus monkey GM-CSFR&#x3b1;-6His).</p><heading id="h-0027" level="1">Example 1: Generation of Recombinant Human GM-CSFR&#x3b1; and Selection of Anti-GM-CSFR&#x3b1; scFv Antibodies</heading><heading id="h-0028" level="2">Generation of Recombinant GM-CSFR&#x3b1;</heading><p id="p-0361" num="0353">The full-length sequence of human GM-CSFR&#x3b1; (hereon referred to as GMRa) was subcloned from the vector pSC-GM-CSFR&#x3b1; (Generay, Shanghai) into the expression vector pTT5 using restriction enzyme recognition sites HindIII and XhoI. His-tag or other conventionally used tags were used to tag GMRa. Expression vectors pTT5-GMRa-6his (ECD), pTT5-Avi-10His-GMRa (ECD), and pTT5-GMRa (400a.a) were generated. &#x201c;ECD&#x201d; stands for extracellular domain, &#x201c;his or His&#x201d; stands for His-tag, and &#x201c;Avi&#x201d; stands for Avidin tag.</p><p id="p-0362" num="0354">Additionally, recombinant cynomolgus monkey GM-CSFR&#x3b1; construct was cloned. Primers were designed based on the sequence of cynomolgus monkey GM-CSFR&#x3b1; in NCBI database (XM_024791666.1), and used to obtain GM-CSFR&#x3b1; cDNA by reverse transcription of RNA from peripheral blood mononuclear cells (PBMC) of cynomolgus monkeys. The ECD-encoding sequence was amplified from the GM-CSFR&#x3b1; cDNA and cloned into an eukaryotic expression vector pTT5 to generate pTT5-mGMRa-6his(ECD).</p><p id="p-0363" num="0355">The expression and purification of recombinant human GM-CSFR&#x3b1;, including GMRa-6his(ECD), Avi-10His-GMRa(ECD), and mGMRa-6his(ECD) were carried out according to manufacturer's protocol. Briefly, 293F cells were transfected with the expression vectors, and the cells were cultured at 37&#xb0; C., under 8% CO<sub>2 </sub>and 120 rpm for 5 days. The culture media was collected and proteins expressing His-tag were purified using Ni Sepharose purification according to manufacturer's protocol. Specifically, the Qiagen Ni-NTA superflow cartridges were used for immobilized metal affinity chromatography (IMAC) analysis. The cartridges were first equilibrated with buffer A1 (50 mM Na<sub>3</sub>PO<sub>4</sub>, 0.15M NaCl. pH 7.2) with a flow rate of 150 cm/h. The pH of the supernatant of the culture media was adjusted to 7.2 and flown through the cartridges at room temperature at 150 cm/h. Next, buffer A1 (6 times the volume of that of the cartridges) was used to equilibrate the cartridges at 150 cm/h. A 50 mM PB solution (0.15M NaCl and 0.2M Imidazole, pH 7.2) with a volume that is 10 times that of the cartridges was used to wash the cartridges and the elution was collected.</p><heading id="h-0029" level="2">Generation of Biotinylated GM-CSFR&#x3b1; Antigen</heading><p id="p-0364" num="0356">Biotinylation of Avi-10His-GMRa using the biotin ligase B0101A (GeneCopoeia) was carried out according to the manufacturer's protocol. Briefly, buffer A/B and BirA ligase were added to Avi-10His-GMRa, followed by 2 hours of incubation at 30&#xb0; C. The biotinylated GMRa is referred to as Bavih-GMRa. The efficiency of biotinylation was measured using ELISA. Briefly, Bavih-GMRa was serially diluted at a 1:2 ratio, from a starting concentration of 500 ng/mL, before being used to coat the ELISA plate. SA-HRP was used for detection and standard biotinylation products were used as control. The biotinylation efficiency was determined to be 70%. The bioactivity of Bavih-GMRa was confirmed using TF-1 cell proliferation assay.</p><p id="p-0365" num="0000">Selection of Anti-GM-CSFR&#x3b1; scFv Antibodies</p><p id="p-0366" num="0357">Generation of yeast scFv antibody display library: RNA collected from 2000 human blood samples was reverse-transcribed into cDNA, and the V<sub>H </sub>and V<sub>K </sub>fragments were amplified using V<sub>H</sub>- and V<sub>K</sub>-specific primers. Upon gel extraction and purification, scFvs were generated by linking V<sub>H </sub>and V<sub>K</sub>, and were cloned into the yeast display plasmid PYD1, which were then electroporated into yeast to generate the yeast scFv antibody display library.</p><p id="p-0367" num="0358">Selection of anti-GM-CSFR&#x3b1; scFv antibodies: scFvs which recognized GM-CSFR&#x3b1; were isolated from the yeast display library. Briefly, magnetic-activated cell sorting (MACS) was used to enrich for cells expressing anti-GM-CSFR&#x3b1; scFv antibodies. 1000 OD yeast cells were subjected to centrifugation for 5 minutes at 2500 g. Cell pellet was obtained and resuspended in 1 L of SGCAA culture media with OD600=1 as the starting concentration. Expression was induced for 40-48 hours at 20&#xb0; C. and 250 rpm. After centrifugation and washing with PBSM, the pellet was resuspended in 5-10 times volume of 1 &#x3bc;M Bavih-GMRa (in PBSM), and incubated for an hour at 4&#xb0; C. After centrifugation and washing with PBSM, unbound antigens were washed off with PBSM. Magnetic beads were added and mixed thoroughly before incubation for 30 minutes at 4&#xb0; C. on a rotator. The supernatant was discarded after centrifugation at 2500 g for 5 minutes, and the pellet was resuspended in PBSM with 5-10 times the volume. 7 mL of cells was added to the column at a time until all cells were passed through the column. Bound cells were collected and upon further culturing and centrifugation were subjected to plasmid isolation.</p><p id="p-0368" num="0359">Generation of phage display library and selection of scFv antibodies: scFv antibody fragments from the selected yeast cells were PCR amplified using scFv-F and scFv-R primers. To generate phage display libraries, the scFv fragments were then cloned into the phage display vector pDAN5 using SfiI. Upon ligation, the vector was used to transduce TG1 phage display electroporation-competent cells to obtain the phage scFv antibody display library, scFv antibodies specific to GM-CSFR&#x3b1; were isolated from the phage display library in a series of repeated selection cycles. Briefly, phage scFv library (2&#xd7;10<sup>11 </sup>PFU) was added to biotinylated GM-CSFR&#x3b1;, and incubated for 2 hours at 37&#xb0; C. GM-CSFR&#x3b1; with phage bound was captured on streptavidin coated magnetic beads. Unbound phage were washed away. After washing with TBST for 8-15 times (increasing number of washes for every round of selection), phage that specifically bound to GM-CSFR&#x3b1; were washed off with Glycine-HCl (pH2.2). These phages were used to transduce TG1 cells in log phase, with the addition of Ampicillin, and cultured for an hour. Upon the addition of helper phage, the cells were cultured on a rocking bed for overnight at 200 rpm at 28&#xb0; C. Culture media was collected the next day, centrifuged to obtain the supernatant, and was subjected to the next round of selection. A panel of positive scFv antibodies was obtained at the end of the selection process.</p><p id="p-0369" num="0360">Monoclonal scFv antibodies were selected and subjected to ligand binding assays. The first assay was designed to identify scFv antibodies that bound human GM-CSFR&#x3b1; and/or cynomolgus monkey GM-CSFR&#x3b1;. Briefly, a 96-well plate was coated with GMRah (human GM-CSFR&#x3b1;-6His) or mGMRah (cynomolgus monkey GM-CSFR&#x3b1;-6His) in PBS at 0.2 &#x3bc;g/well and left overnight at 4&#xb0; C. Before loading the scFv antibodies, the plates were washed with TBST, blocked for 1-2 hours at 37&#xb0; C. using 5% milk and washed again with TBST. Each scFv sample was first diluted to 40 &#x3bc;g/mL, and 150 &#x3bc;L was added to the first row of wells. The 40 &#x3bc;g/mL scFv samples were then serially diluted at a 1:3 ratio and added to the remaining wells. After incubating for an hour at 37&#xb0; C., followed by washing with TBST for 6 times, 100 &#x3bc;l of the primary antibody and secondary antibody mixture (mouse anti-flag (1:2500) and anti-mouse FC-AP (1:2000)) was added to each well. After incubation for an hour under 37&#xb0; C., the plate was washed for 3 times using TBST, pNPP was then added at 50 &#x3bc;L/well and incubated for 10-20 minutes at 37&#xb0; C. 3M NaOH was used to stop the reaction. The ELISA results (OD410) were then analyzed and the binding curves were generated by PRISM.</p><p id="p-0370" num="0361">The second assay was designed to identify scFv antibodies that were capable of inhibiting binding of GM-CSF to GM-CSFR&#x3b1;, as measured by competitive ELISA. Briefly, a 96-well plate was coated with 0.5 &#x3bc;g/well of GM-CSF and 5% milk, incubated for 1-2 hours at 37&#xb0; C., and followed by washing with TBST. Each scFv antibody sample was first diluted to 40 &#x3bc;g/mL, and 100 &#x3bc;L was added to the first row of wells. The 40 &#x3bc;g/mL scFv antibody samples were then serially diluted at a 1:2 ratio and added to the remaining wells. 50 &#x3bc;L of 2.5 &#x3bc;g/mL Bavih-GMRa in PBS was added to each well. After incubating for an hour at 37&#xb0; C., the wells were washed with TBST for 6 times. 100 &#x3bc;L of SA-HRP (1:20,000) was then added to each well and incubated for an hour at 37&#xb0; C. The wells were washed with TBST for 6 times before adding 50 &#x3bc;L/well of TMB, and incubated for 5-10 minutes at 37&#xb0; C. 2M H<sub>2</sub>SO<sub>4 </sub>was used to stop the 3375 reaction. The ELISA results (OD450) were analyzed, and the binding curves were generated by PRISM.</p><p id="p-0371" num="0362">TF-1 proliferation assay: scFv antibodies able to inhibit binding between GM-CSF and GM-CSFR&#x3b1; were assessed for biological activity in a TF-1 proliferation assay, which analyzed the ability of the antibodies to inhibit the proliferation of TF-1 cells stimulated with GM-CSF. TF-1 is a human premyeloid cell line established from a patient with erythroleukemia. This cell line is factor-dependent for survival and proliferation, and is routinely maintained in human GM-CSF. Briefly, TF-1 cells were maintained in RPMI1640, 10% FBS, 10 ng/mL GM-CSF media, and were passaged twice every week. Cells were washed with media without GM-CSF (RPMI1640, 10% FBS) for three times, and resuspended in the same media. Approximately 10,000 cells were added to each well of a 96-well plate and cultured overnight. The following day, the scFv antibodies were serially diluted at a 1:10 ratio (from 10 &#x3bc;g/mL to 0.0001 &#x3bc;g/mL), and were added to the cells. After incubating at 37&#xb0; C. for an hour, GM-CSF (Peprotech) was added at a final concentration of 200 &#x3bc;g/mL. The following day, cell survival was analyzed using the Celltiter-glo assay kit (Promega). IC<sub>50 </sub>was calculated by PRISM.</p><heading id="h-0030" level="1">Example 2: Generation and Characterization of Full-Length Human Anti-GM-CSFR&#x3b1; Antibodies</heading><heading id="h-0031" level="2">Generation of Full-Length Anti-GM-CSFR&#x3b1; Antibodies</heading><p id="p-0372" num="0363">The most potent scFv antibodies were reformatted as human IgG1 or IgG4 antibody molecules with a human IgG1 or IgG4 heavy chain constant domain, and a human kappa light chain constant domain. VL and VH were amplified from the prokaryotic expression vector and introduced into eukaryotic expression vectors pTT5-L (containing kappa constant domain) and pTT5-H1 (containing IgG1 heavy chain constant domain), or pTT5-H4 (containing IgG4 heavy chain constant domain). Plasmids expressing the light and heavy chains were extracted and used to transform 293F cells. After the cells were cultured at 37&#xb0; C., 8% CO<sub>2 </sub>and 120 rpm for five days, the culture media was purified using Protein A affinity chromatography. Briefly, Protein A column was first equilibrated with a PBS buffer containing 50 mM PBS and 0.15M NaCl (pH7.2), at a flow rate of 150 cm/h and with a volume that is six times the volume of the column. The supernatant of the culture media (pH was adjusted to 7.2) was passed through the column at 150 cm/h. Upon further equilibration, the column was washed off using 50 mM sodium citrate (pH3.5) and the elution was collected. Out of the full-length antibodies that were generated, T119 was selected as the lead parent antibody. Using the scFv of T119, a phage scFv display library containing mutations in the CDR regions was generated. Variants that were able to bind human GM-CSFR&#x3b1; with high affinity, and with low dissociation rate were assessed for biological activity in the TF-1 proliferation assay, scFv antibodies that showed improved biological activity as compared to the scFv of T119 were used to generate full-length antibodies. A further round of selection of the full-length antibodies using the TF-1 proliferation assay was carried out. The selected lead-optimized antibodies were then subjected to further biochemical and biological analysis.</p><heading id="h-0032" level="2">Affinity of Anti-GM-CSFR&#x3b1; Antibodies</heading><p id="p-0373" num="0364">The affinity of the parent antibody T119 and the lead-optimized antibodies (reformatted as human IgG1) for human GM-CSFR&#x3b1; was evaluated using ELISA. As shown in <figref idref="DRAWINGS">FIGS. <b>1</b>A-<b>1</b>C</figref>, the lead-optimized antibodies exhibited improved binding affinity as compared to T119. Next, the affinity of the parent antibody T119 and lead-optimized antibodies E35, E200a, E87, and E108 (reformatted as human IgG4) for cynomolgus monkey GM-CSFR&#x3b1; (mGMRah) was evaluated using ELISA. As shown in <figref idref="DRAWINGS">FIG. <b>2</b></figref>, the anti-GM-CSFR&#x3b1; antibodies cross-reacted with cynomolgus monkey GM-CSFR&#x3b1;.</p><heading id="h-0033" level="2">Specificity of Anti-GM-CSFR&#x3b1; Antibodies</heading><p id="p-0374" num="0365">Cross-reactivity to homologous proteins: Using ELISA, antibodies E35, E87, and E108 (reformatted as human IgG4) were tested for cross-reactivity to homologous proteins of GM-CSFR&#x3b1;, including IL3RA, IL5RA, and G-CSFR. As shown in <figref idref="DRAWINGS">FIG. <b>3</b></figref>, the antibodies bound specifically to GMRah as compared to the other homologous proteins tested, suggesting that the anti-GM-CSFR&#x3b1; antibodies have specificity for GM-CSFR&#x3b1;.</p><p id="p-0375" num="0366">Binding specificity to GM-CSFR&#x3b1;-expressing WIL2S cells: The anti-GM-CSFR&#x3b1; antibody E35-IgG4 was further assessed for binding to WIL2S cells expressing GM-CSFR&#x3b1;. Anti-GM-CSFR&#x3b1; antibody E35-IgG4 was fluorescently labeled with GYL-650 (Dylight Amine-Reactive Dyes, Thermo Fisher) according to manufacturer's protocol. WIL2S cells expressing GM-CSFR&#x3b1; were generated via electroporation with an expression vector containing the full-length GM-CSFR&#x3b1;, and untreated WIL2S were used as controls. 48 hours after electroporation, both electroporated and untreated cells were transferred into 15 mL conical tubes, centrifuged for 5 minutes at 1000 rpm, and resuspended in DPBS. 1&#xd7;10<sup>6 </sup>cells were then added to each Eppendorf tube and centrifuged for 5 minutes at 1000 g. GM-CSFR&#x3b1;-expressing WIL2S cells were treated with 15 &#x3bc;g/mL of E35-IgG4 in 100 &#x3bc;L 1% BSA (GMRa-E35), and control WIL2S cells were treated with either 100 &#x3bc;L of 1% BSA (CK) or 5 &#x3bc;g/mL of E35-IgG4 in 100&#x3bc;L 1% BSA (NC-E35). Cells from all three groups were incubated for 40 minutes at 37&#xb0; C., washed with 1 mL PBS twice, resuspended in 0.2 mL PBS, and subjected to FACS analysis. As shown in <figref idref="DRAWINGS">FIG. <b>4</b></figref>, E35-IgG4 did not bind to control WIL2S cells but showed strong binding to WIL2S cells expressing GM-CSFR&#x3b1;.</p><heading id="h-0034" level="2">Characterization of Binding Affinity and Dissociation Constant (Ks)</heading><p id="p-0376" num="0367">The binding affinity of anti-GM-CSFR&#x3b1; antibodies E35, and E87b (reformatted as human IgG4) were characterized using Biacore T200 (GE). Antibodies E35 and E87b were stabilized on sensor chip CM5. The affinities for GMRah at various concentrations were measured. The range of concentrations included 10, 5, 2.5, 1.25, 0.625, 0.3125, 0.15625, 0.078, 0.039, 0.0195, and 0 nm. The concentrations of 0.625 and 0 nM were repeated once. Using the SPR technology, the association and dissociation rates were measured, and binding affinity was determined. Table 5 shows the K<sub>on</sub>, K<sub>off</sub>, and K<sub>d </sub>of E35 and E87b.</p><p id="p-0377" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="4" rowsep="1">TABLE 5</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Antibody</entry><entry>K<sub>on </sub>(l/Ms)</entry><entry>K<sub>off</sub>(l/s)</entry><entry>K<sub>d </sub>(M)</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>E35</entry><entry>5.37E+06</entry><entry>4.78E&#x2212;05</entry><entry>8.90E&#x2212;12</entry></row><row><entry/><entry>E87b</entry><entry>3.58E+06</entry><entry>2.42E&#x2212;05</entry><entry>6.75E&#x2212;12</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/>Anti-GM-CSFR&#x3b1; Antibodies Compete with GM-CSF for Binding to GM-CSFR&#x3b1;</p><p id="p-0378" num="0368">Competitive ELISA experiments were carried out as described in Example 1 to assess the ability of the anti-GM-CSFR&#x3b1; antibodies to recognize the ligand-binding site on GM-CSFR&#x3b1; and compete with GM-CSF for binding to GM-CSFR&#x3b1;. As shown in <figref idref="DRAWINGS">FIGS. <b>5</b>A-<b>5</b>D</figref>, the parent antibody T119 and lead-optimized antibodies (reformatted as human IgG4) were able to block GM-CSF from binding to human GM-CSFR&#x3b1;, suggesting competitive binding of the antibodies to the ligand-binding site on GM-CSFR&#x3b1;.</p><heading id="h-0035" level="2">Anti-GM-CSFR&#x3b1; Antibody Stability Assays</heading><p id="p-0379" num="0369">Thermal stability analysis: The thermal stability of TI 19-IgG1, E35-IgG1, E35b-IgG1, and Mab-IgG1 were analyzed using the UNcle platform. The thermal melting (Tm) and thermal aggregation (Tagg) values for each antibody were measured. T<sub>m </sub>indicates the unfolding temperature of the antibody during a thermal ramp, and T<sub>agg </sub>indicates the aggregation temperature of the antibody during a thermal ramp. As shown in Table 6 and <figref idref="DRAWINGS">FIGS. <b>6</b>A-<b>6</b>B</figref>. T119-IgG1, E35-IgG1 and E35b-IgG1 showed increased thermal melting temperature as compared to Mab-IgG1, with E35-IgG1 and E35b-IgG1 exhibiting higher melting temperature than the parent T119-IgG1. TI 19-IgG1, E35-IgG1 and E35b-IgG1 also showed increased thermal aggregation temperature as compared to Mab-IgG1, with E35-IgG1 and E35b-IgG1 exhibiting higher aggregation temperature than the parent TI 19-IgG1. These results suggest that E35-IgG1 and E35b-IgG1 exhibited improved thermal stability as compared to the parental T119-IgG1 antibody, as well as the control Mab-IgG1 antibody.</p><p id="p-0380" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="28pt" align="left"/><colspec colname="4" colwidth="35pt" align="left"/><colspec colname="5" colwidth="35pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="5" rowsep="1">TABLE 6</entry></row><row><entry/><entry namest="offset" nameend="5" align="center" rowsep="1"/></row><row><entry/><entry/><entry/><entry>T<sub>m</sub>1 </entry><entry>T<sub>agg </sub>266 </entry><entry>T<sub>agg </sub>473 </entry></row><row><entry/><entry>Well</entry><entry>Sample</entry><entry>(&#xb0; C.)</entry><entry>(&#xb0; C.)</entry><entry>(&#xb0; C.)</entry></row><row><entry/><entry namest="offset" nameend="5" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>H1</entry><entry>2 mg/ml Mab-IgG1</entry><entry>67.8</entry><entry>64.56</entry><entry>65.6</entry></row><row><entry/><entry>I1</entry><entry>2 mg/ml T119-IgG1</entry><entry>69.53</entry><entry>56.65</entry><entry>70.01</entry></row><row><entry/><entry>J1</entry><entry>2 mg/ml E35-IgG1</entry><entry>73.52</entry><entry>67.15</entry><entry>77.37</entry></row><row><entry/><entry>K1</entry><entry>2 mg/ml E35b-IgG1</entry><entry>70.42</entry><entry>69.01</entry><entry>77.64</entry></row><row><entry/><entry namest="offset" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0036" level="2">TF-1 Proliferation Assay</heading><p id="p-0381" num="0370">TF-1 proliferation assay was performed as described in Example 1. The parent antibody T119 and lead-optimized antibodies (reformatted as human IgG4) were tested for their abilities to inhibit TF-1 cell proliferation. As shown in <figref idref="DRAWINGS">FIG. <b>7</b></figref>, the lead-optimized antibodies showed comparable or improved ability to inhibit TF-1 cell proliferation as compared to the parental T119 antibody.</p><heading id="h-0037" level="2">Granulocyte Shape Change Assay</heading><p id="p-0382" num="0371">The anti-GM-CSFR&#x3b1; antibodies were further evaluated using human granulocyte shape change assays. Briefly, PBMCs were removed from 10 mL human peripheral blood using Ficoll gradient. Upon removal of PBMCs and the Ficoll buffer, red blood cells were lysed using cell lysis buffer. The remaining cells were washed with PBS and cell culture media. 100,000 cells were added to each well of a 96-well plate, and incubated for 30 minutes at 37&#xb0; C. Cells were then treated with 100 &#x3bc;g/mL GM-CSF, as well as serially diluted antibodies (1:10 dilution; 10 &#x3bc;g/mL to 0.0001 &#x3bc;g/mL). After incubation for 3 hours at 37&#xb0; C., the cells were subjected to FACS analysis, and the shape change of the granulocytes was evaluated based on the GEO mean of the forward scatter. As shown in <figref idref="DRAWINGS">FIG. <b>8</b></figref>. E35, E108 and E87b (reformatted as human IgG4) prevented granulocyte shape change. The IC<sub>50 </sub>of each antibody is shown in Table 7 below.</p><p id="p-0383" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="4" rowsep="1">TABLE 7</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Antibody</entry><entry>E35</entry><entry>E108</entry><entry>E87b</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>IC50 (&#x3bc;g/mL)</entry><entry>0.002050</entry><entry>0.002066</entry><entry>0.001505</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0384" num="0372">The anti-GM-CSFR&#x3b1; antibody E35 (reformatted as human IgG4) was further evaluated using cynomolgus monkey granulocyte shape change assays. Cynomolgus monkey granulocytes were purified from whole blood, and treated with 100 &#x3bc;g/mL GM-CSF, as well as serially diluted E35 (1:10 dilution; 10 &#x3bc;g/mL to 0.0001 &#x3bc;g/mL). The cells were subjected to FACS analysis, and the shape change of the granulocytes was evaluated based on the GEO mean of the forward scatter. The results showed that E35 prevented cynomolgus monkey granulocyte shape change (<figref idref="DRAWINGS">FIG. <b>9</b></figref>), with an IC50 of 0.002527 &#x3bc;g/mL.</p><heading id="h-0038" level="2">Human Granulocyte Survival Assay</heading><p id="p-0385" num="0373">Granulocytes are able to survive for longer in the presence of GM-CSF. In the human granulocyte survival assay, the ability of the anti-GM-CSFR&#x3b1; antibodies to inhibit this response was assessed. Briefly, granulocytes were isolated from human peripheral blood and treated with 100 &#x3bc;g/mL GM-CSF. Antibodies were serially diluted at a 1:10 ratio (10 &#x3bc;g/mL to 0.0001 &#x3bc;g/mL) and were added to the cells. After incubation for 48 hours, cell survival was analyzed using the Celltiter-glo assay kit (Promega). As shown in <figref idref="DRAWINGS">FIG. <b>10</b></figref>, E35. E108, and E87b effectively inhibited granulocyte survival. Table 8 shows the IC50 of each antibody for inhibiting human granulocyte survival.</p><p id="p-0386" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="4" rowsep="1">TABLE 8</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Antibody</entry><entry>E35-IgG4</entry><entry>E108-IgG4</entry><entry>E87b-IgG4</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>IC50 (&#x3bc;g/mL)</entry><entry>0.004200</entry><entry>0.005521</entry><entry>0.002528</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0039" level="2">Inhibitory Effect on Cytokine Release</heading><p id="p-0387" num="0374">Inhibitory effect on CD11b expression: Anti-GM-CSFR&#x3b1; antibodies E35 and E87b, as well as Mab were evaluated for their abilities to inhibit the expression of CD11b from cells in the human peripheral blood. Briefly, 50 &#x3bc;L of human peripheral blood was added to each well of a 96-well plate, and incubated with serially diluted antibodies (1:10 dilution; 10 &#x3bc;g/mL to 0.0001 &#x3bc;g/mL). After incubating for 1 hour at 37&#xb0; C., 10 ng/mL GM-CSF was added, and followed by incubation for an additional hour. FITC conjugated anti-CD11b antibody (BD53310) was used to label CD11b by incubating for 30 minutes at 4&#xb0; C. Red blood cells were then lysed using 1 mL red blood cell lysis buffer (BD349202), and after two washes with PBS, the expression of CD11b was analyzed using FACS. As shown in <figref idref="DRAWINGS">FIG. <b>11</b></figref> and Table 9. E35 and E87b showed improved abilities to inhibit CD11b expression as compared to Mab. The IC50 of the antibodies are shown in Table 9.</p><p id="p-0388" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="4" rowsep="1">TABLE 9</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Antibody</entry><entry>Mab-IgG4</entry><entry>E35-IgG4</entry><entry>E87b-IgG4</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>IC50 (&#x3bc;g/mL)</entry><entry>0.1813</entry><entry>0.1111</entry><entry>0.1439</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0389" num="0375">Inhibitory effects on cytokine production: To evaluate the inhibitory effects of anti-GM-CSFR&#x3b1; antibodies on cytokine production, PBMCs were isolated from 10 mL human peripheral blood using Ficoll gradient, washed with PBS twice, and resuspended in the cell culture media. 1,000,000 cells (100 &#x3bc;L) were added to each well of a 96-well plate, and 50 &#x3bc;L of serially diluted antibodies (100-0.001 &#x3bc;g/mL) were added to the wells and incubated for an hour at 37&#xb0; C. LPS and GM-CSF were then added to a final concentration of 100 ng/mL and 50 ng/mL, respectively. After incubating at 37&#xb0; C. for 48 hours, the supernatant was collected and the levels of TNF&#x3b1; and IL-1&#x3b2; were analyzed using the Human Macrophage/Microglia Panel (Biolegend, 740503). As shown in <figref idref="DRAWINGS">FIG. <b>12</b>A</figref> and Table 10, E35 and E87b (reformatted as human IgG4) showed improved inhibitory effect on TNF&#x3b1; secretion as compared to Mab-IgG4. As shown in <figref idref="DRAWINGS">FIG. <b>13</b></figref> and Table 11. E35 and E87b (reformatted as human IgG4) both exhibited improved inhibitory effect on IL-1&#x3b2; secretion as compared to Mab-IgG4.</p><p id="p-0390" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="4" rowsep="1">TABLE 10</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Antibody</entry><entry>Mab</entry><entry>E35</entry><entry>E87b</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>IC50 (&#x3bc;g/mL)</entry><entry>3.094</entry><entry>0.2777</entry><entry>0.06664</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0391" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="4" rowsep="1">TABLE 11</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Antibody</entry><entry>Mab</entry><entry>E35</entry><entry>E87b</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>IC50 (&#x3bc;g/mL)</entry><entry>0.01263</entry><entry>0.003535</entry><entry>0.01333</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0392" num="0376">The supernatant was further analyzed for levels of TNF&#x3b1; using ELISA. The ELISA results confirmed that E35 and E87b exhibited improved inhibitory effect on TNF&#x3b1; secretion as compared to Mab (<figref idref="DRAWINGS">FIG. <b>12</b>B</figref> and Table 12).</p><p id="p-0393" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="4" rowsep="1">TABLE 12</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Antibody</entry><entry>Mab</entry><entry>E35</entry><entry>E87b</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>IC50 (&#x3bc;g/mL)</entry><entry>1.741</entry><entry>0.3290</entry><entry>0.09349</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0040" level="2">Pharmacokinetics of Anti-GM-CSFR&#x3b1; Antibodies</heading><p id="p-0394" num="0377">PK values in rat: 10 healthy adult rats (approximately 0.2 kg by weight) were separated into two groups by weight, with 5 in each group. Rat in the first group were injected intravenously with 20 mg/kg of Mab-IgG4 or E35-IgG4, while rat in the second group were injected intravenously with 2 mg/kg of Mab-IgG4 or E35-IgG4. Blood was collected first at one hour after injection, and subsequently at 2 days, 3 days, 5 days, 9 days, and 15 days after injection. After centrifugation, the plasma was used for analyzing antibody concentration using ELISA. Briefly, synthetic GM-CSFR&#x3b1; was used to cover the wells of a 96-well plate. On the following day, after washing with PBST, blocking with 200 &#x3bc;L PBS-milk for an hour, followed by another wash with PBST, the plasma was added and incubated for an hour at 37&#xb0; C. The plate was washed with 0.1% TBST for 6 times before 100 &#x3bc;L of Goat-anti-human Fe antibody-AP (1:3000 in PBS) was added to each well and incubated for an hour. After washing with 0.1% TBST for 6 times, 50 &#x3bc;L of pNPP was added to each well and color was developed for 10-20 minutes at 37&#xb0; C. The results were read by a microplate reader at 410 nm which suggested that the half-life of E35-IgG4 was longer than that of Mab-IgG4 (<figref idref="DRAWINGS">FIGS. <b>14</b>A-<b>14</b>B</figref> and Table 13).</p><p id="p-0395" num="0000"><tables id="TABLE-US-00015" num="00015"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="84pt" align="left"/><colspec colname="3" colwidth="56pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="3" rowsep="1">TABLE 13</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Antibody</entry><entry/><entry/></row><row><entry/><entry>T1/2</entry><entry>Mab-IgG4</entry><entry>E35-IgG4</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="49pt" align="right"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="56pt" align="left"/><tbody valign="top"><row><entry/><entry>T1/2 (20 mg/kg)</entry><entry>129 </entry><entry>h</entry><entry>190.9 h</entry></row><row><entry/><entry>T1/2 (2 mg/kg)</entry><entry>53.09</entry><entry>h</entry><entry>186.7 h</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0396" num="0378">PK and PD studies in cynomolgus monkey: Four cynomolgus monkeys (approximately 3 kg by weight) were injected with either E35-IgG4 or the control antibody Mab-IgG4 at a concentration of 10 mg/kg. Specifically. Animal #1 and #2 were injected with Mab-IgG4, and Animal #3 and #4 were injected with E35-IgG4, 6 mL of blood was collected from each animal the day before injection (D-1), one hour after injection (D1), and subsequently at D2, D4, D8, D15, D22, D29, and D36. To evaluate the pharmacokinetics of the antibodies, plasma was collected from 1 mL of the blood sample collected at each time point by centrifuging for 15 minutes at 5000 g, and stored at &#x2212;80&#xb0; C. as 50 &#x3bc;L aliquots. The concentrations of E35-IgG4 and Mab-IgG4 were analyzed using ELISA performed as described above for the pharmacokinetics study in rats. As shown in <figref idref="DRAWINGS">FIG. <b>15</b></figref> and Table 14, the half-life of E35-IgG4 was longer than that of Mab-IgG4. To evaluate the pharmacodynamics of the antibodies, granulocytes were isolated from 5 mL of the blood sample collected at each time point and subjected to granulocyte shape change analysis. Briefly, 100 &#x3bc;L of granulocytes (2&#xd7;10<sup>6</sup>/mL) were added to each well of a 96-well plate, and incubated for 30 minutes at 37&#xb0; C., followed by incubation with 100 &#x3bc;g/mL GM-CSF for 3 hours. The cells were then subjected to shape change analysis using FACS as described above for the granulocyte shape change assay. The results showed that E35-IgG4 and Mab-IgG4 both prevented granulocyte shape change. Surprisingly, the effect of Mab-IgG4 only lasted for 14 days after the injection, while the effect of E35-IgG4 lasted for at least 21 days (<figref idref="DRAWINGS">FIGS. <b>16</b>A-<b>16</b>D</figref>).</p><p id="p-0397" num="0000"><tables id="TABLE-US-00016" num="00016"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><thead><row><entry namest="1" nameend="7" rowsep="1">TABLE 14</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry/><entry/><entry/><entry>Average </entry><entry/><entry/><entry/></row><row><entry/><entry>Animal </entry><entry>T1/2</entry><entry>T1/2</entry><entry>T<sub>max</sub></entry><entry>C<sub>max</sub></entry><entry/></row><row><entry>Antibody</entry><entry>No.</entry><entry>(h)</entry><entry>(h)</entry><entry>(h)</entry><entry>(ng/ml)</entry><entry>AUC</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="49pt" align="char" char="."/><colspec colname="4" colwidth="35pt" align="char" char="."/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="49pt" align="char" char="."/><colspec colname="7" colwidth="42pt" align="char" char="."/><tbody valign="top"><row><entry>Mab-IgG4</entry><entry>1</entry><entry>44.86346</entry><entry>69.41</entry><entry>1</entry><entry>95783.719</entry><entry>17340604</entry></row><row><entry/><entry>2</entry><entry>93.956602</entry><entry/><entry>1</entry><entry>76499.663</entry><entry>14508393</entry></row><row><entry>E35-IgG4</entry><entry>3</entry><entry>104.10626</entry><entry>106.4</entry><entry>1</entry><entry>73486.786</entry><entry>14118941</entry></row><row><entry/><entry>4</entry><entry>108.76885</entry><entry/><entry>1</entry><entry>77001.042</entry><entry>15830767</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0041" level="2">Inhibitory Effects on GM-CSF-Induced Increase of Inflammatory Cells</heading><p id="p-0398" num="0379">To examine the inhibitory effects of anti-GM-CSFR&#x3b1; antibodies on GM-CSF-induced increase of inflammatory cells, GM-CSF was administered to cynomolgus monkeys previously injected with E35-IgG4 or NaCl solution as a control, and the levels of white blood cells, neutrophils, lymphocytes, basophils, eosinophils, monocytes, and red blood cells were evaluated following GM-CSF administration. Briefly, 4 cynomolgus monkeys were assigned to two groups, with 2 in each group. E35-IgG4 was administered to one group via intraperitoneal injections on Day 1 and Day 3. The other group was injected with NaCl solution as control. On Day 3, 4 and 5, both groups were injected with 5.0 &#x3bc;g/kg of GM-CSF (twice a day, approximately 8 hours in between injections). Blood samples were collected prior to the first GM-CSF injection and subsequently at 0.5 h, 4.0 h, 28.0 h, 52.0 h, 76.0 h, 124.0 h, and 176.0 h after the first injection, and the levels of various cells types at each time point were analyzed.</p><p id="p-0399" num="0380">The results showed that as compared to the control group, E35-IgG4 completely repressed GM-CSF-induced increase in white blood cells, neutrophils, lymphocytes, basophils, eosinophils, and monocytes. In contrast, the levels of red blood cells remained constant before and after GM-CSF treatment for both groups (<figref idref="DRAWINGS">FIGS. <b>17</b>A-<b>17</b>G</figref>).</p><heading id="h-0042" level="1">Example 3: Identification of E35 Variants that Retain Biological Activity</heading><p id="p-0400" num="0381">The sequence of his-tagged E35-scFv was cloned into a prokaryotic expression vector. Selected residues in the CDR regions were subjected to saturation mutagenesis and screening. The mutated versions were inserted into prokaryotic expression vectors and used to transfect BL21. After plating, 60 clones were randomly selected for sequencing, and 14-19 distinct mutations at each position were obtained, scFvs containing these mutations were generated, purified and subjected to TF-1 proliferation assay to assess their biological activity. The mutations and corresponding IC50 for reducing TF-1 cell proliferation are shown in Table 15 below (numbering is according to the EU index of Kabat):</p><p id="p-0401" num="0000"><tables id="TABLE-US-00017" num="00017"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="343pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 15</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>The unit for IC50 values indicated is &#x3bc;g/mL</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="14"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="21pt" align="left"/><colspec colname="3" colwidth="28pt" align="left"/><colspec colname="4" colwidth="21pt" align="left"/><colspec colname="5" colwidth="28pt" align="left"/><colspec colname="6" colwidth="21pt" align="left"/><colspec colname="7" colwidth="28pt" align="left"/><colspec colname="8" colwidth="21pt" align="left"/><colspec colname="9" colwidth="28pt" align="left"/><colspec colname="10" colwidth="21pt" align="left"/><colspec colname="11" colwidth="28pt" align="left"/><colspec colname="12" colwidth="21pt" align="left"/><colspec colname="13" colwidth="28pt" align="left"/><colspec colname="14" colwidth="21pt" align="left"/><tbody valign="top"><row><entry>Mut.</entry><entry>IC<sub>50</sub></entry><entry>Mut.</entry><entry>IC<sub>50</sub></entry><entry>Mut.</entry><entry>IC<sub>50</sub></entry><entry>Mut.</entry><entry>IC<sub>50</sub></entry><entry>Mut.</entry><entry>IC<sub>50</sub></entry><entry>Mut.</entry><entry>IC<sub>50</sub></entry><entry>Mut.</entry><entry>IC<sub>50</sub></entry></row><row><entry namest="1" nameend="14" align="center" rowsep="1"/></row><row><entry>HE31N</entry><entry>0.11</entry><entry>E35</entry><entry>0.12</entry><entry>HT28H</entry><entry>0.06</entry><entry>LS26L</entry><entry>0.044</entry><entry>LQ27Y</entry><entry>0.065</entry><entry>LS31T</entry><entry>0.060</entry><entry>LS28H</entry><entry>0.058</entry></row><row><entry>HE31G</entry><entry>0.116</entry><entry>HT30P</entry><entry>0.126</entry><entry>HT28V</entry><entry>0.08</entry><entry>LS26N</entry><entry>0.054</entry><entry>LQ27P</entry><entry>0.097</entry><entry>LS31R</entry><entry>0.069</entry><entry>LS28W</entry><entry>0.060</entry></row><row><entry>E35</entry><entry>0.12</entry><entry>HT30D</entry><entry>0.132</entry><entry>HT28E</entry><entry>0.091</entry><entry>LS26A</entry><entry>0.062</entry><entry>LQ27A</entry><entry>0.104</entry><entry>LS31A</entry><entry>0.078</entry><entry>LS28L</entry><entry>0.067</entry></row><row><entry>HE31D</entry><entry>0.13</entry><entry>HT30E</entry><entry>0.132</entry><entry>HT28P</entry><entry>0.093</entry><entry>LS26K</entry><entry>0.069</entry><entry>LQ27I</entry><entry>0.105</entry><entry>LS31H</entry><entry>0.106</entry><entry>LS28R</entry><entry>0.077</entry></row><row><entry>HE31M</entry><entry>0.13</entry><entry>HT30Y</entry><entry>0.142</entry><entry>HT28L</entry><entry>0.100</entry><entry>LS26R</entry><entry>0.072</entry><entry>LQ27F</entry><entry>0.113</entry><entry>LS31Q</entry><entry>0.117</entry><entry>LS28K</entry><entry>0.082</entry></row><row><entry>HE31S</entry><entry>0.14</entry><entry>HT30W</entry><entry>0.151</entry><entry>HT28M</entry><entry>0.11</entry><entry>LS26I</entry><entry>0.073</entry><entry>LQ27T</entry><entry>0.113</entry><entry>E35</entry><entry>0.12</entry><entry>LS28T</entry><entry>0.088</entry></row><row><entry>HE31P</entry><entry>0.17</entry><entry>HT30V</entry><entry>0.158</entry><entry>HT28S</entry><entry>0.11</entry><entry>LS26Q</entry><entry>0.075</entry><entry>LQ27R</entry><entry>0.117</entry><entry>LS31P</entry><entry>0.139</entry><entry>LS28P</entry><entry>0.089</entry></row><row><entry>HE31F</entry><entry>0.18</entry><entry>HT30M</entry><entry>0.174</entry><entry>HT28W</entry><entry>0.11</entry><entry>LS26G</entry><entry>0.078</entry><entry>E35</entry><entry>0.12</entry><entry>LS31M</entry><entry>0.156</entry><entry>LS28I</entry><entry>0.091</entry></row><row><entry>HE31Y</entry><entry>0.2</entry><entry>HT30N</entry><entry>0.178</entry><entry>HT28C</entry><entry>0.12</entry><entry>LS26T</entry><entry>0.081</entry><entry>LQ27V</entry><entry>0.120</entry><entry>LS31L</entry><entry>0.235</entry><entry>LS28F</entry><entry>0.100</entry></row><row><entry>HE31A</entry><entry>0.21</entry><entry>HT30L</entry><entry>0.181</entry><entry>E35</entry><entry>0.12</entry><entry>LS26H</entry><entry>0.089</entry><entry>LQ27L</entry><entry>0.128</entry><entry>LS31G</entry><entry>0.279</entry><entry>LS28V</entry><entry>0.104</entry></row><row><entry>HE31V</entry><entry>0.22</entry><entry>HT30Q</entry><entry>0.192</entry><entry>HT28A</entry><entry>0.13</entry><entry>LS26M</entry><entry>0.089</entry><entry>LQ27E</entry><entry>0.135</entry><entry>LS31W</entry><entry>0.649</entry><entry>LS28E</entry><entry>0.111</entry></row><row><entry>HE31K</entry><entry>0.23</entry><entry>HT30G</entry><entry>0.199</entry><entry>HT28G</entry><entry>0.16</entry><entry>LS26C</entry><entry>0.114</entry><entry>LQ27S</entry><entry>0.138</entry><entry>LS31I</entry><entry>0.681</entry><entry>LS28A</entry><entry>0.116</entry></row><row><entry>HE31W</entry><entry>0.26</entry><entry>HT30S</entry><entry>0.213</entry><entry>HT28N</entry><entry>0.17</entry><entry>E35</entry><entry>0.12</entry><entry>LQ27C</entry><entry>0.142</entry><entry>LS31E</entry><entry>0.832</entry><entry>E35</entry><entry>0.12</entry></row><row><entry>HE31R</entry><entry>0.31</entry><entry>HT30A</entry><entry>0.215</entry><entry>HT28K</entry><entry>0.217</entry><entry/><entry/><entry/><entry/><entry>LS31D</entry><entry>1.34</entry><entry>LS28Q</entry><entry>0.154</entry></row><row><entry>HE31C</entry><entry>0.36</entry><entry>HT30K</entry><entry>0.325</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry>HT30R</entry><entry>0.350</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>LS30L</entry><entry>0.069</entry><entry>LY32L</entry><entry>0.07</entry><entry>LS52A</entry><entry>0.068</entry><entry>LA51G</entry><entry>0.12</entry><entry>E35</entry><entry>0.12</entry><entry>E35</entry><entry>0.12</entry><entry>LN93D</entry><entry>0.045</entry></row><row><entry>LS30W</entry><entry>0.071</entry><entry>E35</entry><entry>0.12</entry><entry>LS52W</entry><entry>0.073</entry><entry>LA51R</entry><entry>0.12</entry><entry>LG50T</entry><entry>0.25</entry><entry>LD92A</entry><entry>0.282</entry><entry>LN93E</entry><entry>0.081</entry></row><row><entry>LS30M</entry><entry>0.073</entry><entry>LY32F</entry><entry>0.21</entry><entry>LS52R</entry><entry>0.089</entry><entry>E35</entry><entry>0.12</entry><entry>LG50A</entry><entry>0.5</entry><entry>LD92Q</entry><entry>0.328</entry><entry>E35</entry><entry>0.12</entry></row><row><entry>LS30A</entry><entry>0.078</entry><entry>LY32M</entry><entry>0.42</entry><entry>LS52L</entry><entry>0.115</entry><entry>LA51H</entry><entry>0.162</entry><entry>LG50D</entry><entry>0.88</entry><entry>LD92W</entry><entry>0.342</entry><entry>LN93T</entry><entry>0.14</entry></row><row><entry>LS30Y</entry><entry>0.082</entry><entry>LY32T</entry><entry>0.51</entry><entry>E35</entry><entry>0.12</entry><entry>LA51K</entry><entry>0.168</entry><entry>LG50Q</entry><entry>0.93</entry><entry>LD92V</entry><entry>0.387</entry><entry>LN93Y</entry><entry>0.156</entry></row><row><entry>LS30K</entry><entry>0.083</entry><entry>LY32Q</entry><entry>0.87</entry><entry>LS52T</entry><entry>0.136</entry><entry>LA51S</entry><entry>0.18</entry><entry>LG50I</entry><entry>1.08</entry><entry>LD92L</entry><entry>0.420</entry><entry>LN93G</entry><entry>0.205</entry></row><row><entry>LS30R</entry><entry>0.088</entry><entry>LY32W</entry><entry>1.17</entry><entry>LS52Q</entry><entry>0.138</entry><entry>LA51T</entry><entry>0.18</entry><entry>LG50S</entry><entry>1.3</entry><entry>LD92T</entry><entry>0.494</entry><entry>LN93A</entry><entry>0.21</entry></row><row><entry>LS30G</entry><entry>0.092</entry><entry>LY32V</entry><entry>1.23</entry><entry>LS52F</entry><entry>0.167</entry><entry>LA51M</entry><entry>0.264</entry><entry>LG50V</entry><entry>1.4</entry><entry>LD92R</entry><entry>0.495</entry><entry>LN93M</entry><entry>0.27</entry></row><row><entry>LS30T</entry><entry>0.092</entry><entry>LY32A</entry><entry>1.35</entry><entry>LS52Y</entry><entry>0.181</entry><entry>LA51F</entry><entry>0.294</entry><entry>LG50N</entry><entry>1.59</entry><entry>LD92M</entry><entry>0.507</entry><entry>LN93F</entry><entry>0.3</entry></row><row><entry>LS30E</entry><entry>0.100</entry><entry>LY32G</entry><entry>1.35</entry><entry>LS52H</entry><entry>0.192</entry><entry>LA51N</entry><entry>0.36</entry><entry>LG50P</entry><entry>1.86</entry><entry>LD92G</entry><entry>0.522</entry><entry>LN93S</entry><entry>0.3</entry></row><row><entry>E35</entry><entry>0.12</entry><entry>LY32C</entry><entry>1.9</entry><entry>LS52N</entry><entry>0.253</entry><entry>LA51V</entry><entry>0.36</entry><entry>LG50R</entry><entry>2.79</entry><entry>LD92H</entry><entry>0.530</entry><entry>LN93I</entry><entry>0.33</entry></row><row><entry>LS30V</entry><entry>0.124</entry><entry>LY32N</entry><entry>2.05</entry><entry>LS52P</entry><entry>1.055</entry><entry>LA51C</entry><entry>0.37</entry><entry>LG50L</entry><entry>3.9</entry><entry>LD92I</entry><entry>0.597</entry><entry>LN93L</entry><entry>0.33</entry></row><row><entry>LS30N</entry><entry>0.132</entry><entry>LY32R</entry><entry>3.12</entry><entry>LS52D</entry><entry>1.751</entry><entry>LA51L</entry><entry>0.5</entry><entry>LG50H</entry><entry>4.29</entry><entry>LD92S</entry><entry>0.598</entry><entry>LN93H</entry><entry>0.45</entry></row><row><entry>LS30F</entry><entry>0.160</entry><entry>LY32E</entry><entry>3.75</entry><entry/><entry/><entry>LA51E</entry><entry>0.81</entry><entry>LG50C</entry><entry>25.7</entry><entry>LD92K</entry><entry>0.640</entry><entry>LN93R</entry><entry>0.6</entry></row><row><entry>LS30C</entry><entry>0.221</entry><entry>LY32P</entry><entry>5.15</entry><entry/><entry/><entry>LA51W</entry><entry>1.59</entry><entry>LG50E</entry><entry>29.85</entry><entry>LD92P</entry><entry>0.881</entry><entry>LN93P</entry><entry>0.66</entry></row><row><entry/><entry/><entry>LY32K</entry><entry>9.6</entry><entry/><entry/><entry>LA51P</entry><entry>2.1</entry><entry>LG50Y</entry><entry>32</entry><entry/><entry/><entry>LN93K</entry><entry>0.78</entry></row><row><entry/><entry/><entry>LY32S</entry><entry>NA</entry><entry/><entry/><entry>LA51Q</entry><entry>18.17</entry><entry>LG50W</entry><entry>NA</entry></row><row><entry namest="1" nameend="14" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0402" num="0382">Based on these results, it was determined that scFv antibodies having the following amino acid sequences derived from the E35 scFv retained their biological activities as evaluated by the TF-1 proliferation assay:</p><p id="p-0403" num="0000">(i) E, H, N, G, D, M, S, P, F, Y, A, V, K, W, R, or C at position 31 of the V<sub>H</sub>;<br/>(ii) S, L, N, A, K, R, I, Q, G, T, H, M, or C at position 26 of the V<sub>L</sub>;<br/>(iii) Q, Y, P, A, I, F, T, R, V, L, E, S, or C at position 27 of the V<sub>L</sub>;<br/>(iv) S, H, W, L, R, K, T, P, I, F, V, E, A, or Q at position 28 of the V<sub>L</sub>;<br/>(v) S, L, W, M, A, Y, K, R, G, T, E, V, N, F, or C at position 30 of the V<sub>L</sub>;<br/>(vi) S, T, R, A, H, Q, P, M, L, or G at position 31 of the V<sub>L</sub>;<br/>(vii) Y, L or F at position 32 of the V<sub>L</sub>;<br/>(viii) G, or T at position 50 of the V<sub>G</sub>;<br/>(ix) A, G, R, H, K, S, T, M, F, N, or V at position 51 of the V<sub>L</sub>;<br/>(x) S, A, W, R, L, T, Q, F, Y, H, or N at position 52 of the V<sub>L</sub>;<br/>(xi) D, A, Q, or W at position 92 of the V<sub>L</sub>;<br/>(xii) N, D, E, T, Y, G, A, M, F, S, I, or L at position 93 of the V<sub>L</sub>;<br/>(xiii) amino acid residues selected from T, H, V, E, P, L, M, S, W, C, A, G, N, or K at position 28 of the V<sub>H</sub>;<br/>(xiv) amino acid residues selected from T, P, D, E, Y, W, V, M, N, L, Q, G, S, A, K, or R at position 30 of the V<sub>H</sub>.</p><p id="p-0404" num="0383">E35 variants containing combinatorial mutations were also generated. The IC50 for reducing TF-1 cell proliferation of full-length IgG4 antibodies containing the E35 variants were analyzed and are shown in Table 16 below. These results suggested that E35 variants containing combinatorial mutations exhibited improved efficacy for reducing TF-1 cell proliferation.</p><p id="p-0405" num="0000"><tables id="TABLE-US-00018" num="00018"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="56pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="3" rowsep="1">TABLE 16</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Antibody</entry><entry>IC50 (&#x3bc;g/mL)</entry><entry>Normalization</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>E35-IG4</entry><entry>0.0474</entry><entry>1.0000</entry></row><row><entry/><entry>E35-VL93D-IG4</entry><entry>0.03714</entry><entry>0.7835</entry></row><row><entry/><entry>E35-VH28H-IG4</entry><entry>0.05693</entry><entry>1.2011</entry></row><row><entry/><entry>E35-VH28E-IG4</entry><entry>0.03073</entry><entry>0.6483</entry></row><row><entry/><entry>E35-VH28H-VL93L-IG4</entry><entry>0.01628</entry><entry>0.3435</entry></row><row><entry/><entry>E35-VH28H-VL93D-IG4</entry><entry>0.02783</entry><entry>0.5871</entry></row><row><entry/><entry>E35-VH28H-VL30L-IG4</entry><entry>0.02959</entry><entry>0.6243</entry></row><row><entry/><entry>E35-VH28H-VL30C-IG4</entry><entry>0.04306</entry><entry>0.9084</entry></row><row><entry/><entry>E35-VH28E-VL30L-IG4</entry><entry>0.02682</entry><entry>0.5658</entry></row><row><entry/><entry>E35-VH28E-VL30C-IG4</entry><entry>0.02077</entry><entry>0.4382</entry></row><row><entry/><entry>E35-VH28H-VL30L-93D-IG4</entry><entry>0.02414</entry><entry>0.5093</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0406" num="0384">The exemplary heavy chain variable domain and light chain variable domain sequences of E35 variants are shown in Table 17 below.</p><p id="p-0407" num="0000"><tables id="TABLE-US-00019" num="00019"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="91pt" align="left"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 17</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry/><entry>V<sub>H</sub></entry><entry>V<sub>L</sub></entry></row><row><entry/><entry/><entry>SEQ</entry><entry>SEQ</entry></row><row><entry/><entry/><entry>ID</entry><entry>ID</entry></row><row><entry>Antibody</entry><entry>Substitution</entry><entry>NO</entry><entry>NO</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="91pt" align="left"/><colspec colname="3" colwidth="21pt" align="char" char="."/><colspec colname="4" colwidth="49pt" align="char" char="."/><tbody valign="top"><row><entry>AbM-1</entry><entry>LS26A</entry><entry>91</entry><entry>150</entry></row><row><entry>AbM-2</entry><entry>LS26C</entry><entry>91</entry><entry>151</entry></row><row><entry>AbM-3</entry><entry>LS26G</entry><entry>91</entry><entry>152</entry></row><row><entry>AbM-4</entry><entry>LS26H</entry><entry>91</entry><entry>153</entry></row><row><entry>AbM-5</entry><entry>LS26I</entry><entry>91</entry><entry>154</entry></row><row><entry>AbM-6</entry><entry>LS26K</entry><entry>91</entry><entry>155</entry></row><row><entry>AbM-7</entry><entry>LS26L</entry><entry>91</entry><entry>156</entry></row><row><entry>AbM-8</entry><entry>LS26M</entry><entry>91</entry><entry>157</entry></row><row><entry>AbM-9</entry><entry>LS26N</entry><entry>91</entry><entry>158</entry></row><row><entry>AbM-10</entry><entry>LS26Q</entry><entry>91</entry><entry>159</entry></row><row><entry>AbM-11</entry><entry>LS26R</entry><entry>91</entry><entry>160</entry></row><row><entry>AbM-12</entry><entry>LS26T</entry><entry>91</entry><entry>161</entry></row><row><entry>AbM-13</entry><entry>LQ27A</entry><entry>91</entry><entry>162</entry></row><row><entry>AbM-14</entry><entry>LQ27C</entry><entry>91</entry><entry>163</entry></row><row><entry>AbM-15</entry><entry>LQ27E</entry><entry>91</entry><entry>164</entry></row><row><entry>AbM-16</entry><entry>LQ27F</entry><entry>91</entry><entry>165</entry></row><row><entry>AbM-17</entry><entry>LQ27I</entry><entry>91</entry><entry>166</entry></row><row><entry>AbM-18</entry><entry>LQ27L</entry><entry>91</entry><entry>167</entry></row><row><entry>AbM-19</entry><entry>LQ27P</entry><entry>91</entry><entry>168</entry></row><row><entry>AbM-20</entry><entry>LQ27R</entry><entry>91</entry><entry>169</entry></row><row><entry>AbM-21</entry><entry>LQ27S</entry><entry>91</entry><entry>170</entry></row><row><entry>AbM-22</entry><entry>LQ27T</entry><entry>91</entry><entry>171</entry></row><row><entry>AbM-23</entry><entry>LQ27V</entry><entry>91</entry><entry>172</entry></row><row><entry>AbM-24</entry><entry>LQ27Y</entry><entry>91</entry><entry>173</entry></row><row><entry>AbM-25</entry><entry>LS28A</entry><entry>91</entry><entry>174</entry></row><row><entry>AbM-26</entry><entry>LS28E</entry><entry>91</entry><entry>175</entry></row><row><entry>AbM-27</entry><entry>LS28F</entry><entry>91</entry><entry>176</entry></row><row><entry>AbM-28</entry><entry>LS28H</entry><entry>91</entry><entry>177</entry></row><row><entry>AbM-29</entry><entry>LS28I</entry><entry>91</entry><entry>178</entry></row><row><entry>AbM-30</entry><entry>LS28K</entry><entry>91</entry><entry>179</entry></row><row><entry>AbM-31</entry><entry>LS28L</entry><entry>91</entry><entry>180</entry></row><row><entry>AbM-32</entry><entry>LS28P</entry><entry>91</entry><entry>181</entry></row><row><entry>AbM-33</entry><entry>LS28Q</entry><entry>91</entry><entry>182</entry></row><row><entry>AbM-34</entry><entry>LS28R</entry><entry>91</entry><entry>183</entry></row><row><entry>AbM-35</entry><entry>LS28T</entry><entry>91</entry><entry>184</entry></row><row><entry>AbM-36</entry><entry>LS28V</entry><entry>91</entry><entry>185</entry></row><row><entry>AbM-37</entry><entry>LS28W</entry><entry>91</entry><entry>186</entry></row><row><entry>AbM-38</entry><entry>LS30A</entry><entry>91</entry><entry>187</entry></row><row><entry>AbM-39</entry><entry>LS30C</entry><entry>91</entry><entry>188</entry></row><row><entry>AbM-40</entry><entry>LS30E</entry><entry>91</entry><entry>189</entry></row><row><entry>AbM-41</entry><entry>LS30F</entry><entry>91</entry><entry>190</entry></row><row><entry>AbM-42</entry><entry>LS30G</entry><entry>91</entry><entry>191</entry></row><row><entry>AbM-43</entry><entry>LS30K</entry><entry>91</entry><entry>192</entry></row><row><entry>AbM-44</entry><entry>LS30L</entry><entry>91</entry><entry>193</entry></row><row><entry>AbM-45</entry><entry>LS30M</entry><entry>91</entry><entry>194</entry></row><row><entry>AbM-46</entry><entry>LS30N</entry><entry>91</entry><entry>195</entry></row><row><entry>AbM-47</entry><entry>LS30R</entry><entry>91</entry><entry>196</entry></row><row><entry>AbM-48</entry><entry>LS30T</entry><entry>91</entry><entry>197</entry></row><row><entry>AbM-49</entry><entry>LS30V</entry><entry>91</entry><entry>198</entry></row><row><entry>AbM-50</entry><entry>LS30W</entry><entry>91</entry><entry>199</entry></row><row><entry>AbM-51</entry><entry>LS30Y</entry><entry>91</entry><entry>200</entry></row><row><entry>AbM-52</entry><entry>LS31A</entry><entry>91</entry><entry>201</entry></row><row><entry>AbM-53</entry><entry>LS31G</entry><entry>91</entry><entry>202</entry></row><row><entry>AbM-54</entry><entry>LS31H</entry><entry>91</entry><entry>203</entry></row><row><entry>AbM-55</entry><entry>LS31L</entry><entry>91</entry><entry>204</entry></row><row><entry>AbM-56</entry><entry>LS31M</entry><entry>91</entry><entry>205</entry></row><row><entry>AbM-57</entry><entry>LS31P</entry><entry>91</entry><entry>206</entry></row><row><entry>AbM-58</entry><entry>LS31Q</entry><entry>91</entry><entry>207</entry></row><row><entry>AbM-59</entry><entry>LS31R</entry><entry>91</entry><entry>208</entry></row><row><entry>AbM-60</entry><entry>LS31T</entry><entry>91</entry><entry>209</entry></row><row><entry>AbM-61</entry><entry>LY32F</entry><entry>91</entry><entry>210</entry></row><row><entry>AbM-62</entry><entry>LY32L</entry><entry>91</entry><entry>211</entry></row><row><entry>AbM-63</entry><entry>LG50T</entry><entry>91</entry><entry>212</entry></row><row><entry>AbM-64</entry><entry>LA51F</entry><entry>91</entry><entry>289</entry></row><row><entry>AbM-65</entry><entry>LA51G</entry><entry>91</entry><entry>213</entry></row><row><entry>AbM-66</entry><entry>LA51H</entry><entry>91</entry><entry>214</entry></row><row><entry>AbM-67</entry><entry>LASIK</entry><entry>91</entry><entry>215</entry></row><row><entry>AbM-68</entry><entry>LA51M</entry><entry>91</entry><entry>216</entry></row><row><entry>AbM-69</entry><entry>LA51R</entry><entry>91</entry><entry>217</entry></row><row><entry>AbM-70</entry><entry>LA51S</entry><entry>91</entry><entry>218</entry></row><row><entry>AbM-71</entry><entry>LA51T</entry><entry>91</entry><entry>219</entry></row><row><entry>AbM-72</entry><entry>LS52A</entry><entry>91</entry><entry>220</entry></row><row><entry>AbM-73</entry><entry>LS52F</entry><entry>91</entry><entry>221</entry></row><row><entry>AbM-74</entry><entry>LS52H</entry><entry>91</entry><entry>222</entry></row><row><entry>AbM-75</entry><entry>LS52L</entry><entry>91</entry><entry>223</entry></row><row><entry>AbM-76</entry><entry>LS52N</entry><entry>91</entry><entry>224</entry></row><row><entry>AbM-77</entry><entry>LS52Q</entry><entry>91</entry><entry>225</entry></row><row><entry>AbM-78</entry><entry>LS52R</entry><entry>91</entry><entry>226</entry></row><row><entry>AbM-79</entry><entry>LS52T</entry><entry>91</entry><entry>227</entry></row><row><entry>AbM-81</entry><entry>LS52W</entry><entry>91</entry><entry>229</entry></row><row><entry>AbM-83</entry><entry>LS52Y</entry><entry>91</entry><entry>231</entry></row><row><entry>AbM-84</entry><entry>LD92A</entry><entry>91</entry><entry>232</entry></row><row><entry>AbM-85</entry><entry>LD92Q</entry><entry>91</entry><entry>233</entry></row><row><entry>AbM-86</entry><entry>LD92W</entry><entry>91</entry><entry>234</entry></row><row><entry>AbM-87</entry><entry>LN93A</entry><entry>91</entry><entry>235</entry></row><row><entry>AbM-88</entry><entry>LN93D</entry><entry>91</entry><entry>236</entry></row><row><entry>AbM-89</entry><entry>LN93E</entry><entry>91</entry><entry>237</entry></row><row><entry>AbM-90</entry><entry>LN93F</entry><entry>91</entry><entry>238</entry></row><row><entry>AbM-91</entry><entry>LN93G</entry><entry>91</entry><entry>239</entry></row><row><entry>AbM-92</entry><entry>LN93I</entry><entry>91</entry><entry>240</entry></row><row><entry>AbM-93</entry><entry>LN93L</entry><entry>91</entry><entry>241</entry></row><row><entry>AbM-94</entry><entry>LN93M</entry><entry>91</entry><entry>242</entry></row><row><entry>AbM-95</entry><entry>LN93S</entry><entry>91</entry><entry>243</entry></row><row><entry>AbM-96</entry><entry>LN93T</entry><entry>91</entry><entry>244</entry></row><row><entry>AbM-97</entry><entry>LN93Y</entry><entry>91</entry><entry>245</entry></row><row><entry>AbM-98</entry><entry>HT28A</entry><entry>246</entry><entry>126</entry></row><row><entry>AbM-99</entry><entry>HT28C</entry><entry>247</entry><entry>126</entry></row><row><entry>AbM-100</entry><entry>HT28E</entry><entry>248</entry><entry>126</entry></row><row><entry>AbM-101</entry><entry>HT28G</entry><entry>249</entry><entry>126</entry></row><row><entry>AbM-102</entry><entry>HT28H</entry><entry>250</entry><entry>126</entry></row><row><entry>AbM-103</entry><entry>HT28K</entry><entry>251</entry><entry>126</entry></row><row><entry>AbM-104</entry><entry>HT28L</entry><entry>252</entry><entry>126</entry></row><row><entry>AbM-105</entry><entry>HT28M</entry><entry>253</entry><entry>126</entry></row><row><entry>AbM-106</entry><entry>HT28N</entry><entry>254</entry><entry>126</entry></row><row><entry>AbM-107</entry><entry>HT28P</entry><entry>255</entry><entry>126</entry></row><row><entry>AbM-108</entry><entry>HT28S</entry><entry>256</entry><entry>126</entry></row><row><entry>AbM-109</entry><entry>HT28V</entry><entry>257</entry><entry>126</entry></row><row><entry>AbM-110</entry><entry>HT28W</entry><entry>258</entry><entry>126</entry></row><row><entry>AbM-111</entry><entry>HT30A</entry><entry>259</entry><entry>126</entry></row><row><entry>AbM-112</entry><entry>HT30D</entry><entry>260</entry><entry>126</entry></row><row><entry>AbM-113</entry><entry>HT30E</entry><entry>261</entry><entry>126</entry></row><row><entry>AbM-114</entry><entry>HT30G</entry><entry>262</entry><entry>126</entry></row><row><entry>AbM-115</entry><entry>HT30K</entry><entry>263</entry><entry>126</entry></row><row><entry>AbM-116</entry><entry>HT30L</entry><entry>264</entry><entry>126</entry></row><row><entry>AbM-117</entry><entry>HT30M</entry><entry>265</entry><entry>126</entry></row><row><entry>AbM-118</entry><entry>HT30N</entry><entry>266</entry><entry>126</entry></row><row><entry>AbM-119</entry><entry>HT30P</entry><entry>267</entry><entry>126</entry></row><row><entry>AbM-120</entry><entry>HT30Q</entry><entry>268</entry><entry>126</entry></row><row><entry>AbM-121</entry><entry>HT30R</entry><entry>269</entry><entry>126</entry></row><row><entry>AbM-122</entry><entry>HT30S</entry><entry>270</entry><entry>126</entry></row><row><entry>AbM-123</entry><entry>HT30V</entry><entry>271</entry><entry>126</entry></row><row><entry>AbM-124</entry><entry>HT30W</entry><entry>272</entry><entry>126</entry></row><row><entry>AbM-125</entry><entry>HT30Y</entry><entry>273</entry><entry>126</entry></row><row><entry>AbM-126</entry><entry>HE31A</entry><entry>274</entry><entry>126</entry></row><row><entry>AbM-127</entry><entry>HE31C</entry><entry>275</entry><entry>126</entry></row><row><entry>AbM-128</entry><entry>HE31D</entry><entry>276</entry><entry>126</entry></row><row><entry>AbM-129</entry><entry>HE31F</entry><entry>277</entry><entry>126</entry></row><row><entry>AbM-130</entry><entry>HE31G</entry><entry>278</entry><entry>126</entry></row><row><entry>AbM-131</entry><entry>HE31K</entry><entry>279</entry><entry>126</entry></row><row><entry>AbM-132</entry><entry>HE31M</entry><entry>280</entry><entry>126</entry></row><row><entry>AbM-133</entry><entry>HE31N</entry><entry>281</entry><entry>126</entry></row><row><entry>AbM-134</entry><entry>HE31P</entry><entry>282</entry><entry>126</entry></row><row><entry>AbM-135</entry><entry>HE31R</entry><entry>283</entry><entry>126</entry></row><row><entry>AbM-136</entry><entry>HE31S</entry><entry>284</entry><entry>126</entry></row><row><entry>AbM-137</entry><entry>HE31V</entry><entry>285</entry><entry>126</entry></row><row><entry>AbM-138</entry><entry>HE31W</entry><entry>286</entry><entry>126</entry></row><row><entry>AbM-139</entry><entry>HE31Y</entry><entry>287</entry><entry>126</entry></row><row><entry>AbM-140</entry><entry>E35-28H-93L-IG4</entry><entry>250</entry><entry>241</entry></row><row><entry>AbM-141</entry><entry>E35-28H-30L-IG4</entry><entry>250</entry><entry>193</entry></row><row><entry>AbM-142</entry><entry>E35-28E-30C-IG4</entry><entry>248</entry><entry>188</entry></row><row><entry>AbM-143</entry><entry>E35-28E-30L-IG4</entry><entry>248</entry><entry>193</entry></row><row><entry>AbM-144</entry><entry>E35-28H-30L93D-IG4</entry><entry>250</entry><entry>288</entry></row><row><entry>AbM-145</entry><entry>E35-28H-30C-IG4</entry><entry>250</entry><entry>188</entry></row><row><entry>AbM-146</entry><entry>E35HT28H-LN93D-IG4</entry><entry>250</entry><entry>236</entry></row><row><entry>AbM-147</entry><entry>E35-LS30L-LN93D-IG4</entry><entry>91</entry><entry>288</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0043" level="1">Example 4: Epitope Mapping of Andi-GM-CSFR&#x3b1; Antibodies</heading><p id="p-0408" num="0385">Amino acid residues in proximity to the binding sites of GM-CSF on GM-CSFR&#x3b1; were identified based on their crystal structures, the numbering of GM-CSFR&#x3b1; is according to the crystal structure (PDB id: 4RS 1) as shown in <figref idref="DRAWINGS">FIG. <b>20</b></figref>. Using the Discovery Studio software, the predicted binding sites for E35 were identified, and the amino acid residues within the binding sites and in proximity to the binding sites were selected and subjected to alanine scanning. GM-CSFR&#x3b1; proteins with these selected mutations were expressed. The binding affinity of E35-IgG4, E87b-IgG4 and T119-IgG4 for each mutated GM-CSFR&#x3b1; protein was analyzed using ELISA. <figref idref="DRAWINGS">FIGS. <b>18</b>A-<b>18</b>C</figref> show the ELISA binding curves of the antibodies for mutated GM-CSFR&#x3b1;. As used herein, GMRah represents His-tagged wild-type human GM-CSFR&#x3b1; (GM-CSFR&#x3b1;-6His). Mutations at various positions of the amino acid sequence of the wild type GM-CSFR&#x3b1; were generated using alanine scanning as described above. As shown in <figref idref="DRAWINGS">FIGS. <b>18</b>A-<b>18</b>C</figref>, mutation at position C60 significantly affected the binding affinity E35, E87b, and T119 and was determined to be a mutation that affected the protein structure of GM-CSFR&#x3b1;. Based on these results, exemplary epitopes of antibodies E35, E87b, and T119 were identified as comprising amino acid residues as shown in Table 18. The numbering of the amino acid residues in GM-CSFR&#x3b1; (SEQ ID NO: 292) is shown in <figref idref="DRAWINGS">FIG. <b>20</b></figref>.</p><p id="p-0409" num="0000"><tables id="TABLE-US-00020" num="00020"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="14"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="28pt" align="center"/><colspec colname="9" colwidth="28pt" align="center"/><colspec colname="10" colwidth="28pt" align="center"/><colspec colname="11" colwidth="28pt" align="center"/><colspec colname="12" colwidth="28pt" align="center"/><colspec colname="13" colwidth="28pt" align="center"/><colspec colname="14" colwidth="28pt" align="center"/><thead><row><entry namest="1" nameend="14" rowsep="1">TABLE 18</entry></row><row><entry namest="1" nameend="14" align="center" rowsep="1"/></row><row><entry>Antibody</entry><entry>R49</entry><entry>V50</entry><entry>V51</entry><entry>N57</entry><entry>E59</entry><entry>S61</entry><entry>T63</entry><entry>L191</entry><entry>K194</entry><entry>K195</entry><entry>I196</entry><entry>R283</entry><entry>I284</entry></row><row><entry namest="1" nameend="14" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>E35</entry><entry/><entry>GMR-</entry><entry>GMR-</entry><entry/><entry>GMR-</entry><entry/><entry>GMR-</entry><entry/><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry></row><row><entry/><entry/><entry>V50</entry><entry>V51</entry><entry/><entry>E59</entry><entry/><entry>T63</entry><entry/><entry>K194</entry><entry>K195</entry><entry>I196</entry><entry>R283</entry><entry>I284</entry></row><row><entry>E87b</entry><entry/><entry>GMR-</entry><entry/><entry/><entry>GMR-</entry><entry/><entry/><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry></row><row><entry/><entry/><entry>V50</entry><entry/><entry/><entry>E59</entry><entry/><entry/><entry>L191</entry><entry>K194</entry><entry>K195</entry><entry>I196</entry><entry>R283</entry><entry>I284</entry></row><row><entry>T119</entry><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry><entry>GMR-</entry><entry/><entry/><entry>GMR-</entry><entry>GMR-</entry><entry/><entry>GMR-</entry><entry>GMR-</entry></row><row><entry/><entry>R49</entry><entry>V50</entry><entry>V51</entry><entry>N57</entry><entry>E59</entry><entry>S61</entry><entry/><entry/><entry>K194</entry><entry>K195</entry><entry/><entry>R283</entry><entry>I284</entry></row><row><entry namest="1" nameend="14" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002496A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An isolated anti-GM-CSFR&#x3b1; antibody that specifically binds to an epitope on human GM-CSFR&#x3b1;, wherein the epitope comprises amino acid residues Val50, Glu59, Lys194, Lys195, Arg283, and Ile284 of human GM-CSFR&#x3b1;.</claim-text></claim><claim id="CLM-002-4" num="002-4"><claim-text><b>2</b>-<b>4</b>. (canceled)</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. An isolated anti-GM-CSFR&#x3b1; antibody, wherein the anti-GM-CSFR&#x3b1; antibody comprises:<claim-text>a heavy chain variable domain (V<sub>H</sub>) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising X<sub>1</sub>LX<sub>2</sub>X<sub>3</sub>H (SEQ ID NO: 76), wherein X<sub>1 </sub>is E, N, G, D, M, S, P, F, Y, A, V, K, W, R or C, X<sub>2 </sub>is S, C or P, and X<sub>3 </sub>is I or M;</claim-text><claim-text>an HC-CDR2 comprising GFDX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>EX<sub>5</sub>X<sub>6</sub>YAQKX<sub>7</sub>QG (SEQ ID NO: 77), wherein X<sub>1 </sub>is P, G, T, S, or V, X<sub>2 </sub>is E, D, G, or A, X<sub>3 </sub>is D, G, I, W, S, or V, X<sub>4 </sub>is G, E, D, or H, X<sub>5 </sub>is T or A, X<sub>6 </sub>is N or I, and X<sub>7 </sub>is S or F; and</claim-text><claim-text>an HC-CDR3 comprising GRYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>YGFDY (SEQ ID NO: 78), wherein X<sub>1 </sub>is C, T, S, I, A, or V, X<sub>2 </sub>is S, G, E, F, W, H, I, V, N, Y, T, or R, X<sub>3 </sub>is T, H, L, F, P, I, S, Y, K, A, D, V, N, or G, X<sub>4 </sub>is D, A, M, Y, F, S, T, G, or W, X<sub>5 </sub>is T, S, F, Q, A, N, L, E, I, G, or M, and X<sub>6 </sub>is C, T, N, S, or A;</claim-text><claim-text>and a light chain variable domain (V<sub>L</sub>) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RAX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>VX<sub>4</sub>X<sub>5</sub>X<sub>6</sub>LA (SEQ ID NO: 293), wherein X<sub>1 </sub>is S, L, N, A, K, R, I, Q, G, T, H, M, or C, X<sub>2 </sub>is Q, Y, P, A, I, F, T, R, V, L, E, S, or C, X<sub>3 </sub>is S, H, W, L, R, K, T, P, I, F, V, E, A, or Q, X<sub>4 </sub>is S, L, W, M, A, Y, K, R, G, T, E, V, N, F, or C, X<sub>5 </sub>is S, T, R, A, H, Q, P, M, L, or G, and X<sub>6 </sub>is Y, L, or F;</claim-text><claim-text>a LC-CDR2 comprising X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>SRAT (SEQ ID NO: 294), wherein X<sub>1 </sub>is G or T, X<sub>2 </sub>is A, G, R, H, K, S, T, M, or F, and X<sub>3 </sub>is S, A, W, R, L, T, Q, F, Y, H, or N; and</claim-text><claim-text>a LC-CDR3 comprising QQYX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>PX<sub>4</sub>T (SEQ ID NO: 79), wherein X<sub>1 </sub>is N, D, S, R, A, T, L, Y, Q, W or G, X<sub>2 </sub>is N, D, E, T, Y, G, A, M, F, S, I or L, X<sub>3 </sub>is W, S, P, V, G, or R, and X<sub>4 </sub>is P, Y, H, S, F, N, D, V, or G.</claim-text></claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The isolated anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the anti-GM-CSFR&#x3b1; antibody comprises:<claim-text>a V<sub>H </sub>comprising a HC-CDR1 comprising ELX1X2H (SEQ ID NO: 295), wherein X1 is S, C or P, and X2 is I or M; an HC-CDR2 comprising GFDX1X2X3X4EX5X6YAQKX7QG (SEQ ID NO: 77), wherein X1 is P, G, T, S, or V, X2 is E, D, G, or A, X3 is D, G, I, W, S, or V, X4 is G, E, D, or H, X5 is T or A, X6 is N or I, and X7 is S or F; and an HC-CDR3 comprising GRYX1X2X3X4X5X6YGFDY (SEQ ID NO: 78), wherein X1 is C, T, S, I, A, or V, X2 is S, G, E, F, W, H, I, V, N, Y, T, or R, X3 is T, H, L, F, P, I, S, Y, K, A, D, V, N, or G, X4 is D, A, M, Y, F, S, T, G, or W, X5 is T, S, F, Q, A, N, L, E, I, G, or M, and X6 is C, T, N, S, or A;</claim-text><claim-text>and a V<sub>L </sub>comprising a LC-CDR1 comprising RASQSVSSYLA (SEQ ID NO: 51); a LC-CDR2 comprising GASSRAT (SEQ ID NO: 52); and a LC-CDR3 comprising QQYX1X2X3PX4T (SEQ ID NO: 79), wherein X1 is N, D, S, R, A, T, L, Y, Q, W or G, X2 is N, D, E, T, Y, G, A, M, F, S, I or L, X3 is W, S, P, V, G, or R, and X4 is P, Y, H, S, F, N, D, V, or G.</claim-text></claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The isolated anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00005">claim 5</claim-ref>, comprising:<claim-text>a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1; an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 5-16; and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50; and</claim-text><claim-text>a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51; a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52; and a LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-75.</claim-text></claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. An isolated anti-GM-CSFR&#x3b1; antibody, comprising a V<sub>H </sub>comprising an HC-CDR1, an HC-CDR2, and an HC-CDR3 of a V<sub>H </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 80-121; and a V<sub>L </sub>comprising a LC-CDR1, a LC-CDR2, and a LC-CDR3 of a V<sub>L </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 122-144.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The isolated anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00001">claim 1</claim-ref>, comprising:<claim-text>(i) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54;</claim-text><claim-text>(ii) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56;</claim-text><claim-text>(iii) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 23; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57;</claim-text><claim-text>(iv) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57;</claim-text><claim-text>(v) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 53;</claim-text><claim-text>(vi) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57;</claim-text><claim-text>(vii) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 54;</claim-text><claim-text>(viii) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 35; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57;</claim-text><claim-text>(ix) a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50; and a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57.</claim-text></claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The isolated anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00001">claim 1</claim-ref>, comprising a V<sub>H </sub>comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 27; a V<sub>L </sub>comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 57.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The isolated anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00005">claim 5</claim-ref>, comprising amino acid residues:<claim-text>(i) E, H, N, G, D, M, S, P, F, Y, A, V, K, W, R, or C at position 31 of the V<sub>H</sub>; and/or</claim-text><claim-text>(ii) S, L, N, A, K, R, I, Q, G, T, H, M, or C at position 26 of the V<sub>L</sub>; and/or</claim-text><claim-text>(iii) Q, Y, P, A, I, F, T, R, V, L, E, S, or C at position 27 of the V<sub>L</sub>; and/or</claim-text><claim-text>(iv) S, H, W, L, R, K, T, P, I, F, V, E, A, or Q at position 28 of the V<sub>L</sub>; and/or</claim-text><claim-text>(v) S, L, W, M, A, Y, K, R, G, T, E, V, N, F, or C at position 30 of the V<sub>L</sub>; and/or</claim-text><claim-text>(vi) S, T, R, A, H, Q, P, M, L, or G at position 31 of the V<sub>L</sub>; and/or</claim-text><claim-text>(vii) Y, L or F at position 32 of the V<sub>L</sub>; and/or</claim-text><claim-text>(viii) G, or T at position 50 of the V<sub>L</sub>; and/or</claim-text><claim-text>(ix) A, G, R, H, K, S, T, M, F, N, or V at position 51 of the V<sub>L</sub>; and/or</claim-text><claim-text>(x) S, A, W, R, L, T, Q, F, Y, H, or N at position 52 of the V<sub>L</sub>; and/or</claim-text><claim-text>(xi) D, A, Q, or W at position 92 of the V<sub>L</sub>; and/or</claim-text><claim-text>(xii) N, D, E, T, Y, G, A, M, F, S, I, or L at position 93 of the V<sub>L</sub>; and/or</claim-text><claim-text>(xiii) amino acid residues selected from T, H, V, E, P, L, M, S, W, C, A, G, N, or K at position 28 of the V<sub>H</sub>; and/or</claim-text><claim-text>(xiv) amino acid residues selected from T, P, D, E, Y, W, V, M, N, L, Q, G, S, A, K, or R at position 30 of the V<sub>H</sub>,</claim-text><claim-text>wherein the numbering is according to the EU index of Kabat.</claim-text></claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The isolated anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00005">claim 5</claim-ref>, comprising:<claim-text>a V<sub>H </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 80-121, and 246-287; and</claim-text><claim-text>a V<sub>L </sub>comprising the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 122-144, 150-245, and 288-289.</claim-text></claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The isolated anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00012">claim 12</claim-ref>, comprising:<claim-text>(i) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 80, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 80; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 123;</claim-text><claim-text>(ii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 85, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 85; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 125, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 125;</claim-text><claim-text>(iii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 86, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 86; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 126;</claim-text><claim-text>(iv) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 91, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 91; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 126;</claim-text><claim-text>(v) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 99, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 99; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 122, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 122;</claim-text><claim-text>(vi) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 101, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 101; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 126;</claim-text><claim-text>(vii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 103, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 103; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 123, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 123;</claim-text><claim-text>(viii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 99, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 99; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 126; or</claim-text><claim-text>(ix) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 121, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 121; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 126, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 126.</claim-text><claim-text>(x) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 250; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 241, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 241;</claim-text><claim-text>(xi) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 250; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 193, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 193;</claim-text><claim-text>(xii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 248, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 248; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 188, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 188;</claim-text><claim-text>(xiii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 248, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 248; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 193, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 193;</claim-text><claim-text>(xiv) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 250; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 288, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 288;</claim-text><claim-text>(xv) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 250; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 188, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 188;</claim-text><claim-text>(xvi) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 250, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 250; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 236, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 236; or</claim-text><claim-text>(xvii) a V<sub>H </sub>comprising the amino acid sequence of SEQ ID NO: 91, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 91; and a V<sub>L </sub>comprising the amino acid sequence of SEQ ID NO: 288, or a variant thereof having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 288.</claim-text></claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. An isolated anti-GM-CSFR&#x3b1; antibody that specifically binds to GM-CSFR&#x3b1; competitively with, or specifically binds to the same epitope as the isolated anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00005">claim 5</claim-ref>.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The isolated anti-GM-CSFR&#x3b1; antibody according to <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein:<claim-text>(1) the anti-GM-CSFR&#x3b1; antibody comprises an Fc fragment; and/or</claim-text><claim-text>(2) the anti-GM-CSFR&#x3b1; antibody is chimeric, human, or humanized; and/or</claim-text><claim-text>(3) the anti-GM-CSFR&#x3b1; antibody has a Tm of at least about 69&#xb0; C.; and/or</claim-text><claim-text>(4) the anti-GM-CSFR&#x3b1; antibody binds to the human GM-CSFR&#x3b1; with a K<sub>d </sub>from about 0.1 pM to about 1 nM.</claim-text></claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The isolated anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the anti-GM-CSFR&#x3b1; antibody is a full-length IgG antibody.</claim-text></claim><claim id="CLM-17-18" num="17-18"><claim-text><b>17</b>-<b>18</b>. (canceled)</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The isolated anti-GM-CSFR&#x3b1; antibody according to <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the anti-GM-CSFR&#x3b1; antibody is an antigen binding fragment selected from the group consisting of a Fab, a Fab&#x2032;, a F(ab)&#x2032;<sub>2</sub>, a Fab&#x2032;-SH, a single-chain Fv (scFv), an Fv fragment, a dAb, a Fd, a nanobody, a diabody, and a linear antibody.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. An isolated nucleic acid molecule that encodes the anti-GM-CSFR&#x3b1; antibody according to <claim-ref idref="CLM-00005">claim 5</claim-ref>.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. A vector comprising the nucleic acid molecule of <claim-ref idref="CLM-00020">claim 20</claim-ref>.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. An isolated host cell comprising the anti-GM-CSFR&#x3b1; antibody of <claim-ref idref="CLM-00005">claim 5</claim-ref>.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. A method of producing an anti-GM-CSFR&#x3b1; antibody, comprising:<claim-text>a) culturing the host cell of <claim-ref idref="CLM-00022">claim 22</claim-ref> under conditions effective to express the anti-GM-CSFR&#x3b1; antibody; and</claim-text><claim-text>b) obtaining the expressed anti-GM-CSFR&#x3b1; antibody from the host cell.</claim-text></claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. A pharmaceutical composition comprising the anti-GM-CSFR&#x3b1; antibody according to <claim-ref idref="CLM-00005">claim 5</claim-ref>, and a pharmaceutically acceptable carrier.</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. A method of treating a disease or condition in an individual in need thereof, comprising administering to the individual an effective amount of the pharmaceutical composition of <claim-ref idref="CLM-00024">claim 24</claim-ref>.</claim-text></claim><claim id="CLM-26-27" num="26-27"><claim-text><b>26</b>-<b>27</b>. (canceled)</claim-text></claim></claims></us-patent-application>